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The role of metabolites and the cancer-associated immune system
Ryan King, Ph.D.
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Metabolic and immune alterations are ubiquitous hallmarks of cancer that are
established during the foundational mutations and are further selected upon to generate
highly aggressive tumors. Recent evidence suggests that cancer cells employ an altered
metabolism to induce immune evasion. To further discover the relationship between
metabolism and immunity in cancer, this thesis aimed to discover potential candidates of
interest by first examining the mucin family for differences, as they exert a wide range of
activities in cancer, including altered metabolism and immune alterations. Unique
differences lead to further profiling in pancreatic and esophageal cancer. In pancreatic
cancer, CD73 was discovered to have a large significant impact on patient survival,
which was recapitulated in vivo and postulated to exert immune suppression through a
GM-CSF, MDSC, and CD4+ axis. This metabolic control was seen to ablate tumor
growth and can severely limit growth when inhibiting CD73 in combination with
gemcitabine. To further examine the potential effect of metabolic differences in cancer,
esophageal cancer was further explored, as it contained to have two largely different
metabolic profiles. Here, the largest pathway difference was discovered to be immune
alterations. These two subtypes appeared to have many immune differences, including
immune infiltration, cytokine profiles, and predicted response to checkpoint therapy.
Lastly, the study sought to find the enzymes that had the highest correlation with a
transcriptional immune dysfunction signature in order identify other potential metabolic
enzymes to target to prevent immune evasion.
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Chapter I: Introduction

2
1.1 Immune evasion as a critical hallmark of cancer
Immune evasion and reprogrammed cancer metabolism are two critical emerging
hallmarks of cancer that control both the progression and aggression of cancer. The
immune system is renowned for its cancer surveillance of injured and malignant cells,
whereby it seeks to destroy early lesions before becoming an aggressive cancer (1-6).
Both the innate and adaptive immune system play a critical role in surveillance, whereby
hindering immunity reveals increased spontaneous tumor development and increased
sensitivity to mutagens. In immunosuppressed patients, elevated spontaneous cancer
occurs for many types of cancers and ultimately generates an overall elevated risk of
cancer (7, 8). Several mouse models showed that wild type tumors are accepted into
their immune dysregulated counterparts; however, many cancers that were developed in
a host with a dysfunction immune environment were rejected in the immunocompetent
mice (6, 9, 10). These data indicate that developing cancerous lesions are selected by
the immune system to acquire mechanisms to avoid immune destruction. These findings
helped lead to the current hypothesis of cancer surveillance, which proposes the lesion
will be either resolved, persist in equilibrium, or will escape immune regulation (2, 5).
Further involvement of the immune system in surveillance can be seen with oncogeneinduced senescence, whereby alterations of critical genes associated with tumorigenesis
can induce senescence (11-13). Oncogene-induced senescence can then further
promote immune clearance of potentially cancerous cells (11, 12, 14-16). With these
safeguard mechanisms in place, it begs the question of how cancer is allowed to prosper
in a healthy environment.

1.2 Altered metabolism as a critical hallmark of cancer
Metabolism is another critical hallmark of cancer, which can be reprogrammed by
critical genes involved in the transformation of malignant tissue (1, 17-20). Otto Warburg
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noticed the highly elevated rates of fermentation and believed that altered metabolism is
critical for cancer cell survival and must be a part of the first phase of the malignant
transformation (21). Indeed, many of the critical founding mutations for multiple cancers
are seen to alter the metabolic phenotype. This includes critical genes such as KRAS,
whereby oncogenic KRAS is seen to elevate rates of glucose uptake and metabolism,
increased channeling into the nonoxidative pentose phosphate pathway (PPP), and
promotes hexosamine biosynthesis (18, 22-24). Oncogenic KRAS mutations also can
reprogram metabolism through altering nucleotide biosynthesis, uptake and
consumption of fatty acids and amino acids, altering redox potential, and stimulates
autophagy and scavenging pathways. Interestingly, an inducible KRAS model showed
the ability to modulate the tumor immune environment, which includes alterations with
cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), which
was discovered to promote immunosuppressive recruitment of myeloid-derived
suppressor cells (MDSCs) to reduce CD8+ T cell-mediated cancer cell clearance (25,
26). Likewise, alterations with tumor suppressor TP53, which occurs in roughly 50% of
cancers, is seen to serve as a metabolic sensor that impacts nucleotide synthesis,
glycolysis, PPP, lipid, amino-acid, iron, and redox metabolism (27, 28). It has been
observed to influence the mitochondrial tricarboxylic acid cycle (TCA) and oxidative
phosphorylation, as well as playing a role with autophagy, AMP-activated protein kinase
(AMPK), protein kinase B (AKT), and mammalian target of rapamycin (mTOR) signaling
(27).
c-Myc is another important oncogene that a critical role in orchestrating the
means for proliferation by enabling cell division and metabolic reprogramming to support
it (29-31). As such, c-Myc is elevated in many chancers either directly through
amplification or by other signals fostering its expression. Although c-Myc is known to
promote glucose import and glycolysis, glutamine uptake and utilization, c-Myc also
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elevates the pathways that utilize these metabolites. This includes the elevated flux
through the PPP, glycine and serine production, nucleotide synthesis, elevated lipid and
cholesterol production, production of glutathione, and can promote mitochondrial
biogenesis. The metabolic reprogramming by c-Myc is so intense, it can promote
decreased utilization of glucose and generate greater production of lactate under
hypoxia (31). Furthermore, c-Myc enables the cancer cell to refill the TCA intermediates
under hypoxia and during glucose deprivation. It can even better enable proliferation in a
glucose depleted environment compared to an environment with glucose without the
induction of c-Myc. EGFR is another oncogene seen to enhance glycolysis, PPP, prime
pyrimidine biosynthesis, and support the redox state in cancer cells potentially
independent of the altered phosphorylation status of c-Myc (32). Lastly, retinoblastoma
is a critical tumor suppressor that is primarily known to regulate the cell cycle (33, 34).
Decreased retinoblastoma allows the cellular metabolism to overcome senescence‐
associated metabolism and revert the metabolism profile closer to what is seen in
proliferating cells, as seen by oxidative metabolism and partially by glycolysis (33).
Additionally, the retinoblastoma–E2 factor axis may indirectly regulate glycolytic,
oxidative, and glutamine usage through modulating the expression of Ras, c-Myc,
hypoxia-inducible factor 1-alpha (HIF-1α), AKT, and mTOR (34).
It stands to show that many of the critical founding genes to induce a malignant
cancerous transformation also promote a change in metabolism. It is theoretically
possible that a metabolic axis is responsible, in part, for the growth and immune escape
of cancer cells. Other mechanisms to induce growth and aggressiveness, aside from the
founding mutations, are also linked with a change in metabolism. One common feature
among a variety of cancers is the upregulation and de novo expression of mucins, which
are frequently observed to increase tumor aggressiveness and decreased prognosis for
the patients (35-38). For this reason, mucins and their frequent aberrant glycosylation
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are used as biomarkers for cancer, targeted pharmacologically, and as tumor-associated
antigens for vaccines (36, 39). Mucins are also seen to promote a glycolytic tumor
supporting metabolism to foster growth (40-43). One such critical mucin is mucin 1
(MUC1), which is capable of metabolically reprogramming the cancer cell to promote
glycolysis, PPP, fatty acid synthesis, and nucleotides through its cytoplasmic tail (41, 42,
44, 45). It can also decrease ER stress, alter mitochondrial activity, regulate autophagy,
modulate reactive oxygen species, and serves as a modulator of other critical
metabolism altering genes, such as TP53, c-Myc, and HIF-1α (41, 42, 44). Poorly
vascularized regions in cancer, such as those with a high degree of desmoplasia, can
cause an elevation in HIF-1α, which responds to hypoxia, pseudohypoxia caused by a
decrease in α‐ketoglutarate, elevated 2‐hydroxyglutarate, or buildup of downstream TCA
metabolites, and other hypoxia-independent mechanisms (42, 46, 47). HIF-1α can rewire the metabolism, by supporting glucose uptake and glycolysis, inhibiting oxidative
phosphorylation respiration metabolism, providing intermediates for the synthesis of
nucleotide and lipid metabolites, and a host of enzymes, including ecto-nucleoside
triphosphate diphosphohydrolase (CD39) and ecto-5'-nucleotidase (CD73) (42, 47-50).
Hence, changes in metabolism are not only seen as a predominant feature associated
with the founding transformation, but is also associated with common features promoting
its elevated aggressiveness. Therefore, it can be rationalized that metabolites play a
critical role with tumor initiation and progression.
1.3 Immune evasion through altered metabolites
Classically, it is believed that altered metabolism is promoted by tumors to
enhance the growth of the rapidly dividing cancer by supplying the energy and the
required biomass as building blocks. However, with the immune system continually
performing cancer surveillance in healthy individuals, it is possible that metabolic
alterations are selected upon, especially the alterations that can promote immune
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evasion. Interestingly, it appears that cancer cells are capable of utilizing metabolic
approaches to inhibit the inflammatory response.
Interferon (IFN)-γ-inducible indoleamine 2,3-dioxygenase (IDO) is a commonly
upregulated enzyme in multiple tumors and draining lymph nodes (51, 52). IDO
catalyzes the conversion of tryptophan to N-formyl-L-kynurenine, which is rapidly and
spontaneously decomposed to kynurenine (51, 53). Tryptophan is an essential and rare
amino acid comprising about 1% of amino acids in cellular proteins (53). Through local
depletion of tryptophan, it was observed to help starve bacteria to diminish infection (51,
53). However, IDO is seen to correlate with decreased T cell proliferation, decreased
activation, decreased Th17 polarization, increased tolerance, and elevated T cell
apoptosis (51, 52, 54). Furthermore, elevated Treg infiltration is seen, which might be
explained by the ability of IDO to stabilize Tregs, promote Tregs polarization, and to
enhance Treg suppressive functions (51, 52, 54). Additionally, IDO is seen to inhibit NK
cells (55). Mechanistically, this is believed to inhibit the mTOR kinase pathway and
through the activation of general control nonderepressible 2 (GCN2), an amino-acid
sensitive kinase, which can cause an arrest in proliferation (51, 54). However, it has
been recently reported that kynurenine may also contribute to the repressive
mechanism, as the addition of kynureninase prolonged survival and decreased volume
through a CD8 T cells mechanism, while the levels of tryptophan were unaltered (56).
Thus, kynurenine is another suppressive metabolite that is known to promote immune
suppressive mechanisms, including the promotion of Tregs.
Other amino-acid mechanisms exist in addition to IDO in order to regulate the
immune environment. One mechanism MDSCs can use to hinder tumor clearance is
through starving T cells of cysteine (57-59). T cells lack cystathionase and the SLC7A11
transporter for cystine, making them unable to convert methionine to cysteine and
unable to convert it from extracellular cystine, respectively. This makes cysteine an
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essential amino acid for T cells, while other cells, such as MDSCs, can uptake and
convert to make cysteine. MDSCs produce reactive oxygen species (ROS) and reactive
nitrogen species to promote their maintenance and proliferation, as well as hindering T
cells (55, 57, 58). To protect themselves from the ROS, MDSCs upregulate uptake
cysteine, the rate-limiting metabolite in producing the antioxidant glutathione (60, 61).
This ultimately leads to starving the T cells of cysteine (57, 59). Additionally, MDSCs can
deplete the environment of arginine to suppress T cells (57, 58, 62, 63). While arginine
can be synthesized de novo, it can be thought of as an essential amino acid in certain
physiological conditions (62). MDSCs have been observed to increase the cationic
amino acid transporter 2B and arginase-1 (Arg1), which drains the local environment of
arginine (57, 58, 62, 63). As a result, activated T cells decrease CD3ζ expression and
significantly decrease proliferation in reduced arginine environments and arrest in G0–
G1 phase when arginine is depleted. Like IDO, amino-acid deprivation is seen to act
through activating the kinase GCN2, which phosphorylates the eukaryotic translation
initiation factor (eIF) 2α to inhibit the ability of eIF2B to replenish the eIF2 complex with
guanosine triphosphate, ultimately inhibiting the initiation of translation (62). However, in
addition to the generation of ROS, reactive nitrogen species, and amino-acid
deprivation, MDSCs, cancer cells, and other components in the tumor microenvironment
can upregulate CD39 and CD73 to modulate the immune environment (57, 64-66).
1.4 Immunoregulatory properties of ATP and adenosine
Proinflammatory adenosine triphosphate (ATP) is converted to
immunosuppressive adenosine by CD39 and CD73 (64). CD39 contains the dual
function of hydrolyzing ATP to adenosine diphosphate and subsequently to adenosine
monophosphate (AMP), whereby CD73 quickly converts AMP to adenosine.
Alternatively, AMP can be generated for CD73 by the alternative pathway of NAD+
catabolism by CD38 and CD203a (67). Mice depleted of CD73 or CD39 show critical
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inflammation, which is mirrored by inhibition of adenosine receptors A2A or A2B that
also shows suppression of anti-inflammatory mechanisms (64, 65, 68-74). Several
notable sources of adenosine exist in cellular physiology, which includes release through
channels from stress, such as hypoxia and cellular death, and Tregs.
Hypoxia is known to increase ATP and adenosine and can impact the adenosine
axis at several levels (75-77). Hypoxia stabilizes HIF-1α to transcriptionally reprogram
the cell, including adenosine related components. CD39 and CD73 expression are
promoted in hypoxia, the latter of which has a confirmed hypoxia response element
(HRE) (50, 78). Additionally, the adenosine receptor A2A and A2B are promoted in
hypoxia and are also under HRE control. Low oxygen can increase ATP accumulation in
the extracellular environment utilizing pannexin-1, the most widely expressed pannexin
(79-82). In addition to low oxygen stress, pannexin-1 can release ATP in response to
stressed environments such as altered membrane stretch/strain and apoptosis. The
abundance of ATP in the environment subsequently alerts the immune cells of the
potential danger and stress.
ATP promotes an inflammatory environment, which must be carefully regulated
to prevent the issues associated with chronic inflammation (64, 70). Immune cells, such
as macrophages, neutrophils, and dendritic cells (DCs), are recruited in response to the
increased ATP, and slowly convert it to adenosine in a negative feedback mechanism,
which is seen to inhibit their function and promote anti-inflammatory functions (83-98).
Anti-inflammatory Tregs are also controlled in part by extracellular ATP, as seen through
the purinoceptor P2X7, which has been shown to repress the suppressive ability of
Tregs, decrease Foxp3, and when in the presence of IL-6, promote a Th17 signature
(99). Tregs can also express high levels of CD39 and CD73 to quickly convert
proinflammatory ATP to adenosine, which is utilized by Tregs to expand and increase
their immunosuppressive activity in a fearful positive feedback mechanism (65, 66, 100,
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101). Tregs also serve as a surprisingly large source of ATP, which apoptotic Tregs
release and can be quickly converted to adenosine in a mechanism observed to be more
immunosuppressive than living Tregs in vivo and in vitro (102). By degrading ATP and
generating adenosine, T-regs can abolish signaling through the T cell receptor (TCR)
and can hamper the T cell ATP autocrine feedback loop used in part to sustain activity
(66, 100). Tregs can, therefore, modulate T cell activation simply through the regulation
and use of external metabolites, which demonstrates the power that metabolism has on
immune function.
1.5 Immunoregulatory mechanisms of ATP and adenosine
The dichotomous role of ATP and adenosine and their control over the immune
response can be greatly visualized by their impact in T cells (Figure 1.1). Adenosine’s
mechanism of action is similar to other infamous anti-inflammatory molecules, such as
prostaglandin E2, histamine, and epinephrine, whereby cyclic adenosine
monophosphate (cAMP) is elevated upon agonist stimulation to promote protein kinase
A (PKA) signaling to ablate TCR signaling and inhibit nuclear localization of nuclear
factor of activated T cells (NFAT) (103, 104). Elevated levels of cAMP will also hinder T
cell proliferation (105). The cAMP pathway is one of the reasons why secondary
stimulation of CD28 by antigen-presenting cells (APCs) is critical for a full response, as it
can decrease the inhibitory cAMP elevation (103, 106).
TCR binding to its antigen on a major histocompatibility complex II is known to
readily elevate localized concentrations of cAMP within the lipid raft (103, 106, 107).
Without further co-stimulation through CD28, cAMP through PKA will ablate the
signaling. This pathway is carried out by cAMP binding to the regulatory units of PKA
localized to the TCR lipid raft by A-kinase anchoring proteins (AKAP) and allowing the
catalytic units of PKA to phosphorylate C-terminal Src kinase (Csk) anchored to
phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG/Cbp)

10
(103, 107-109). PKA activation of Csk allows for the inhibitory phosphorylation of
lymphocyte-specific protein tyrosine kinase (Lck), which localizes to CD4 and CD8. Lck
is needed to carry out the response of bound CD4 or CD8 to the TCR complex, as Lck
carries out the double phosphorylation of the immunoreceptor tyrosine-based activation
motifs (ITAMs) present on CD3ζ for zeta-chain-associated protein kinase 70 (ZAP-70) to
bind. ZAP-70 can then further propagate the TCR signal through phosphorylation of
linker for activation of T cells (LAT) to allow binding for multiple proteins, including the
adaptor SLP-76 and its direct phosphorylation (110-113). This large complex binds and
initiates several factors, including interleukin-2 tyrosine kinase (Itk), which ultimately
promotes phospholipase C gamma 1 (PLCγ1) to convert lipid phosphatidylinositol-4,5bisphosphate (PIP2) to the second messengers diacylglycerol (DAG) and inositol 1,4,5trisphosphate (IP3) (108, 110, 111, 113, 114).
DAG and IP3 can further potentiate the activation signal and control NFAT
through two independent mechanisms (103, 108). Control over the dephosphorylation of
NFAT is critical, as it can localize to the nucleus where it can carry out critical roles in the
T cell, such as regulating T cell activation, differentiation, and functions, such as cytokine
secretion and metabolic reprogramming (115-119). In addition to the PKA inhibitory
phosphorylation of NFAT, PLCγ1 converted DAG allows plasma membrane localization
of nearby CD28 to Ca2+-independent protein kinase C-theta (PKCθ), upon which binding
of DAG exposes the activation loop for further activation by the germinal-center kinaselike kinase (GLK) (103, 107, 119-122). PKCθ phosphorylation can induce a variety of
events, including migration to the nucleus to indirectly bind to the promoters of immune
response genes and microRNAs, activation of NF-κB and activation protein-1 (AP-1),
and increasing NFAT activity (108, 120, 123-125). Although PKCθ is seen to have a role
with modulating NFAT, there appears to be a Ca2+-dependent mechanism which can
also synergize with the NFAT phosphatase calcineurin (124-130). Through a series of
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mechanisms, PLCγ1 induces IP3 to ultimately elevate intracellular levels of Ca2+, which
can stimulate calcineurin dephosphorylation of NFAT (103, 108, 131-134).
Additionally, Ca2+ can cause the mitochondria to increase the rate of ATP
synthesis, which is critical for the future energy demand of a T cell engaged with its
cognate antigen (135). After TCR engagement, ATP is rapidly increased and is required
for full Ca2+ release and T cell functionality (136). Some of the additional ATP is secreted
into the extracellular matrix in an autocrine manner through pannexin-1 (135, 137). Here,
ATP can bind to the P2X7 receptor to further activate pannexin-1, elevate Ca2+, and
increase glycolysis to elevate ATP in a feed-forward mechanism to assist the T cell with
energetic demands to deal with the cognate antigen (135-139). P2X7 receptor has also
been found to increase T cell functions other than metabolism (136, 137). Stemming
from Ca2+ induction of ATP increase, this autocrine feed-forward mechanism is seen to
have memory of this event as seen by having a long-lasting metabolic reprogramming
after the TCR engagement has ended (135, 137). The signaling by the adenosine
receptor also seems to show memory of the activation and can result in long-lasting
inhibition of TCR signaling, hyporesponsiveness, and anergy (140-143). Thus, ATP and
adenosine are critical components in activating and maintaining T cells.
1.6 Scope of the dissertation
The immune system contains the ability to regulate and abolish cancer cells.
Therefore, theoretically, for cancer to occur, this control must be disrupted. Metabolic
alterations are a hallmark of cancer that are triggered during the founding mutations,
enhanced through progression, and can influence the immune system. These
mechanisms can potentially disrupt the immune system and allow for immune evasion.
Therefore, I hypothesize that the metabolic status of the tumor microenvironment can
alter the immune landscape. To examine this underexplored area, the frequently altered
family of mucins, which can influence metabolism and immunity, were explored
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bioinformatically for leads. MUC1 was discovered to be the most expressed mucin
mRNA across the multiple cancers examined and was observed to be significantly
overexpressed in pancreatic cancer, where it is frequently mutated compared to other
cancers. Given that MUC1 can metabolically reprogram cancer cells, enzymes
contributing to significant survival differences were examined for the top enzymatic lead
to test the immune impact (42). Finally, following the polar opposite mucin mRNA
differences with esophageal cancer, the metabolic alterations were examined along with
the predicted immune impact. At the end of the dissertation, I have provided a future
outlook on potential areas for further exploration.
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Figure 1.1:
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Figure 1.1: The adenosine receptor and downstream cAMP is critical for the
effects of signal 1 and 2 on T cell activation and the ATP that is utilized to sustain
the signal. Signal 1 is propagated by the T cell receptor, a complex of CD3 subunits, but
can be abolished by the accumulation of cyclic adenosine monophosphate (cAMP),
which can be promoted by the adenosine receptor. The adenosine receptor A2A is a Gprotein-coupled receptor, which can bind to Gα and Gβγ subunits, and releases the
adenylyl cyclase (AC) stimulatory Gα (Gαs) upon binding adenosine. AC promotes the
conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate
(cAMP). Nearby A-kinase anchoring protein (AKAP) houses protein kinase A (PKA),
which releases catalytic PKA upon cAMP binding to the regulatory subunits of PKA.
Catalytic PKA can phosphorylate C-terminal src kinase (Csk), which is localized via
phosphoprotein membrane anchor with glycosphingolipid microdomains, which is also
known as csk-binding protein (PAG/Cbp). Csk can then perform an inhibitory
phosphorylation on lymphocyte-specific protein tyrosine kinase (Lck), which is brought
over to the T cell receptor (TCR) complex via CD4 or CD8 when it binds to the major
histocompatibility complex class II (MHCII). Lck phosphorylates of the immunoreceptor
tyrosine-based activation motifs (ITAMs) on CD3ζ, which is needed for zeta-chainassociated protein kinase 70 (ZAP-70) to bind. ZAP-70. ZAP-70 can phosphorylate SH2
Domain-Containing Leukocyte Protein Of 76 KDa (SLP-76), which through
intermediates, ultimately activates phospholipase C gamma 1 (PLCγ1). PLCγ1 can
convert phosphatidylinositol-4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3)
and diacylglycerol (DAG). DAG allows kinase C-theta (PKCθ) phosphorylation, which
promotes the nuclear localization of the nuclear factor of activated T cells (NFAT), as
well promoting the activator protein 1 (AP-1) and the nuclear factor kappa-light-chainenhancer of activated B cells (NF-κB) complex. PKCθ can also initiate a chain of events
that leads to the endoplasmic reticulum releasing calcium (Ca2+) that can be uptaken by
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the mitochondria to stimulate the production of adenosine triphosphate (ATP) from
adenosine diphosphate (ADP). Ca2+ can also promote calcineurin, which among many
things, can promote nuclear localization of NFAT. Signal 2 occurs after signal 1 to
ensure an antigen presenting cell is inducing activation. This is done by CD80 or CD86
binding and activating the co-stimulatory receptor CD28, which can allow
phosphoinositide 3-kinase (PI3K) to produce phosphatidylinositol (3,4,5)-trisphosphate
(PIP3). PIP3 is bound by protein kinase B (PKB), which allows a complex of β-arrestin
and phosphodiesterase-4 (PDE4). PDE4 can degrade cAMP into 5' adenosine
monophosphate. Thus, signal 2 can allow signal 1 to proceed without the inhibitory
cAMP from blocking the TCR complex. The elevated Ca2+ and ATP can promote ATP
flux by pannexin-1 into the extracellular matrix, which can then stimulate purinergic
receptor P2X 7 (P2X7), purinergic receptor P2X 4 (P2X4), and purinergic receptor
P2Y11 (P2Y11) in an autocrine fashion. P2X7 and P2X4 can help maintain the high
levels of ATP and Ca2+.

16
Chapter 2: Genomic profiling of the mucin family across cancers
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Introduction
Mucin-based biomarkers have been utilized in clinic for multiple cancers,
highlighting the functional significance of mucins in cancer (144, 145). Mucins display
altered expression and abnormal glycosylation in early and late stages of cancer (146148). Multiple membrane-tethered mucins associate with malignant potential and a poor
prognosis, while secreted mucins correlate with an improved prognosis (149). A number
of mucin family members have been discovered to possess signaling potential of great
significance. MUC1, the most studied mucin that is involved in the pathogenesis of the
multiple cancer types, serves as a scaffold, a signaling adaptor, a transcriptional coactivator, and a metabolic and immune regulator (41, 150, 151). It triggers intracellular
signaling, leading to transcriptional changes in the nucleus, in response to alterations in
the extracellular microenvironment of the tumor cells (150, 152). MUC1 intracellular
signaling impinges upon a plethora of signaling pathways, including MAPK, NF-B, JAKSTAT, HIF, Wnt, p53, ERα, and c-Src (147, 153). Depending on the cellular context and
growth cues in extracellular microenvironments, MUC1 also regulates a variety of
cellular responses such as growth, differentiation, apoptosis, cell fate, oxidative stress
death protection, immunosurveillance, adhesion, polarity, inflammation, colonization, and
metabolism (41, 150, 151, 154). MUC1 expression correlates with poor prognosis (155,
156). MUC4 is another well-studied mucin that possesses signaling capabilities mainly
by allowing increased signaling through ErbB2 (147). MUC4 expression is associated
with proliferation, blocking apoptosis, metastasis, and gemcitabine resistance. Hence, it
is no surprise that the increased expression of MUC4 is seen in several types of cancer
and associates with poor prognosis (157). MUC13 is another transmembrane mucin that
negatively impacts ovarian cancer patient survival, observed to have roles in increasing
cancer cell motility and proliferation (153). Contrary to these cancer-promoting mucins,
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MUC2 interacts with inflammatory pathways and helps protect against tumor
development (153).
Due to the aberrant expression, signaling regulation and glycosylation of mucins
in cancer, mucins have been explored as biomarkers (144, 145, 148, 158). MUC16
(CA125) is a well-known ovarian cancer marker upregulated in >80% of cases (147) and
serves as a FDA-approved marker for ovarian relapse (146). It is a possible predictor of
prognosis in pancreatic cancer, which also display an aberrant increase in MUC16 (144,
159). MUC1 expression is commonly altered; it is seen abnormally expressed in
approximately 900,000 of 1.4 million tumors diagnosed in the United States each year
(153). CA19-9 and DU-PAN2 are clinically used markers for MUC1 in pancreatic cancers
with the former being FDA approved (146). N-terminal fragments of MUC1 can be
detected in the serum of pancreatic cancer patients by the CA15-3 serum assay, and
MUC1 expression together with serum levels are associated with a poor prognosis and
recurrence in resected patients (156). MUC21 may be a good candidate diagnostic
biomarker for lung adenocarcinomas (160).
Aside from diagnosis, mucins also serve as markers for aggressive behavior in
cancer (153). In breast cancer, secreted mucins correlate with tumor size, stage,
survival, and metastatic potential, while expression of membrane mucins correlate with
grade, vascular invasion, metastasis spread, and recurrence (161). MUC1 is associated
with invasion and metastasis in several tumors (149). MUC3 expression correlates with
a poor prognosis and tumor size, invasion, and metastasis (146). MUC4 associates with
poor prognosis in several cancer types and may serve as a potential marker for
pancreatic cancer (147, 152, 153, 157). Contrastingly, high expression of MUC5AC
correlates with an increased survival (146), while high MUC1 expression is beneficial in
gastric carcinoma prognosis (162). These studies show the importance of mucins in
cancer while highlighting existing differences in cancers that need to be addressed.
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Different cancers utilize a variety of mucins that may impact prognosis through
multiple mechanisms. These mucins have been utilized as biomarkers and as
vaccination targets (146, 157). However, differences in the roles played by mucin genes
have been observed across cancers, with many mucins being understudied.
Furthermore, the complete landscape of genomic alterations of mucin has not been
studied in many cancers and histological subtypes. Hence, we undertook a pan-mucin
genomic study across multiple cancers to investigate potential new avenues and to
discover new alterations that may impact the mucin functions in cancers. These tissues
include cancers of the breast, bladder, colon, esophagus, kidney, lung, ovary, pancreas,
rectum, stomach, and uterine corpus. Furthermore, we explored multiple genomic roles,
such as DNA mutations, mRNA expression, copy number, methylation, de novo
expression and silencing, and examined if these alterations significantly impact survival.
Methods
TCGA data retrieval
TCGA clinical files, mRNA, copy number, and methylation were downloaded
using the TCGA Data Matrix on 10/5/15. DNA mutation oncotated files mapped to the
human genome assembly 19 (hg19) coordinates were downloaded from firebrowse.org
(4) on 11/16/15.
Clinical Attributes
Tailored regular expressions were formed for each of the cancer’s clinical patient
files, in which the information was stored in a new master spread sheet for all
downstream processes. Patients with unclear histological subtypes or pathologic tumor
staging were removed. Breast cancer histology was formed utilizing the IHC positive and
negative results. Stages were aggregated based only on their numerical value. Patients
with attributes for both last follow up and days to death had days to death utilized instead
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of last follow up. Smoking status, age, ethnic origins were recorded as well. All data
analyses utilized here were performed with Perl5 version 16.3 (www.perl.org) and
statistical calculations were performed in R version 3.1.3 (www. www.r-project.org).
DNA Mutation Analysis
Utilizing only the primary tumor data of patients with clinical attributes as
mentioned above, mutation annotation format (MAF) files had all patients of the same
cancer, histology, and stage merged together and tracked by the patient identifier.
Duplicates MAF entries, such as the same patient having whole genome and whole
exome sequencing information, were unified into a single entry. Mutations were
examined for false positives by examining against the reference base(s) as well as all
available normal and resequenced tumor tissue before storing the data into merged
MAFs and generating Annovar files through perl.
SNVs were annotated by Annovar, version release Mar 22, 2015 (163). Annovar
output was traced back to the original patient. The aggregate MAF file by histology and
stage were then extracted for calculating frequencies. When examining the aggregated
MAF file, if a nonsynonymous mutation was observed, the damaging status was
examined against Annovar’s output, which utilized MetaLR prediction to make a
damaging prediction (164). Perl then generated files in formats to be visualized in
Microsoft Excel 2013, GraphPad Prism 5 (GraphPad Software Inc., CA, USA), and
MutationMapper (165, 166). TCGA coordinates were used in MutationMapper; however,
coordinates in mutation mapper may disagree. Due to this reason, MUC16 appears
truncated and the x-axis of MUC4 was extended to meet the last amino acid in the
TCGA coordinates.
Mutation Survival
Aggregate MAFs, based on the same tumor, histology, and stage, were
examined for non-silent mutations, which had at least two patients with mutations
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occurring at the same spot. For mutations impacting more than one base, only the first 5’
base was examined. Only mutations of interest were then examined by both R survival
library and Prism 5 utilized files generated by Perl.
mRNA, Copy Number, and Methylation Status Analysis
Only primary tumor data was analyzed and was compared to normal samples in
the same TCGA category (e.g., KIRC and KIRP were considered separate). A minimum
of two samples was required for a Mann-Whitney test in R for mRNA and copy number
and three samples for methylation. Methylation utilized either a 450K methylation chip or
a 27K chip for ovarian and stomach cancers, which had poor 450K chip sample size on
the date downloaded. In the event the TCGA analyzed a patient’s sample for methylation
more than once, the vial closest to the first extraction was used. Transcription start and
stop sites were obtained from the University of California Santa Cruz (UCSC) hg19 table
browser and analyzed for the longest 5’ and 3’ coordinates and omitted any transcript
coordinates that have not been verified. These gene coordinates were used for
determining copy number and methylation locations. Methylation analysis was
performed to examine all methylation locations for all bases starting from the
transcription start site and up to and including the 5,000th base upstream. Copy number
analysis was performed by first splitting data into histological subtypes and stages and
then examining probe intensities utilizing equal weights per probe and per distance.
Should the probe extend past the gene, the probe’s distance was adjusted to meet only
the span it covered on the gene. In another words, a segment mean was multiplied by
the distance the probe covered and was divided by total distance. This score was
multiplied by the number of probes with the segmean score and divided by all possible
probes that cover the gene. The total sum of the segmean scores within the promoter
area was multiplied by the number of total segments examined. Two to the power of this
score was taken and this was multiplied by 2. Should the score deviate at least 0.5 away
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from 2.0, a score representing two copies, it was considered altered. Gene expression
was log2 (x + 1) scaled. Perl generated data to be visualized in Prism as well as R.
Heatmaps were constructed using R package gplots. MUC3A, MUC5AC, MUC19 and
MUC22 were not included due to the TCGA annotation file not including these genes.
De novo expression and silencing
To examine if the percentage of gene expression turning on/off was significant, a
Fisher’s exact test with independence was utilized. To maintain independence, the same
patient could not have their normal non-cancerous tissue and tumor mRNA analyzed
together. Therefore, four categories were made for each histological subtype and stage
specific grouping: expression or no expression for both normal and cancer samples. The
category size for patients with only cancer examined was first counted, then normal
tissues were counted. Our aim was to make as even sample categories as possible.
Therefore, if a patient had both normal and cancer data, the patient was retained in the
smaller group (normal or cancer) for comparisons. Normal group received the patient if
the sample sizes were equal. Patient identifiers were thus sorted into cancer or normal
groups in order of alphanumerical sort comparison in Perl. At the very end of group
assignment, the mRNA levels were examined to assess if the patient had or did not have
expression. These groups were then examined by the Perl module
Text::NSP::Measures::2D::Fisher2::twotailed. Graphpad Prism 5 tested if mRNA levels
were different using Kruskal-Wallis test and a Dunns post hoc test to prevent the
assumption of a Gaussian distribution.
Statistical Analysis
Survival is defined as the time from diagnosis to death on each patient. The logrank test was used to compare the survival between groups. Both the univariate and
multivariate Cox-proportional hazard regressions were used to evaluate the associations
between the copy number, methylation, log2 scaled mRNA expression levels with the
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survival of each patient (167). The confounding effects of age, cancer stage (stages 1
and 2 vs. stages 3 and 4), and smoking status when available (smoking history vs. no
smoking history) was adjusted in all multivariate Cox-proportional hazard regression
models. All Cox proportional hazard analyses were restricted to cohorts in which at least
five patients experienced death events, and have at least five patients in each of the
categories defined based on the cancer stage or smoking status when adjusted in the
model. The Benjamini-Hochberg method was used to control the false discovery rate for
each site for multiple comparisons (168).
Results
Mutation patterns across 11 mucin-expressing tissues
Mucins vary considerably in gene size, but when controlling for gene length,
distinct mutation rates for individual mucins appear across different tissues and
histological cohorts. For normalizing mutations with gene length, we divided the total
number of mutations by the number of sequenced patients and then divided by the
largest transcript length reported by UCSC from the human genome assembly 19 (hg19)
to compare mutation rates relative to size. The rate of mutations varies from mucin to
mucin depending on the histological cohort (Figures 2.1A, 2.1B, and Dataset 2.1). Full
cohort information, acronyms, and sizes can be found in Table 2.1. Kidney renal
papillary cell carcinoma (KIRP) shows the largest relative mutation rate for MUC2, while
no other histological subtypes appear to favor MUC2 mutations to a similar degree
(Figure 2.1C). Furthermore, only KIRP shows a strong mutational preference towards
MUC2 and a marginal background mutation rate towards other mucins, suggesting the
high mutation rate is not due to a high mutational rate in this cohort. Like KIRP, kidney
renal clear cell carcinoma (KIRC) trends with lower rate of mucin mutations, except for
MUC4, which shows a cluster of in-frame deletions for KIRC (Figure 2.1D).
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Uterine corpus endometrioid endometrial adenocarcinoma (UEC) appears to
acquire more mutations in multiple mucins, including MUC5B and MUC17, which
becomes very prominent in stage III (Figures 2.1A, 2.1B, and Dataset 2.1). UEC tumors
also have mutations in other mucins, such as MUC4 and MUC16, however, the mutation
rates are much lower (Figures 2.1D and 2.1E). Uterine serous endometrial
adenocarcinoma (USEC) does not appear to show a similar mutational rate for mucins
(Dataset 2.1 and Table 2.2). A few notable examples also include MUC6 and stomach
adenocarcinoma not otherwise specified (STA NOS) (Dataset 2.2). Lung squamous cell
carcinoma (LUSC) and lung adenocarcinoma (LUAD) share MUC16 and MUC17
mutations at a similar rate between the histological subtypes. Lastly, despite many
cancers observed not to harbor mutations in MUC12 and MUC19, breast cancer
appears to have a unique profile.
Mutations across mucins
Examining the types of mutations and their rates may help decipher the biological
significance. Furthermore, location specific mutations may indicate a significant role of
the residue or protein domain(s) in cancer pathogenesis. We discovered distinct
mutation profiles for mucins, which associated with certain tissue and histological
subtypes. A total of five tissues were observed with MUC1 mutations (Table 2.2). Nonpapillary bladder cancer, pancreatic ductal adenocarcinomas (PDAC), and stomach
intestinal adenocarcinoma not otherwise specified (SIA NOS) were the only tissues that
were observed to have MUC1 mutation(s) at stage II cancer (Figures 2.2A and Table
2.2). Half of stage II PDAC MUC1 mutations are T112P. Altogether, 5/8 of stage II
MUC1 mutations are T112P and 31.25% of MUC1 mutations observed in all stages were
T112P. MUC2 mutations increase with the increasing disease stage in KIRP, appearing
in 9.5% of stage I KIRP (n = 95) and up to 50% of stage IV KIRP cancers (n = 10). Most
of these mutations are non-structurally damaging non-synonymous mutations (Dataset
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2.2). MUC2 shows a large cluster of mutations with a Gaussian distribution across
tissues with the mode at T1538 (Figure 2.2B). Many of the multiple mutations appear to
target threonine and appear to include multiple silent mutations, perhaps suggesting a
role of the region in regulating transcription, mRNA stability, or non-coding RNAs. Amino
acid changes observed in more than one patient in the cluster spanning from residues
1353-1652 target the threonine codon in over 85% of the cases. Within this dense
cluster, three non-damaging T1488P mutations are observed in KIRP, while three
T1568M mutations are observed once in KIRP, rectal adenocarcinoma (READ), and
UEC. UEC has a large percent of the MUC3A mutations with 11 out of the 35 of the
mutations in MUC3A, of which, over a third of the UEC mutations occur at S207, with
two in-frame insertions and one non-synonymous mutation (Table 2.2 and Dataset 2.2).
The mutation pattern on MUC4 suggests that it might play a functional role in
KIRC pathogenesis (Figure 2.2C and Table 2.2). MUC4 in frame deletions appear in a
large fraction (2.9%-5.4%) for KIRC. Furthermore, compared to silent mutations, nondamaging MUC4 mutations are drastically increased in KIRC, resulting in amino acid
changing mutations to be 19.8% in stage I (n = 197), 35.0% in stage II (n = 40), 32.2% in
stage III (n = 112), and 44.1% in stage IV (n = 68). UEC also has an increased rate of
non-damaging mutations for MUC4 that increase with the increasing stages, ultimately
resulting in 41.4% single nucleotide variation (SNVs) mutations in stage III (n = 29)
(Figure 2.1D). This dataset reveals all 10 H4205Q MUC4 mutations occur as 10 G<C;
half of which are from KIRC, three from bladder cancer, and two from LUAD (Figure
2.2C and Table 2.2). In KIRC, high rates of in-frame deletions occur compared to other
tissues for MUC4 (Figure 2.2C and Table 2.2). Seven different locations were observed
to have an in-frame deletion that was identical to another in-frame deletion observed in
another patient (Table 2.2). Only an in-frame insertion of serine at 2026 was seen to
match for other tissues, which includes two occurrences in LUSC and once in colon
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adenocarcinoma (COAD), but was not observed in KIRC. There are eight locations in
which the same resulting amino acid change is observed three times, half of which are
only seen in KIRC. Lastly, multiple positions in MUC4 had at least two mutations at the
same position, which overall suggests a role of mutations in MUC4, especially in KIRC.
MUC5B is another large mucin gene that is mutated the most in UEC with 30.9%,
46.7% and 79.3% amino acid changing mutations in stages I-III (Table 2.2 and Dataset
2.2). Mutations appear evenly spread; however, KIRP shows three D682G mutations,
while T4373 shows four deletions, two of which are in-frame that are observed in PDAC,
with the remaining in UEC and KIRC (Table 2.2, Dataset 2.2, and Figure 2.3). MUC6 has
a relatively high mutation rate in stage II PDAC, where 9.6% (n =114) of the mutations
caused amino acid changes, while no silent mutations were discovered. Furthermore,
breast invasive carcinoma (BRCA) harbors three frameshift insertions at L2241, while
KIRC has two at P1570. Low frequency of silent mutations were observed with MUC7.
Three of the seven non-damaging UEC stage I (n =149) mutations were found to be
S336L in MUC7.
Despite its length, MUC12 has a very interesting mutation pattern that is not
readily apparent along with a few interesting locations. A wide range of mutations in
MUC12 have been found to associate with many BRCA histological subtypes as well as
UEC. Most striking is estrogen-receptor and progesterone-receptor-positive BRCA stage II (n = 279) with 12.2% patient tumors having amino acid altering mutations.
Furthermore, UEC has a high mutation rate with 13.5% in stage I (n = 149) and 31.0% (n
= 29) in stage III. Most strikingly, multiple mutations appear to target arginine (R) in
BRCA, where it is converted into either cysteine (C) or histidine (H). This is exemplified
with the four BRCA mutations occurring at R1220, in which three arginines change to
histidines, while the remaining one becomes a cysteine. Another event is seen at R2777
in BRCA, in which two mutations result in histidine and one becomes cysteine. Lastly,
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three A1933 frame shift insertions and three P4621T mutations and were observed in
BRCA. Despite the low mutation rate, this suggests a possible connection between
MUC12 and BRCA, as the mutations appear low in most tissues except for BRCA and
uterine corpus endometrial carcinoma (UCEC).
MUC16 is a very large transmembrane protein whose mutation rate is relatively
high in COAD and colon mucinous adenocarcinoma (COMA) cancers, LUAD, bladder
urothelial carcinoma (BLCA), PDAC, and UEC (Figure 2.1E). Non-damaging
nonsynonymous mutations occur in 62.5% of stage II COAD, which is 3.3-fold higher
than silent mutations. Stage II COMA has 13 amino acid alerting mutations in 8
specimens, a mutation rate of 1.63 mutations per patient, which is 2.2-fold higher than
the silent mutation rate. Stage I READ has twice as many samples and sees a similar
mutational rate of 1.63 mutations per patient. LUAD shows a high but roughly flat amino
acid damaging mutation rates of 67.7%, 73.5%, 72.9%, and 66.7% across stages I-IV,
respectively. LUAD shows a trend of increased nonsense mutations in MUC16. UEC
shows a high degree of nonsense mutations as well. In the case of PDAC, 43.0% of
specimens have amino acid altering mutations, with 14.9% of these mutations resulting
in frameshifts or deletions. Oddly, 7/17 silent mutations seen in PDAC stage II all occur
at the same base (chr19: 9090831) in an A>G manner (Table 2.2), which was observed
by The Exome Aggregation Consortium on 12/4/2015 to occur in 1/120,714 samples, but
only in an A>C manner (169). In other cancers, R8606 has four amino acid changing
mutations (Table 2.2).
MUC20 mutations do not appear to be common, only three A515 frameshift
deletions standout (Table 2.2 and Figure 2.3). MUC13 also has a very low mutation
profile with three R324W SNVs and two S185 amino acid altering mutations predicted to
be damaging. The same holds true for MUC15, with perhaps two mutations at S91L
being of mild interest.
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Frequent mutations of interest were casually examined for possible impact on
survival for when there was more than one mutation residing in the same stage within
the same histology. Since half of the MUC1 mutations in stage II PDAC specimens had
mutations at T112P in MUC1 (Figure 2.2A, Table 2.2), we examined the mutational
impact on survival in the cohort. Unfortunately, examining T112P survival shows that the
patients with these mutations have not been enrolled long enough in the TCGA program
to generate meaningful statistics, as all three patients had early-censored events (Figure
2.4A). The observation of a very common mutation at H4205Q in MUC4 (Figure 2.2C)
caused us to further examine the impact of MUC4 mutations on patient survival (Figure
2.4B). Despite high occurrences, these mutations appear to improve survival of the
patient in stage III KIRC (Figure 2.4B). A significant change was not observed in stage I
KIRC. Further examination of the impact of MUC4 mutations on patient survival
highlights that not all mutations in a gene are potentially beneficial to the patient. A
nearly significant (p=0.0795) in-frame mutation at 4045 is associated with increased
aggressive behavior of the tumor, while all other mutations appeared to have improved
survival compared to patients without MUC4 mutations in KIRC stage I patients (Figure
2.4C).
Mucin mRNA expression in cancer
Primary solid tumor mRNA expression data were separated by tissue, histology,
and stage and were compared to the respective normal non-cancerous tissues. In
comparison to the normal tissue, no change in mucin expression was observed to be
unilaterally altered in the same direction through all tissues, which highlights the
importance of the tissue origin (Figures 2.5A and 2.5B). MUC1 has very high expression
compared to the other mucins in cancerous tissues examined, except for a minor
decrease in expression in the colorectal cancers (Figure 2.6). MUCL1 shows high
expression in stomach cancer, especially in SIA NOS where up to 16.5-fold changes
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were observed. Colorectal cancers are the only tissues to display a significant decrease
in MUC2 (Figure 2.5A). MUC2 shows an interesting role with esophageal histological
subtypes, showing a significant 5.5-7.1 fold increase for esophagus adenocarcinoma not
otherwise specified (EA NOS) in comparison to esophagus squamous cell carcinoma
(ESCA), where the latter showed no significant change. Only four of the mucins
examined showed similar trends in expression changes between ESCA and EA NOS
when significant. Like the esophageal histological subtypes, distinct mucin expression
profiles were observed in the lung histological subtypes, LUSC and LUAD, as 9/15
mucins show a contrary trend in the significantly altered mRNA profiles. Contrastingly,
KIRP and KIRC have very similar mucin expression profiles between the histological
subtypes, only disagreeing in the in the regulation of MUC4 and MUC17. We observed a
very strong distinction in the expression of MUC17 between KIRP and KIRC. KIRC
shows a dramatic increase in MUC17 expression, ranging from 15.4 to 29.4 fold change,
while MUC17 expression is not significantly altered in KIRP. Despite MUC17 appearing
to be turned off in multiple breast cancer histological subtypes, several cohorts suffer
from weak sample size (Table 2.1). Significant decreases in MUC6 was observed in
ESCA ranging from -3.8 to -5.4 fold, while no significant change was observed in ES
NOS. MUC7 appears to have little to no expression in many cancer tissues (Figure 2.5).
Examining a possible role with altered expression of MUC7 is further confounded by
small sample sizes of different histological subtypes in multiple cancers, including BRCA
and stomach cancers cohorts (Table 2.1 and Figure 2.7). A drastic fold change in MUC7
expression is seen in LUSC, ranging from 10.0 to 15.3-fold chance when significant, but
this is attributed to the little-to-no expression of MUC7 in normal tissue, as only 1/51
normal specimens had detectable expression after normalization. MUC15 primarily
shows a widespread decreased expression in cancers compared to normal, particularly
strong in KIRC and KIRP, where the expression change ranges from -6.6 to -15.5-fold
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(Figure 2.5). Contrastingly, COAD shows significant MUC15 expression increase, which
ranges from 7.2 to 20.2 fold when significant. KIRC and KIRP also share a slight 3.7 to
5.7-fold increase in MUC12 expression.
De novo expression and silencing of mucins in cancer
Mucins are currently being utilized as cancer diagnostic biomarkers; therefore,
we sought to explore mucin mRNA profiles for de novo expression or silencing in
tumors. This endeavor discovered MUC21 to have significant de novo expression, as the
normalized expression was not observed in any of the normal colon (n = 41) or rectal
tissue (n = 39), but was seen to increase in COAD and READ (Figures 2.8A and 2.8C;
Table 2.3). COMA demonstrates an induction of MUC15 (Figure 2.8B), as 34 of 41
adjacent non-cancerous samples do not have expression of MUC15 after normalization.
Stage I COMA has zero samples (n = 5) with noticeable expression of MUC15 , while
the percentage of stage II-IV patients expressing MUC15 increased (6 of 14, 10 of 14,
and 4 of 4, respectively) and had strong expression ranging from 7.2 to 20.2 fold
increase compared to normal adjacent tissue. COAD patients had a relatively modest
change in MUC15 (Figure 2.8E). Of note, significant impact of mucin mRNA expression
changes on survival is seen mainly in the kidney in both univariate and multivariate
analyses when corrected for false discovery rate (Table 2.4). Effect of MUC21
expression increase on survival was significant in both univariate (q=0.005) and multiple
regression (q=0.003) showing a hazard ratio (HR) of 1.9 and 2.1 respectively, although
only for KIRP, which may signify an underlying harmful role of MUC21 functioning in
cancer.
In contrast to the increased MUC15 expression in COMA and COAD (Figures
2.8B and 2.8E), we observed expression silencing for MUC15 in kidney histological
subtypes KIRP and KIRC (Figures 2.8D and 2.8F). There is also a questionable status of
MUC7 expression in BRCA, in which most histological subtypes appear to have some
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specimens without MUC7 expression after normalization; however, triple negative breast
cancer and low sample size confounds the analysis of MUC7 in BRCA (Table 2.1 and
Figure 2.7). Furthermore, MUCL1 expression is significantly induced in ESCA; however,
a small fraction of normal tissues also express MUCL1 when normalized (Figure 2.8G).
Mucin copy number in cancer
Next we assessed somatic copy number alterations (SCNAs) and conservatively
examined for SCNA occurrence by evaluating the median copy number. Here we report
frequent copy number gains in MUC1 and the locus 3q29 containing MUC4 and MUC20
(Figure 2.9A and 2.9B). MUC1 copy gain state predominates for several cohorts of
BRCA, stages I and II of ovarian serous cystadenocarcinoma (OSC), and stage II UEC.
The region containing MUC4 and MUC20 demonstrated increased copy numbers in over
50% of the patients with any stage of LUSC, stages II-IV OSC (Figure 2.9C), and stages
I and II in USEC (Figures 2.9A and 2.9B). Several other cohorts demonstrated somatic
copy number amplifications in up to 50% of the patients for the genes MUC2, MUC6,
MUC5AC, MUC5B in locus 11p15.5; however, due to the conservative nature of the
analysis and possible sample size, related cohorts were not seen. After adjusting for
multiple hypothesis testing within each histology, only MUC1 in KIRP was found to
significantly impact patient survival for both univariate (HR=20.1; q=5.8E-6) and
multivariate (HR=12.9; q=0.01), indicating a possible negative role of MUC1 copy
number increase in patient survival (Table 2.5).
Mucin methylation in cancer
In the cancers examined, mucin gene promoters typically underwent a significant
decrease in methylation (Figure 2.10). In normal tissues, MUC1 is the least methylated
mucin, except for the normal adjacent tissue in patients with BRCA, where MUC12 is the
least methylated with MUC1 following behind with 1.1% more methylation (Figure
2.10A). Following this trend, MUC12 and MUCL1 are also lowly methylated in normal
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tissues. MUC4 relatively shows high levels of methylation in normal tissue, which is
especially evident in cancer (Figure 2.10B). However, as with the broadly decreased
methylation seen in mucins, MUC4 shows significantly decreased methylation in 34
cancer cohorts and increased methylation in 12 cohorts. With the transformation into a
cancer cell, low methylation states are no longer restricted to MUC1, MUCL1, and
MUC12. BLCA cohort alone shows a strong decrease in most mucin methylation (Figure
2.10). MUC1, despite low methylation in normal tissues, demonstrates even lower
methylation status across multiple cancers.
Many interesting methylation observations exist, however, a few peculiar
instances standout. All histological subtypes of UCEC demonstrate a strong decrease in
MUC15 and MUC20, in which the average methylation for both of these genes drops to
50% of that of the normal tissues (Figure 2.10). The MUC15 methylation status is
significantly decreased in OSC, where the fold change ranges from -2.9 to -3.4,
compared to the non-cancerous normal ovarian tissues. Both KIRP and KIRC show a
unique methylation pattern for mucin gene promoters. An increase in mucin promoter
methylation was not commonly observed in cancers, yet in KIRP and KIRC, MUC15
promoter methylation increased strongly. Gene promoters for MUC20, MUC17, and
even the typically lowly methylated MUC12 promoter, demonstrate increased
methylation in KIRP and KIRC. The MUC15 promoter methylation has strong impact on
patient survival with LUAD; it was discovered to have a significant (q=0.0001)
astounding HR of 64.1 when corrected by a multiple regression analysis and a univariate
HR of 30.2 (q=0.0017) (Table 2.6).
Discussion
Only a small subset of mucins have been studied extensively for their roles in
cancer biology. Considering the significant roles played by mucins in cancer biology and
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patient survival, it is imperative to investigate the role of the multiple mucins across
cancers. To further understand the genomic significance of mucins, 37 histological
subtypes across 12 cancers were examined for mutations, mRNA, copy number,
methylation profile, de novo expression and silencing, and the impact on survival.
Depending on the tissue and the histological subtype, mucins may or may not be
exploited in cancer (146, 170). The results presented here highlight existing as well as
new features, which may serve as potential targets in their respective histological
subtypes where cancers are suggested to be utilizing mucin function.
MUC1 has a well-known role in cancer biology (41, 147). We highlight here that
expression of MUC1 mRNA is higher than most mucins in a majority of cancers and may
in part be fostered by increased demethylation of the promoter in multiple cancer tissues
(Figure 2.10). MUC1 is overexpressed in more than 90% of breast carcinomas (147) and
we hereby report that copy number might play a significant role in this tissue, as copy
gain was frequently seen in breast cancer (Figures 2.9A and 2.9B). These observations
are further supported by a significant correlation of MUC1 mRNA in breast cancer with
copy number (q=3.65E-09) (Table 2.7), but not with methylation (Table 2.8), after
correcting for multiple hypotheses. Furthermore, we report that only a few cancer
subtypes carry MUC1 mutations, where extracellular region point mutation T112P was
commonly seen and responsible for 50% of the MUC1 mutations observed in PDAC
(Figure 2.1 and Table 2.2). The T112P mutation was also observed in other tissues.
However, the only cohort with enough mutations to test survival was in stage II PDAC, in
which the corresponding patients were too newly enrolled to obtain any meaningful
statistics for survival comparisons (Figure 2.4A).
MUC2 has a known tumor suppressor role as seen in colorectal cancer where
MUC2 suppresses inflammation (153, 171). Therefore, the significant decrease in MUC2
expression in colorectal cohorts is not surprising; however, for the other tissues
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examined, only increased expression was observed when statistically significant for
MUC2 (Figure 2.5A). This includes EA NOS, which showed a significant 5.5 to 7.1-fold
increase in MUC2 mRNA. Furthermore, MUC2 has an increase in mRNA in KIRC, but
not KIRP. KIRP is seen to bare a high burden of non-damaging nonsynonymous
mutations and increases through the stages up to 50% in stage IV (Figure 2.1C).
Furthermore, MUC2 is seen to have a Gaussian distribution of mutations around T1538
(Figure 2.2B), many of which are threonine, a key component for glycosylation (172). A
large part of the Gaussian distribution stem from KIRP, including three T1488P
mutations (Table 2.2 and Figure 2.2). These data suggest potential functional
significance of a mutationally important domain in MUC2 for cancer cell aggressiveness.
However, it has been demonstrated by immunohistochemical staining that kidney renal
carcinoma (n = 16) was negative for MUC2 (173), potentially signifying an artifact
generated from little-to-no mRNA in normal tissue and a marginal 2-fold change in KIRC
(Figure 2.5). If there is truly low abundance of mRNA, it is rather unclear why mutations
in MUC2 appear to cluster together in KIRP.
MUC4 is a well-characterized protein for its significance towards cancer biology
(152). Acting as a ligand for the interaction with ErbB, MUC4 can bind HER2 and
activate several downstream signaling proteins, including ERK1/2, Akt, FAK, and c-Src
among others (147, 174, 175). These MUC4-induced pathways play a critical role in cell
growth, proliferation, disruption of tight junctions and adherens junctions, tumor
progression, and blocking apoptosis (147, 153, 176, 177). It is no surprise that MUC4 is
overexpressed, associated with poor prognosis, and potentially serves as a biomarker
for cancer (147, 177-182). However, depending on the tissue, decreased expression of
MUC4 can correlate with poor prognosis as well as an improved prognosis, such as the
observation has been previously reported in OSC (177, 182). Therefore, evaluating the
presence and the resultant functional significance of MUC4 genomic alterations in
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various histological and stage subsets is important to further understand the role of
MUC4 in cancer. Here we also report that although statistically significant changes in
mRNA levels are also observed, the fold change is not very drastic (Figure 2.5A),
suggesting that impact on survival may be due to other possible factors, such as posttranscriptional modifications, including altered glycosylation. Furthermore, methylation is
known to play a significant role in MUC4 expression (171). In normal tissues and in
many cancers, the MUC4 promoter is highly methylated and a moderate decrease in
methylation is observed in cancer, except for a very minor increase in OSC and
colorectal cancers that does not exceed 1.08-fold increase. Copy number alterations
may contribute significantly to MUC4 expression, as the genomic segment containing
MUC4 and MUC20 demonstrates copy gains in over 50% of the specimens in all stages
of LUSC, later stages of OSC, and in USEC. Positive significant correlations between
mRNA and copy number were seen in breast and pancreatic cancer histological
subtypes (r=0.14 and r=0.38, respectively) (Table 2.7). Here we also shed light on the
significance of mutations in MUC4, especially in KIRC. Although MUC4 is a rather large
gene, repeated mutations and matching in-frame deletions in the same position where
seen, especially H4205Q, which we believe should be further investigated. Table 2.2
and Figure 2.3 show additional mutations which maybe of functional interest, including
MUC6 and MUC12, the latter of which shows a high preference in which base is
mutated. It is interesting to note that these genes, MUC4, MUC6, and MUC12, were
recently identified as being significantly mutated in smokers in contrast to non-smokers
(183).
Examining de novo expression of mucins to serve as biomarkers led to the
finding of MUC21 in colorectal cancers, although the increase in mRNA is very low. The
expression of MUC7 is observed not to occur in some of the tissues examined and thus
added difficultly in interpreting the significance. However, MUC7 is expressed in normal
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submucosal glands in the lungs (184); in which the data presented here shows LUSC
with a significant 10.0 to 15.3 fold increase compared to non-cancerous tissue. This high
fold change and de novo expression of MUC7 in LUSC is attributed in part due to 50 out
of 51 normal adjacent specimens having zero expression after normalization (Figure 2.5,
Table 2.3). Still, the observed increase in MUC7 expression might lead to a possible
novel marker in cancers (Figure 2.7). Lastly, a possible role of MUCL1 was explored,
which showed an astounding increase in many stomach cancer histological subtypes
(Figure 2.5).
The mucosal profile of the kidney stands out in many areas. Tissue and histology
specific mutations are seen to reside in the kidney (Figures 2.1C and 2.1D), some of
which have a significant impact on survival (Figures 2.4B and 2.4C). Furthermore, KIRC
and KIRP both show a dramatic decrease in MUC15 mRNA, while MUC17 saw a 15.4 to
29.4-fold significant increase in only KIRC (Figure 2.5). KIRP on the other hand, did not
show a statistically significant change in MUC17 expression in all stages, ranging from
only 1.9 to 2.4-fold change above normal in all stages. This suggests MUC17 as a
potential biomarker to distinguish between the histological subtypes. The kidney mucin
profile is perhaps the most interesting in regard to methylation changes. This study
reveals demethylations of mucin CpG are very frequent in cancer (Figure 2.10).
However, MUC12, MUC15, MUC17, and MUC20 had a significant increase in
methylation in only KIRP and KIRC, which goes against the overall observed
demethylation of mucins in the cancers examined here. Of these four mucins, only
MUC15 was observed to have a dramatic decrease in KIRP and KIRC mRNA ranging
from -6.6 to -15.5 fold change compared to normal expression (Figure 2.5). Lastly,
MUC15 and MUC20 methylation also appears to be of interest beyond renal carcinomas
(Figure 2.10). A significant decrease in MUC15 methylation was observed in OSC and to
a lesser extent, MUC15 and MUC20 in UCEC. Despite the lack of normal ovarian
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samples preventing an analysis on the mRNA fold change, MUC15 and MUC20 showed
significant correlation with mRNA expression and methylation in both ovarian and uterus
corpus cancers (Table 2.8). Only MUC20 showed marginal significance for mRNA
upregulation in USEC (Figure 2.5). Lastly, despite not being of kidney origin, LUAD
MUC15 methylation was associated with a multiple regression HR of 64.1 (q=0.0001)
and a univariate HR of 30.2 (q=0.0017) (Table 2.6). Within the kidney, MUC21 mRNA
expression demonstrated significant impact on survival in univariate analysis in KIRP.
Furthermore, within KIRP, MUC1 copy number had a large impact on survival for both
univariate (HR=20.1; q= 5.8E-6) and multivariate (HR=12.9; q=0.01) analyses (Table
2.5).
Here we have presented genomic evidence spanning multiple tissues for further
exploration of mucin function in cancers. Many significantly aberrant mRNA expression
levels were observed in conjunction with histological subtypes favoring certain mucin
mutations as well as location specific mutations. It is our hope the data supplied here will
aid further explorations of potentially novel functions of mucin family members. We
would like to highlight that many roles of mucins cannot be explained by genomic
analysis alone. Many mucins may have aberrant glycosylation, phosphorylation,
subcellular localization, and are involved in functions which may act independently of
genomic alterations discussed here (146, 147, 152, 153, 185, 186). We hope the study
presented here will open new lines of investigations into the functional role, biomarker
functions, and therapeutic agents against mucins in cancer.
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Figure 2.1
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Figure 2.1: DNA mutations in histology and stage-controlled cohorts. TCGA
mutation data was organized into cohorts based on histology and stage for all patients.
Cohort names, stages, and specimen sizes can be found in Table 2.1. Cohorts with 10
or more samples were grouped by (A) stage I or (B) stage II and had total patients
divided by total mutations to achieve percent mutated. This value was normalized to the
kilobase pairs (kb) of the longest transcript possible utilizing the transcription start and
end coordinates provided by UCSC genome table browser’s list of known genes. The
specific type of mutation was examined specifically for (C) MUC2, (D) MUC4, (E) and
MUC16. The more damaging the mutation category, the closer it appears (C–E). Shades
of red indicate deletion, shades of green for gain, yellow for splice site, blue for
noncoding, and shades of grey for single nucleotide variations.
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Figure 2.2: DNA mutations by location. DNA mutations in all cohorts were aggregated
together to examine for commonly mutated genomic regions. Figures were generated by
cBioPortal Mutation Mapper (165, 166), in which each lollipop denotes a unique mutation
location for (A) MUC1, (B) MUC2, (C) and MUC4. Exact mutations with patient identifiers
can be found in Table 2.1. Red circles indicate a frameshift, nonsense, or a splice site
mutation. Black circles denote inframe additions or deletions. Grey circles indicate either
silent or nonsynonymous mutations. Purple indicates multiple color categories reside at
the same location. Green, red, or yellow bars indicate domains.
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Figure 2.3: DNA mutations by location. DNA mutations of all cohorts were aggregated
together to examine for commonly mutated regions. Figures were generated by
cBioPortal Mutation Mapper (165, 166), in which each lollipop denotes a unique mutation
location. Multiple mutations are separated by a forward slash. Red circles indicate a
frameshift, nonsense, or a splice site mutation. Black circles denote inframe additions or
deletions. Grey circles indicate either silent or nonsynonymous mutations. Purple
indicates multiple color categories reside at the location. Green, red, and yellow bars
indicate domains. TCGA coordinates were used; however, if the coordinates in mutation
mapper were different, extension is seen, such as MUC12, or an abrupt stop is
observed, such as MUC16.
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Figure 2.4: Survival of patients based on mutation status. Patients were split into
categories based on histological subtype and stage. A minimal cohort size of two was
required to examine if the first amino acid change was shared in any other patient(s). (A)
Kaplan Meier survival plot with Mantel-Cox survival analysis in PDAC stage II patients
with no mutations in MUC1, only T112P mutations, or any mutations besides T112P. (B)
Impact of the most common MUC4 mutations on patient survival by Mantel-Cox analysis
in KIRC stage III patients. (C) Mantel-Cox survival analysis demonstrates the impact of a
repeated inframe mutation in stage I KIRC patients. Yellow lines indicate survival in
patients with the specific mutation, orange lines represent patients with a mutation(s)
other than the specified mutation, and green lines indicate survival in patients with no
mutations in the given gene. Vertical bars indicates a censorship, due to a living or
withdrawn patient. All p-values are from a Mantel-Cox survival analysis comparing the
adjacent group to the mutation-free group.
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Figure 2.5: Mucin mRNA expression in cancer. mRNA cohorts were separated based
on histology and stage, in which a minimum size of two was taken. Table 2.1 contains
the full cohort names and sample sizes. Fold change of mRNA in cancer was compared
in relation to adjacent non-cancerous normal tissues. If either all the cancer or normal
tissue had zero expression, the fold change was set to zero and colored yellow. (A)
Cohorts which had a significant fold change as determined by a Mann-Whitney (p <
0.05) were colored. Cases where Mann-Whitney testing would be impractical had the
yellow bars appear in the heatmap. All other cases (p > 0.05) have white where the fold
change is insignificant statistically. (B) The fold change between normal tissue and the
cancer cohort was displayed regardless of significance. Heatmap color scales are
depicted on the left.
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Figure 2.6: Heatmap of mucin mRNA in cancer. mRNA cohorts were separated based
on histology and stage, in which a minimum size of two was required. Expression is
graphed with units of log2(RSEM + 1). Table 2.1 contains the full cohort names and
sample sizes.
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Figure 2.7: De novo expression and silencing of MUC7 examined in breast cancer.
mRNA expression was plotted in normal adjacent tissue and each of the four stages in
cancer. A Dunn’s test was performed to examine for mRNA differences
compared to normal expression (*p < 0.05; **p < 0.01; ***p < 0.001). The Fisher’s exact
test in Table 2.3 was consulted for significance (†p < 0.05; ††p < 0.01; ††† < 0.001)
examining normalized RSEM for patients with expression and without expression.
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Figure 2.8: De novo expression and silencing of mucins in cancer. mRNA
expression was plotted for the normal tissue and for each of the four stages in cancer. A
Dunn’s test in prism was performed for mRNA differences compared to the normal
expression (*p < 0.05; **p < 0.01; ***p < 0.001). Table 2.3 Fisher’s exact test was
consulted for significance (†p < 0.05; ††p < 0.01; †††p < 0.001) to examine if there is a
significant change in the expression status, with expression being on or off. Histological
subtypes examined include (A) MUC21 in COAD, (B) MUC21 in READ, (C) MUC15 in
COMA, (D) MUC15 in COAD, (E) MUC15 in KIRP, (F) MUC15 in KIRC, and (G) MUCL1
in ESCA.
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Figure 2.9: Mucin copy number alterations in cancer. Patients were split into cohorts
with a minimum size of two for histology and stage. Table 2.1 contains the full cohort
names and sample sizes. Figure key color is determined by the median of the copy
number, which was determined by the calculated segmean as described in methods.
Heatmap color scales are depicted on the left. (A) Copy number status that deviated at
least 0.5 from diploid were rounded and considered to have copy gain or loss. (B) Copy
number median is displayed regardless of copy number status. (C) A table highlighting
the percentage of patients with the corresponding copy number status for the region
3q29 containing MUC4 and MUC20 in LUSC and OSC. Histology, stage, and patients in
the cohort are listed in the first three columns. The percent of patients in the categories
are given with the following copy number statuses: deletion (Del; n = 0), copy loss (Loss;
n = 1), diploid (Diploid; n = 2), copy gain (Gain; n = 3), and amplified (Amp; n = 4 or
greater).
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Figure 2.10: Methylation status of mucins. Promoter methylation was examined in (A)
normal tissue and (B) cancer genomes, as well as (C) the resulting fold change.
Significant (p < 0.05) fold changes determined by a Mann-Whitney test are colored,
where white indicates a non-significant change between normal and cancer promoters.
A yellow bar indicates that a 27K methylation chip was analyzed instead of a 450K chip
and the gene was not examined in the chip. A minimum sample size of two was required
for each cohort. Table 2.1 contains the full cohort names and sample sizes. Heatmap
color scales are depicted on the right.
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Table 2.1

Primary
Tissue
Bladder
Bladder
Bladder
Bladder
Bladder
Bladder
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast

TCGA
Source
BLCA
BLCA
BLCA
BLCA
BLCA
BLCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA
BRCA

Histological
Subtype
BNP
BNP
BNP
BP
BP
BP
----------H
--H
--H
-P-P-PH
E-E-E-E-H
E-H
E-H
EPEPEPEPEPH
EPH
EPH

Colon

COAD

COAD

1

Colon

COAD

COAD

2

Colon

COAD

COAD

3

Stage Specimens
2
67
3
104
4
99
2
62
3
34
4
33
1
19
2
72
3
19
4
2
1
2
2
23
3
10
2
4
3
3
2
3
1
8
2
38
3
18
1
5
2
14
3
3
1
73
2
204
3
84
4
3
1
11
2
57
3
30

Full Name
Non-Papillary
Non-Papillary
Non-Papillary
Papillary
Papillary
Papillary
----------H
--H
--H
-P-P-PH
E-E-E-E-H
E-H
E-H
EPEPEPEPEPH
EPH
EPH
Colon
40 Adenocarcinoma
Colon
95 Adenocarcinoma
Colon
66 Adenocarcinoma
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Colon

COAD

COAD

4

35

Colon

COAD

COMA

1

5

Colon

COAD

COMA

2

14

Colon

COAD

COMA

3

14

Colon

COAD

COMA

4

4

Esophagus ESCA

EA NOS

1

12

Esophagus ESCA

EA NOS

2

23

Esophagus ESCA

EA NOS

3

29

Esophagus ESCA

EA NOS

4

5

Esophagus ESCA

ESCA

1

7

Esophagus ESCA

ESCA

2

55

Esophagus ESCA

ESCA

3

27

Esophagus ESCA

ESCA

4

4

Kidney

KIRC

KIRC

1

268

Kidney

KIRC

KIRC

2

57

Kidney

KIRC

KIRC

3

124

Kidney

KIRC

KIRC

4

84

Kidney

KIRP

KIRP

1

172

Kidney

KIRP

KIRP

2

23

Kidney

KIRP

KIRP

3

52

Kidney
Lung

KIRP
LUAD

KIRP
LUAD

4
1

15
278

Colon
Adenocarcinoma
Colon Mucinous
Adenocarcinoma
Colon Mucinous
Adenocarcinoma
Colon Mucinous
Adenocarcinoma
Colon Mucinous
Adenocarcinoma
Esophagus
Adenocarcinoma NOS
Esophagus
Adenocarcinoma NOS
Esophagus
Adenocarcinoma NOS
Esophagus
Adenocarcinoma NOS
Esophagus Squamous
Cell Carcinoma
Esophagus Squamous
Cell Carcinoma
Esophagus Squamous
Cell Carcinoma
Esophagus Squamous
Cell Carcinoma
Kidney Clear Cell
Renal Carcinoma
Kidney Clear Cell
Renal Carcinoma
Kidney Clear Cell
Renal Carcinoma
Kidney Clear Cell
Renal Carcinoma
Kidney Papillary Renal
Cell Carcinoma
Kidney Papillary Renal
Cell Carcinoma
Kidney Papillary Renal
Cell Carcinoma
Kidney Papillary Renal
Cell Carcinoma
Lung Adenocarcinoma

60

Lung
Lung
Lung

LUAD
LUAD
LUAD

LUAD
LUAD
LUAD

2
3
4

Lung

LUSC

LUSC

1

Lung

LUSC

LUSC

2

Lung

LUSC

LUSC

3

Lung

LUSC

LUSC

4

Pancreas

PAAD

PDAC

1

Pancreas

PAAD

PDAC

2

Pancreas

PAAD

PDAC

3

Pancreas

PAAD

PDAC

4

Pancreas

PAAD

POS

1

Pancreas

PAAD

POS

2

Pancreas

PAAD

PMNC

2

Rectal

READ

READ

1

Rectal

READ

READ

2

Rectal

READ

READ

3

Rectal

READ

READ

4

Rectal

READ

REMA

2

124 Lung Adenocarcinoma
84 Lung Adenocarcinoma
27 Lung Adenocarcinoma
Lung Squamous Cell
245 Carcinoma
Lung Squamous Cell
164 Carcinoma
Lung Squamous Cell
84 Carcinoma
Lung Squamous Cell
7 Carcinoma
PancreasAdenocarcinoma
12 Ductal Type
PancreasAdenocarcinoma
128 Ductal Type
PancreasAdenocarcinoma
3 Ductal Type
PancreasAdenocarcinoma
3 Ductal Type
PancreasAdenocarcinoma8 Other Subtype
PancreasAdenocarcinoma15 Other Subtype
Pancreas-Colloid
(mucinous non-cystic)
3 Carcinoma
Rectal
11 Adenocarcinoma
Rectal
26 Adenocarcinoma
Rectal
31 Adenocarcinoma
Rectal
13 Adenocarcinoma
Rectal Mucinous
2 Adenocarcinoma

61

Rectal

READ

REMA

3

2

Stomach

STAD

STA D

1

7

Stomach

STAD

STA D

2

21

Stomach

STAD

STA D

3

34

Stomach

STAD

STA D

4

6

Stomach

STAD

STA NOS

1

23

Stomach

STAD

STA NOS

2

60

Stomach

STAD

STA NOS

3

50

Stomach

STAD

STA NOS

4

7

Stomach

STAD

SIA NOS

1

13

Stomach

STAD

SIA NOS

2

16

Stomach

STAD

SIA NOS

3

32

Rectal Mucinous
Adenocarcinoma
Stomach
Adenocarcinoma
Diffuse Type
Stomach
Adenocarcinoma
Diffuse Type
Stomach
Adenocarcinoma
Diffuse Type
Stomach
Adenocarcinoma
Diffuse Type
Stomach
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach Intestinal
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach Intestinal
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach Intestinal
Adenocarcinoma Not
Otherwise Specified
(NOS)
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Stomach

STAD

SIA NOS

4

12

Stomach

STAD

SIA T

1

9

Stomach

STAD

SIA T

2

13

Stomach

STAD

SIA T

3

42

Stomach

STAD

SIA T

4

10

Stomach

STAD

STA SR

1

2

Stomach

STAD

STA SR

2

2

Stomach

STAD

STA SR

3

4

Stomach

STAD

STA SR

4

4

Stomach

STAD

SIA M

2

8

Stomach

STAD

SIA M

3

10

Stomach

STAD

SIA M

4

2

Stomach

STAD

SIA P

1

3

Stomach

STAD

SIA P

2

3

Stomach Intestinal
Adenocarcinoma Not
Otherwise Specified
(NOS)
Stomach Intestinal
Adenocarcinoma
Tubular Type
Stomach Intestinal
Adenocarcinoma
Tubular Type
Stomach Intestinal
Adenocarcinoma
Tubular Type
Stomach Intestinal
Adenocarcinoma
Tubular Type
Stomach
Adenocarcinoma
Signet Ring Type
Stomach
Adenocarcinoma
Signet Ring Type
Stomach
Adenocarcinoma
Signet Ring Type
Stomach
Adenocarcinoma
Signet Ring Type
Stomach Intestinal
Adenocarcinoma
Mucinous Type
Stomach Intestinal
Adenocarcinoma
Mucinous Type
Stomach Intestinal
Adenocarcinoma
Mucinous Type
Stomach Intestinal
Adenocarcinoma
Papillary Type
Stomach Intestinal
Adenocarcinoma
Papillary Type
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Uterus

UCEC

UEC

1

220

Uterus

UCEC

UEC

2

20

Uterus

UCEC

UEC

3

51

Uterus

UCEC

UEC

4

12

Uterus

UCEC

UCM

1

5

Uterus

UCEC

UCM

3

3

Uterus

UCEC

USEC

1

19

Uterus

UCEC

USEC

2

7

Uterus

UCEC

USEC

3

25

Uterus

UCEC

USEC

4

6

Endometrioid
endometrial
adenocarcinoma
Endometrioid
endometrial
adenocarcinoma
Endometrioid
endometrial
adenocarcinoma
Endometrioid
endometrial
adenocarcinoma
Mixed serous and
endometrioid
Mixed serous and
endometrioid
Serous endometrial
adenocarcinoma
Serous endometrial
adenocarcinoma
Serous endometrial
adenocarcinoma
Serous endometrial
adenocarcinoma
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Table 2.1: Cohort sizes and acronym information. Table reflects the primary tissue
source, the TGCA name identifier, the histological subtype abbreviation and the full
histological subtype name, the stages available, and the number of patients with these
characteristics.
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Table 2.2
Hugo_Symbol Sample_ID
(PAAD Pancreas-Adenocarcinoma
MUC1
Ductal Type Stage II) TCGA-HZ-7919

Protein_Change
p.T112P

MUC1

(PAAD Pancreas-Adenocarcinoma
Ductal Type Stage II) TCGA-HZ-8317

p.T112P

MUC1

(PAAD Pancreas-Adenocarcinoma
Ductal Type Stage II) TCGA-IB-8127

p.T112P

MUC4

(KIRC Kidney Clear Cell Renal
Carcinoma Stage III) TCGA-B0-5108

p.H4205Q

MUC4

(KIRC Kidney Clear Cell Renal
Carcinoma Stage III) TCGA-CZ-5458

p.H4205Q

MUC4

(KIRC Kidney Clear Cell Renal
Carcinoma Stage I) TCGA-AS-3778
(KIRC Kidney Clear Cell Renal
Carcinoma Stage I) TCGA-CJ-4634

MUC4

(KIRC Kidney Clear Cell Renal
Carcinoma Stage II) TCGA-B2-4101

MUC4

p.H4205Q
p.H4205Q
p.H4205Q
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Table 2.2: DNA mutations and amino acid consequences. Mutations presented in
figure 2.3 are shown here with the gene symbol (Hugo_Symbol), the protein change
(Protein_Change), and the patient’s cancer information and ID (Sample_ID). Table was
restricted for size limitations. Full dataset can be found at
https://www.oncotarget.com/article/17934/.

67
Table 2.3

Tissue Histology
Colon
COAD Adenocarcinoma
Colon
COAD Adenocarcinoma
Colon
COAD Adenocarcinoma
Colon
COAD Adenocarcinoma
Rectal
READ Adenocarcinoma
Rectal
READ Adenocarcinoma
Rectal
READ Adenocarcinoma
Rectal
READ Adenocarcinoma

Stage Gene

Normal Normal
Cancer Cancer
Zero
Expressed Zero
Expressed

I

MUC21

39

0

25

13

II

MUC21

40

0

50

33

III

MUC21

40

0

38

24

IV

MUC21

35

0

17

18

I

MUC21

9

0

5

4

II

MUC21

10

0

14

12

III

MUC21

10

0

18

11

IV

MUC21

10

0

7

5
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Table 2.3: Potential biomarker candidate table. Table examines the de novo
expression or repression of mucin genes to be used as potential biomarker candidates.
Tissue source, histology, and stage for the mucin genes are given. If RNA sequencing
could not detect the gene, it was counted as “normal zero” or “cancer zero” depending if
the sample was normal adjacent tissue or cancerous. If RNA sequencing found the
gene, it was counted as “normal expressed” or “cancer expressed” depending if the
sample was normal adjacent tissue or cancerous. Table was restricted for size
limitations. Full dataset can be found at https://www.oncotarget.com/article/17934/.
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Table 2.4
TCGA Histological
tissue subtype
Kidney Clear Cell
KIRC
Renal Carcinoma
Kidney Clear Cell
KIRC
Renal Carcinoma
Kidney Clear Cell
KIRC
Renal Carcinoma
Kidney Papillary
Renal Cell
KIRP
Carcinoma
BLCA Papillary
Endometrioid
endometrial
UCEC adenocarcinoma
Kidney Clear Cell
KIRC
Renal Carcinoma
Serous
endometrial
UCEC adenocarcinoma
PancreasAdenocarcinoma
PAAD Ductal Type
PancreasAdenocarcinoma
PAAD Ductal Type
Kidney Clear Cell
KIRC
Renal Carcinoma
Serous
endometrial
UCEC adenocarcinoma
Serous
endometrial
UCEC adenocarcinoma
Endometrioid
endometrial
UCEC adenocarcinoma
Endometrioid
endometrial
UCEC adenocarcinoma

Gene

Hazard
Ratio

P value

BH q-value

MUC12

1.24

1.87E-07

2.62E-06

MUC5B

1.21

4.61E-07

5.99E-06

MUC20

0.83

2.85E-05

3.41E-04

MUC21
MUC7

1.91
2.23

3.90E-04
1.04E-03

5.46E-03
1.46E-02

MUC15

1.28

1.21E-03

1.69E-02

MUC17

1.11

1.65E-03

1.82E-02

MUC7

3.39

3.23E-03

4.52E-02

MUC6

0.88

3.27E-03

4.57E-02

MUC21

1.15

3.99E-03

5.18E-02

MUC4

0.89

9.14E-03

9.14E-02

MUC5B

1.30

8.49E-03

1.02E-01

MUC17

1.48

7.85E-03

1.02E-01

MUC7

1.20

7.92E-03

1.03E-01

MUC13

0.83

9.22E-03

1.11E-01
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Table 2.4: Cox proportional hazard model of mRNA impact on survival. A cox
proportionate univariate analysis examined the mRNA expression on survival. This was
calculated for each TCGA tissue source, histological subtype, mucin gene. The hazard
ratio, the associated p-value, and Benjamin Hochberg corrected p-value are listed. Table
was restricted for size limitations. Full dataset can be found at
https://www.oncotarget.com/article/17934/.
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Table 2.5
TCGA tissue
source
KIRP
PAAD
PAAD
BRCA
COAD
COAD

Histological subtype
Kidney Papillary Renal Cell
Carcinoma
Pancreas-Adenocarcinoma
Ductal Type
Pancreas-Adenocarcinoma
Ductal Type
EPColon Adenocarcinoma
Colon Adenocarcinoma

Gene

Hazard
Ratio
P value

BH
q-value

MUC1

20.06

3.22E-07

5.80E-06

MUC20

13.33

0.0006

0.0094

MUC4
MUC7
MUC20
MUC4

13.33
8.80
5.84
5.84

0.0006
0.0011
0.0022
0.0022

0.0094
0.0194
0.0381
0.0381
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Table 2.5: Cox proportional hazard model of copy number impact on survival. A
cox proportionate univariate analysis examined the copy number segment mean on
survival. This was calculated for each TCGA tissue source, histological subtype, mucin
gene. The hazard ratio, the associated p-value, and Benjamin Hochberg corrected pvalue are listed. Table was restricted for size limitations. Full dataset can be found at
https://www.oncotarget.com/article/17934/.
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Table 2.6
TCGA tissue
source
LUAD
KIRC
UCEC
UCEC

Histological subtype
Lung Adenocarcinoma
Kidney Clear Cell Renal Carcinoma
Endometrioid endometrial
adenocarcinoma
Endometrioid endometrial
adenocarcinoma

Hazard
BH
Gene
Ratio
P-value q-value
MUC15 30.1502 0.0001 0.0017
MUC1 0.000004 0.0009 0.0120
MUC2

0.0010

0.0016

0.0206

MUC6

0.0046

0.0039

0.0468
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Table 2.6: Cox proportional hazard model of promoter methylation impact on
survival. A cox proportionate univariate analysis examined the promoter methylation
beta value on survival. This was calculated for each TCGA tissue source, histological
subtype, mucin gene. The hazard ratio, the associated p-value, and Benjamin Hochberg
corrected p-value are listed. Table was restricted for size limitations and only shows
conditions where q < 0.05. Full dataset can be found at
https://www.oncotarget.com/article/17934/.
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Table 2.7
TCGA
tissue
source Histological subtype
Kidney Papillary Renal Cell
KIRP
Carcinoma
OV
Serous Cystadenocarcinoma
Endometrioid endometrial
UCEC
adenocarcinoma
Mixed serous and
UCEC
endometrioid
Serous endometrial
UCEC
adenocarcinoma
LUAD Lung Adenocarcinoma
LUAD Lung Adenocarcinoma
Lung Squamous Cell
LUSC
Carcinoma
Endometrioid endometrial
UCEC
adenocarcinoma
Mixed serous and
UCEC
endometrioid
Serous endometrial
UCEC
adenocarcinoma

Gene

Correlation P value

BH
q-value

MUC12
MUC20

0.617
0.400

0
5.43E-13

0
7.06E-12

MUC20

0.342

2.20E-11

2.86E-10

MUC20

0.342

2.20E-11

2.86E-10

MUC20
MUCL1
MUC20

0.342
0.286
0.279

2.20E-11
4.16E-11
1.35E-10

2.86E-10
5.40E-10
1.62E-09

MUC17

0.280

2.04E-10

2.65E-09

MUC1

0.324

2.72E-10

3.27E-09

MUC1

0.324

2.72E-10

3.27E-09

MUC1

0.324

2.72E-10

3.27E-09
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Table 2.7: Correlation of mucin mRNA and copy number status. Log2(RSEM + 1)
mRNA expression was correlated with copy number segment mean. This was calculated
for each TCGA tissue source, histological subtype, mucin gene. The rho, the associated
p-value, and Benjamin Hochberg corrected p-value are listed. Table was restricted due
to size limitations. Full dataset can be found at
https://www.oncotarget.com/article/17934/.
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Table 2.8
TCGA
tissue
source
BLCA
BRCA
LUAD
LUSC
UCEC
COAD
LUSC
KIRP
COAD
KIRP
PRAD
KIRP
READ
BRCA

Histological subtype
Non-Papillary
EPLung Adenocarcinoma
Lung Squamous Cell Carcinoma
Endometrioid endometrial
adenocarcinoma
Colon Adenocarcinoma
Lung Squamous Cell Carcinoma
Kidney Papillary Renal Cell
Carcinoma
Colon Adenocarcinoma
Kidney Papillary Renal Cell
Carcinoma
Prostate Adenocarcinoma
Acinar Type
Kidney Papillary Renal Cell
Carcinoma
Rectal Adenocarcinoma
EP-

Gene
MUC16
MUC16
MUC16
MUC16

Correlation P value
0.61 0.00E+00
0.74 0.00E+00
0.71 0.00E+00
0.53 0.00E+00

BH
q-value
0.00E+00
0.00E+00
0.00E+00
0.00E+00

MUC16
MUC17
MUC20

0.57
-0.76
-0.58

0.00E+00 0.00E+00
1.25E-44 1.50E-43
4.09E-34 4.50E-33

MUC1
MUC12

-0.60
-0.61

2.20E-28
8.38E-26

2.64E-27
9.22E-25

MUC2

-0.57

7.49E-25

8.24E-24

MUC2

-0.44

3.78E-24

4.53E-23

MUC20
MUC17
MUC2

-0.52
-0.79
-0.52

3.72E-20
1.73E-19
1.50E-18

3.72E-19
2.07E-18
1.65E-17
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Table 2.8: Correlation of mucin mRNA and promoter methylation levels.
Log2(RSEM + 1) mRNA expression was correlated with the mean methylation beta value
of the promoter. This was calculated for each TCGA tissue source, histological subtype,
mucin gene. The rho, the associated p-value, and Benjamin Hochberg corrected p-value
are listed. Table was restricted due to size limitations. Full dataset can be found at
https://www.oncotarget.com/article/17934/.
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Datasets 2.1 and 2.2 can be found online at https://www.oncotarget.com/article/17934/.
Dataset 2.1. Mucin mutation by location across cancers. Figures and tables for
multiple mucins showing the mutation type and mutations per patient, in addition to the
sample size for the associated TCGA tissue source, histology, and stage.
Dataset 2.2. Mutations per gene controlled for gene size in stage III cancers. Figure
and table depict mucin mutations per kilobase per patient x 100 for stage III cancers.
Cohorts were listed if they had a mutation in one of the mucin genes, in which sample
size, TCGA cohort, and histology was given.
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Chapter 3: Pancreatic Cancer Increases Aggressiveness through Elevated CD73
by Suppressing T cells through GM-CSF and MDSCs
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Introduction
Pancreatic cancer is the fourth highest cause of cancer-associated deaths, as it
carries a dismal 5-year survival rate of 9% (187, 188). Pancreatic cancer is predicted to
become the third most common cause of cancer-associated deaths in the European Union
by 2017 (189) and the second leading cause in the United States by 2030 (190). New
cases of pancreatic cancer are nearly equal to pancreatic cancer deaths each year (187,
188), highlighting the urgent need to generate improved therapies.
Metabolic reprogramming and immune evasion are two widely recognized
hallmarks of cancer (1). Although a metabolic shift in cancer cells has long been observed
(191), recent advances have shown how specific alterations in tumor metabolism can
disrupt antitumor immunity (192-198). Cancer cells can disable the effector function of
immune cells in their microenvironment by virtue of their increased energy demand and
concomitant glucose, glutamine, and oxygen consumption, that deprives the immune cells
of required nutrients. Cancer cells can also decrease local metabolites to be
immunosuppressive, as seen by arginase and indoleamine 2,3-dioxygenase, or generate
immunosuppressive metabolites, such as CD73 (56, 64, 199-201).
CD73 is a cell surface ectozyme that helps clear extracellular adenosine
triphosphate (ATP) by converting adenosine monophosphate (AMP) to adenosine (64,
202-205). ATP can be released from dying and stressed cells in a variety of settings,
including the hypoxic and stressed environments, necrotic core of solid tumors, or as a
result of chemotherapy treatment, as well as other cases of apoptosis (80, 81, 204, 206208). ATP serves as a potent proinflammatory signal that triggers recruitment of
neutrophils, eosinophils, dendritic cells (DCs), and macrophages (204, 206, 209).
Stimulation by ATP can further trigger cytokine release and promote immune clearance
(204, 206, 209), and unchecked levels of extracellular ATP without conversion to
adenosine can promote chronic inflammation and tissue damage (70, 141). Regulatory T-
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cells (Tregs) are a chief mediator in controlling the inflammatory response, and one
mechanism by which they oppose inflammation is through ATP degradation and the
ultimate conversion of AMP to adenosine by CD73 (66, 210, 211). Indeed, adenosine
production by Tregs has been seen as one of the larger mechanism of their
immunosuppressive role (102). Adenosine can modulate the immune response through
several mechanisms, including priming, cytokine production, proliferation, functional
immune reprogramming, and functional inhibition of cytotoxic T-cells (Tc) (90, 93, 103,
212, 213). Stimulation of the adenosine receptor A2A (A2A) can impact cytokine
production in Tc and helper T-cells (Th) (214, 215). A2A can promote naïve T-cells (216).
A2A stimulation was further seen to reduce type 1 Tcs and type 1 (215) and type 2 (217)
Ths, in which impairment has been seen to have a lasting impact on effector T cells (140).
Tregs both produce and utilize adenosine for stimulation, proliferation, and to increase
repression of Th and Tc cells (66, 100, 218, 219). Adenosine can even act to suppress
the innate immune system, including DCs (220-223), neutrophils, M1 macrophages (224),
and promote M2 differentiation (196).
Thus, cancer cell expression of CD73 can promote a highly immunosuppressive
microenvironment and can potentially contribute through multiple mechanisms to promote
innate and adaptive resistance to immunotherapy. This is especially relevant for
pancreatic tumors, which is often an immune quiescent tumor with poor immune infiltration
(225). Despite encouraging results in multiple cancers to anti-programmed cell death-1
(PD-1), anti-programmed death-ligand 1 (PD-L1), and anti-cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) antibody immunotherapy (226), discouraging results were
observed in pancreatic cancer, where anti-PD-L1 therapy has failed to show a response
(227). Furthermore, a 2019 phase II trial showed either anti-PD-L1 or CTLA-4 achieved a
0% objective response rate or only 3.1% when combined in metastatic pancreatic ductal
adenocarcinoma (PDAC) patients with previous first-line chemotherapy (228).
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Conversely, PDAC frequently exists in highly hypoxic microenvironment (229), which
promotes CD73 expression (50). We postulated that CD73-mediated immune suppression
may partially explain the failure of immunotherapies targeting PD-L1 and CTLA-4(227,
228).
Because there is a wide array of documented perturbations in expression of
metabolic genes across cancers, we decided to screen The Cancer Genome Atlas
(TCGA) data for enzymatic pathways and genes that had the most apparent influence on
PDAC patient survival. This screen revealed the importance of nucleotide metabolism, for
which CD73 was a top hit. We confirmed CD73’s role in survival in an independent
database and saw increased protein and adenosine levels. Implantations in congenic
immune competent mice revealed a dramatic improvement in mouse tumor burden and
survival upon CD73 knockdown, whereas athymic nude mice lacking T-cells showed only
a marginal alteration. Tumor cytokine profile revealed a decrease in GM-CSF in implanted
CD73 knockdown tumors, which correlated with decreased peripheral blood M-MDSCs
and G-MDSCs, while CD4+ and CD8+ T-cells were elevated. Restoring GM-CSF levels
increased CD73 knockout tumor burden to levels similar to control, and this was
dependent on MDSCs. We furthermore observed that the long-lasting CD73 knockdown
was highly sensitive to CD4 depletion. Combination therapy with anti-CD73 antibody and
gemcitabine also showed an improvement in tumor volume. We hereby propose CD73 to
be a critical immune checkpoint inhibitor employed by pancreatic cancer to increase
growth by modulating GM-CSF to promote MDSCs to inhibit CD4+ and potentially CD8+
T-cells to enable tumor growth.

Materials and Methods
Cell Culture and Reagents
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The cell lines 1245 and 1199 were given by Dr. David Tuveson’s lab after they
isolated the cells from the pancreatic tumor of LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1Cre (KPC) C57BL/6J mice. Cells were cultured in Dulbecco's modified Eagle medium
(Sigma-Aldrich, St Louis, MO, USA) supplemented with 50 IU/mL penicillin, 50 μg/mL
streptomycin, and incubated at 37°C in a humidified incubator with 5% CO 2. Cells were
maintained at 5% fetal bovine serum (FBS) and was increased to 10% FBS prior to and
during experiments. Upon reaching 70-80% confluency, each passage washed the cells
with 1X phosphate-buffered saline (PBS) before adding 0.25% trypsin and plating at 25%
confluency.
Lentivirus Transfection
Stable short hairpin RNA (shRNA) constructs targeting Nt5e were obtained from
Sigma-Aldrich and sgRNA constructs were purchased from Cellecta. Lentiviral constructs
were produced by transfecting HEK293T with the validated knockdown constructs,
containing

either

CCGGGCCACATAACACATCTGGTTACTCGAGTAACCAGATGTGTTATGTGGCTTTTT
G

(KD1),

CCGGGCGACCATCAAAGCAGACATTCTCGAGAATGTCTGCTTTGATGGTCGCTTTT
TG (KD2) (TRCN0000080813 and TRCN0000080814 respectively), Cellecta’s knockout
plasmid, or non-targeting guide RNA (control along with PMD2G and PsPAX2 with
Turbofect, following the manufacturer's protocol. Cells were infected two times with
replication-incompetent lentivirus with polybrene in 48 hrs. After transfection, cells were
selected using puromycin for two to three weeks. For knockout and non-targeting guide
RNA control cells, a low amount of cells were seeded in a 100mm2 dish and single colonies
were isolated and grown in a 96-well before transitioning to 24-,12-, and 6-well plates.
Animal Studies
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All animal experiments were approved by the University of Nebraska Medical
Center Institutional Animal Care and Use Committee. Unless otherwise noted, in-house
bred 6 to 8 week-old same-sex B6(Cg)-Tyrc-2J/J mice were used for orthotopic
implantations. Furthermore, unless stated otherwise, 5x103 cells in 50µL 1x PBS were
injected with a 27.5 gauge needle to the pancreas. 1245 KD2 implanted female B6(Cg)Tyrc-2J/J mice that have survived over a year had subcutaneous implantations by injecting
106 cells per flank in Matrigel (Corning, Corning, NY, USA) alongside 8-week-old female
mice. Tumor measurements were conducted by using either calipers, a Spectrum In Vivo
Imaging System (PerkinElmer, Waltham, MA, USA), or through ultrasound with Vevo 3100
for measurement and Vevo 2100 for analysis (VisualSonics, Toronto, Canada).
Survival with combination therapy in orthotopically implanted mice was done with
IP injections of gemcitabine and/or anti-CD73 antibody in 7-week-old C57BL/6NTac mice
after acclimatization. Therapy began 10 days after implantation by injecting every three
days either 100μL saline, 55mg/kg gemcitabine (Schaumburg, IL, USA) dissolved in
saline, 100μg anti-CD73 antibody (BioXCell, West Lebanon, NH, USA) dissolved in saline,
or both togehter. KPC mice were grown in-house and monitored until the tumor reached
200-400mm3 or when the longest dimensions were 3x3 mm, whereupon the treatment
was administered with the same amount of gemcitabine (Fresenius Kabi, Lake Zurich, IL,
USA) and anti-CD73 (BioXCell).
Immune depletion of CD4 and CD8α was done in C57BL/6NTac male mice by
administering 100μg antibody (BioXCell) diluted in saline via IP injection. IgG2α and IgG2β
(BioXCell) were injected together as a control. Depletion would start 6 days prior to
implantation and occur six times every two days before a week of rest and restarting the
depletion cycle.
The recombinant GM-CSF and MDSC depletion study utilized B6(Cg)-Tyrc-2J/J
male mice between 9-11 weeks. The IgG2β control was the same as above, but with

86
200μg per mouse. Following previous optimization (230), 100ng recombinant GM-CSF2
(Sino Biological, Beijing, China) was dissolved in saline and administered daily beginning
7 days after implantation. Similar to other studies (231, 232), 200μg of anti-Gr-1 (BioXCell)
was injected via IP every two days starting two days before implantation.
TCGA and ICGC Analysis
The Cancer Genome Atlas (TCGA) survival analysis was performed as previously
described (35). In brief, clinical and primary mRNA data was downloaded through the
TCGA Data Matrix. The donor information for the International Cancer Genome
Consortium (ICGC) PDAC dataset collected by the Australian consortium was
downloaded from the ICGC, while the mRNA expression was downloaded from Table 3.2
in a previous publication (233).
TCGA survival was analyzed in R 3.3.2 through the function “survdiff” in R package
survival using the Mantel-Haenszel log-rank test. ICGC and mouse survival was examined
in Graphpad Prism 5 using Mantel-Cox log-rank test for significance. Pathway analysis
was conducted through Database for Annotation, Visualization and Integrated Discovery
(DAVID) v6.8. Kyoto Encyclopedia of Genes and Genomes was used for pathway
visualization and enzyme gene list (234, 235). ActiveState perl v5.24.1 generated the
tables and controlled R as the top-level script.
Cytokine quantification
Cytokine quantification was performed by Eve Technologies (Calgary, Canada) on
a 31-plex mouse cytokine array / chemokine array. For values exceeding standard curve,
values were replaced with the lowest or highest obtained value as recommended by Eve
Technologies.
Histochemistry Staining
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Immunohistochemistry was performed with VECTASTAIN Elite ABC peroxidase
kit following manufacturer’s instructions (Vector Laboratories, Burlingame, CA, USA) and
counterstained with Novocastra Hematoxylin (Leica, Newcastle upon Tyne, UK). 5 μm
sections were stained with CD73 (Sigma-Aldrich, St. Louis, MO, USA), Ki67 (Cell
Signaling Technology, Danvers, MA, USA), and cleaved caspase-3 (Cell Signaling
Technology) antibodies.
The intensity score for immunohistochemistry was calculated by examining the
stain intensity (0 = none; 1 = weak; 2 = intermediate, 3 = strong) and the proportion of the
percentage of positively stained cell (0 = none; 1 = <5%; 2 = 5–25%; 3 = 26–50%; 4 = 51–
75%; 5 = >75%). These scores were multiplied together to generate the final histoscore.
Images were captured at 20X.
H&E staining was performed by deparaffinization and hydration through graded
xylenes and ethanol before submerging in water. Slides were exposed to Gill hematoxylin
stain (Fisher Chemical, Geel, Belgium) for 5 min, rinsed, exposed to acid alcohol (75%
ethanol + 1/25000 HCl (%v/v)), rinsed, and incubated within an ammonia solution (0.084%
NH4OH (%w/v)), before submerging in water for 5 min. Slides were exposed to 80%
ethanol before submerging in alcoholic eosin Y 515 (Leica) for 2 min. Slides were then
exposed to 95% and 100% ethanol before submerging in xylene for 2 min each. Images
were captured at 10X.
Representative images were taken by finding three tissues near the median cohort
weight and volume was used to break a tie. In the case of survival, the three tissues near
the median survival were used. Three tissues were examined when available and the
tissue with the median Ki67 was chosen to be the representative tissue.
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qRT-PCR
RNA isolation and qRT-PCR was performed as described previously (236), but
analyzed on QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific, Waltham,
MA, USA). Primers used for Nt5e were 5’-GGACATTTGACCTCGTCCAAT-3’ (forward)
and

5’-GGGCACTCGACACTTGGTG-3’

(reverse),

and

5’-

GGCTGTATTCCCCTCCATCG-3’ (forward) and 5’-CCAGTTGGTAACAATGCCATGT–3’
(reverse) for Actb.
Immunoblotting
Protein isolation and western blotting were performed as described previously
(237), but with nitrocellulose membranes. In short, cells were washed 2x with PBS and
utilized radio-immunoprecipitation assay for lysis by shaking for 10 min on ice. Lysates
were centrifuged at 13000 rpm for 10 min at 4°C to collect the supernatant. Bradford assay
was used to determine the protein concentration. An equal amount of protein was loaded
in each well for western blotting. Specific proteins were probed by using primary antibodies
against CD73 (Cell Signaling Technology, Danvers, MA, USA) and actin (JLA20;
Developmental Studies Hybridoma Bank, IA, USA).
Flow cytometry
Peripheral blood was collected through submandibular bleeding (238) in
accordance with the institutional animal care and use committee, lysed with AmmoniumChloride-Potassium lysing buffer (150mM NH4Cl, 10mM KHCO3, 0.1 mM
ethylenediaminetetraacetic acid, pH 7.3), processed for BD LSRII by staining with
LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Life Technologies Corporation, Eugene,
OR, USA). Sample volumes were then split in half with primary conjugated antibodies
CD3ε (PE), CD19 (PE-Cy7), CD8α (APC), CD4 (APC-Cy7), and FoxP3 (AF700) from
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BioLegend (San Diego, CA, USA) to examine T-cell subsets. Myeloid subsets were
examined with Ly6G (e605), CD11b(e450), Ly6C (APC/Cy7). Samples were run on a BD
LSR II and analyzed with FlowJo version 10. The pilot study utilized LIVE/DEAD Fixable
Aqua Dead Cell Stain, CD3ε (PE), CD8α (FITC), and CD4 (APC-Cy7).
Mass spectrometry
Similar to other protocols (239, 240), the interstitial fluid was collected by quickly
rinsing the blood off tumors roughly pea-sized before incubating in 250μL saline on ice
for 5 min. An additional 250μL saline was given and sporadically mixed by inverting for
10 min. A 5 s spin was performed on a mini-centrifuge before separating tissue from
interstitial fluid and freezing in liquid nitrogen. The interstitial fluid was thawed and the
supernatant was taken after a spin at 1200 rpm at 4°C for 10 min. Standards were made
and processed in parallel with interstitial fluid by taking 200μL of the supernatant or
standard and adding 800μL of LC-MS grade methanol on dry ice. Samples were then
transferred to a -80°C freezer for 2 h. Samples were spun at 13000 rpm for 10 min and
the supernatant was placed in a speedvac until dry. Resuspension was done with LCMS grade methanol/water/acetonitrile (60:30:10 %vol/vol/vol) and ran through a LCMS/MS with standards. Quantification of peak areas were performed using MassLynx
(Waters Co., Milford, MA, USA) and normalized with the amount of tumor used.
Results
NT5E expression is one of the largest enzymatic contributors to overall patient
survival
To investigate the potential roles metabolic enzymes have on tumor
aggressiveness, we sought to correlate the mRNA expression with overall survival through
an unbiased screen in TCGA. We chose to examine the patients through two strategies.
The first separated patients through the interquartile range (IQR) that had either the
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highest or lowest 25% expression (Table 3.1). The second approach examined if the
mRNA expression was statistically increased or decreased with a Z-score ≥2 or ≤-2
respectively (Table 3.2). Significant hits (p<0.05) from both approaches were examined
through pathway enrichment to examine if a particular function of enzymes are associated
with an impact on survival (Figure 3.1A). Pyrimidine metabolism was the biggest hit with
both approaches with purine metabolism ranking second when combining both
approaches. We further investigated which genes have a strongly significant influence on
survival within in these two nucleotide pathways. Interestingly, pyrimidine and purine share
the same largest survival impact with enzyme commission (EC) 3.1.3.5 when examining
Z-score (Figures 3.2A,B). EC 3.1.3.5 had the largest impact on IQR based survival in
pyrimidine metabolism and the second largest hit in purine metabolism (Figures 3.2C,D).
EC 3.1.3.5 is performed by a few enzymes that catalyze 5’-nucleotides. We aimed to
identify the chief gene behind this enzymatic function.
When ranking Z-score by the log-rank p-value of high vs. normal expression, NT5E
had the second largest impact on survival and the second largest impact when comparing
all cohorts with IQR for all enzymes (Figures 3.2E,F). It is interesting to note the top ranked
enzymes in IQR are GMPS, NT5E, TYMS (Figure 3.2F), which are nucleotide
monophosphate metabolism enzymes and highlight the significance of nucleotide
metabolism pathways on survival shown by Figure 3.1A.
We sought to verify the role of NT5E in survival and saw significantly decreased
survival when mRNA was two standard deviations above normal tissue (Figure 3.1B). IQR
also saw a similar significant change for elevated NT5E (Figure 3.1C). No difference in
survival was seen when comparing patients with normal and low expression of NT5E
mRNA. To validate these findings, we examined the ICGC data and found the same trend
to be highly significant again (Figure 3.1D). We therefore hypothesize that elevated NT5E
expression acts to promote tumor growth and correlates with overall survival.
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CD73 expression increases throughout tumor progression
We sought to determine if CD73, the protein produced by NT5E, and its metabolite
product, adenosine, are correlated with tumor progression. We examined pancreatic
tumors through the University of Nebraska Medical Center’s Rapid Autopsy Program and
observed significant increasing CD73 staining intensity and area from low-grade
pancreatic intraepithelial neoplasia (PanIN) to high-grade PanIN to mature tumor (Figures
3.1E,F). Furthermore, increased CD73 expression through tumor progression was
observed when utilizing KPC mice (Figure 3.1G). Lastly, we observed that the functional
product of CD73, adenosine, was significantly increased in the interstitial fluid of the KPC
tumors at a relatively advanced timepoint (Figure 3.1H). These data suggest that CD73
becomes progressively elevated in pancreatic cancers.
Decreasing CD73 expression decreases tumor growth and increases survival
To assess the impact of CD73 on tumor growth and survival, Nt5e was knocked
down with short hairpin RNA (shRNA) expression in a cell line derived from a KPC tumor
designated as 1245. Parental 1245 cells were engineered to express luciferase (1245Lum)
before knocking down Nt5e to monitor the tumor growth. Knockdowns achieved <5%
mRNA expression compared to the control (Figure 3.3A). When these cells were
orthotopically implanted into syngeneic C57BL/6J mice, we observed a significant
increase in survival and decreased tumor volume for both knockdowns (Figures 3.3B-D).
After re-validating the knockdowns (Figure 3.3E), we implanted fewer cells (5x103) to
extend survival to look for differences at an early and late timepoint. Differences were
much larger at a later timepoint, which showed a slight trend with metastasis (Figures
3.3F-I). The mice with Nt5e knockdown showed a long-lasting durable response (Figure
3.4). An examination of the tumors through hematoxylin and eosin (H&E) revealed
increased levels of intra-tumoral immune cells and a drastic increase in the immune cell
penetration into the tissue edge in Nt5e knockdowns (Figure 3.3J).
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To confirm these results, another independent cell line derived from KPC was
examined called 1199. After confirming a substantial decrease of CD73 in 1199
knockdowns (Figure 3.3K), we performed an orthotopic implantation and observed a very
significant decrease in tumor growth, as well as decreased tumor weight at necropsy
(Figures 3.3L,M). Decreased CD73 also correlated with improved survival (Figure 3.3N)
and was independent of sex between time-matched male and female mice (Figures
3.3O,P). Collectively, these data establish that CD73 promotes tumor aggressiveness and
that decreasing CD73 expression decreases tumor burden and increases survival of mice,
possibly through an immune related function.
CD73 knockdowns decrease MDSCs and increases peripheral CD4+ and CD8+ Tcells
We decided to further investigate the possible immunosuppressive function of
CD73 by quantifying the relative abundance of various immune cell populations in the
peripheral blood of mice implanted with CD73 knockdowns or control 1199 cells using flow
cytometry (Figures 3.5A-F). Relative abundance of monocytic myeloid-derived suppressor
cells (MDSCs) and granulocytic MDSCs were significantly decreased in knockdowns,
while CD4+ and CD8+ T-cells were observed to be increased (Figures 3.5B,C,E,F).
Because the half-life of adenosine in circulation is only a few seconds (241), it was unclear
how the peripheral blood immune cells could be altered by CD73 knockdown. We
hypothesized a cytokine-dependent mechanism and examined a panel of 31 cytokines in
the tumor interstitial fluid of 1199 implanted mice and found the largest change was
associated with GM-CSF (Figure 3.5H). These data suggest that tumoral secretion of GMCSF could be responsible for the changes in peripheral blood immune cell composition.
CD73 knockdown leads to enhanced antitumor immune response
To test if T-cells have a functional role in the anti-tumor phenotype of CD73
knockdowns, we implanted in the T cell deficient athymic nude mice with 1199 knockdown
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or control cells. Although there was a significant difference in tumor volume between
control and CD73 knockdown groups on the last day of the study (Figure 3.6A), all mice
had palpable tumors, in contrast to the previous implantation studies in B6(Cg)-Tyrc-2J/J,
in which some mice lived tumor-free for over a year (Figures 3.3N and 3.4). Furthermore,
the tumor volume and weight upon necropsy was not significantly different for knockdown
1 with a slight significant decrease with knockdown 2 (Figures 3.6B,C). Thus, because the
effect of CD73 knockdown was much less pronounced in athymic nude mice than in their
C57BL/6J immunocompetent counterparts, these data suggest that CD73 knockdown
may enhance T-cell-mediated antitumor immunity.
A central component of adaptive immunity is the existence of memory T-cells,
which demonstrate a more rapid and stronger response upon antigen reexposure than
naive T-cells with the same antigen specificity (242-244). Therefore, if T-cells are behind
the enhanced survival advantage of CD73 knockdowns, then the presence of educated Tcells should impart enhanced antitumor immunity upon reexposure to implanted cancer
cells. After mice survived more than a year following an orthotopic injection of 1245
knockdown 2 cells, mice were re-challenged with control and knockdown 2 cells through
subcutaneous injections alongside naïve mice which have never had cancer (Figure 3.6E,
3.4). The injection of knockdown 2 cells disappeared quickly, while control cells were able
to grow (Figure 3.6F). It was observed that the cancer experienced mice were able to
significantly inhibit the growth of the control tumors compared to both controls. Mice with
potential memory T-cells from prior cancer exposure could help decrease control 1245
cancer growth. These data show an enhanced response in experienced mice, suggesting
a potential role of memory T-cells.
We next depleted CD4 and CD8α to test which T-cell subtype might be more active
in the CD73 knockdowns after validating the depletion strategy (Figure 3.7). Since 1245
knockdown 2 had the strongest phenotype, we thought it would be a robust model to utilize
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in examining for a potential rescue with an antibody depletion study as shown in (Figure
3.6H). Depleting CD4 or CD8α did not appear to significantly alter the growth kinetics or
survival in control mice (Figures 3.6I,J). Despite the strong prolonged survival and reduced
growth of knockdown 2, CD4 depletion was able to drastically decrease survival and to
increase the rate of tumor growth. To our surprise, CD8α depletion did not appear to have
a significant effect on tumor growth. Collectively, these data suggest that CD4 T-cells are
largely responsible for enhanced antitumor immunity and resulting prolonged survival and
retarded tumor growth in the setting of implanted tumor cell CD73 knockdown.
GM-CSF and MDSCs are critical to the functional role of CD73
Knockdown of CD73 in implanted cancer cells results in decreased GM-CSF and
MDSCs in addition to elevated CD4 and CD8 T-cells in the host mouse (Figure 3.5). GMCSF is known to promote MDSCs (245), which in return are known to regulate peripheral
levels of T-cells (246), which suggests this mechanism could be at the heart of the immune
alteration. Utilizing CD73 knockouts in 1245 (Figure 3.8A), we observed a similar
phenotype with decreased weight and volume of tumors, as well as 30% appearing tumor
free, when implanted in syngeneic immune competent mice (Figure 3.8B). In parallel, mice
were also injected with GM-CSF to replenish the associated decrease in knockdowns.
Injection of GM-CSF in mice implanted with CD73 knockout cells was able to greatly
restore tumor growth (Figure 3.8C). However, GM-CSF restoration of tumor growth was
dependent on MDSCs, as mice that were concurrently treated with anti-Gr1 antibody,
which depletes MDSCs, had tumor growth levels similar to IgG2β treated controls (Figure
3.8B,D). These data further support the notion that the growth inhibitory effects of
decreased CD73 are mediated by GM-CSF and that this mechanism requires MDSCs for
a large fraction of the effects.
Combination therapy with anti-CD73 antibody and gemcitabine
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With such drastic changes in growth kinetics upon decreased CD73, we were
curious if this could be beneficial therapeutically. We tested the effects of CD73 antibody
inhibition in combination with gemcitabine, a frequently utilized chemotherapy in
pancreatic cancer.
Combination therapy had a significant improvement in the survival and significantly
decreased tumor growth rates in mice orthotopically-implanted with 1245 cells, as
compared to either treatment alone or the solvent control (Figures 3.9A-C). We tried to
recreate a patient setting by utilizing spontaneous KPC models and waiting for the tumor
to reach an enrollable size before starting treatments. Under this setting, the slope of the
combination was nearly flat and had a significant reduction in tumor growth compared to
all other treatments (Figures 3.9D,E). These data suggest that targeting CD73 with a
chemotherapy can increase survival and decrease tumor burden and is potential
therapeutic angle to be examined clinically.
Discussion
This study sought to identify metabolic enzymes with a large impact on patient
survival in an unbiased screen. Our results highlight how altered expression of metabolic
enzymes, in this case CD73, can impinge on antitumor immunity by malignant cells.
Indeed, IL17D and ARID5A were the first and third top hit when examining high vs. low
IQR expression (Table 3.3), and these two genes carry multiple immune functions (247)
and can promote CD4+ differentiation into pro-inflammatory Th17 (248).
We also performed pathway enrichment analysis on enzymes that impacted
survival and found that purine and pyrimidine pathways are likely highly significant for
patient outcome (Figure 3.1A). We are curious if the skew towards nucleotide metabolism
is influenced by the patient’s chemotherapy, as the frontline therapies utilizes nucleoside
and base anti-metabolites, such as gemcitabine and fluorouracil, which can increase
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nucleotide metabolism as a mechanism of drug resistance (249). Chemotherapy can also
promote antigenicity, for which these genes of interest could further enhance or suppress
their utilization (250, 251). Therefore, targeting these pathways may further enhance the
effect seen with chemotherapy, which was observed in this study (Figure 3.9). Because
the nucleotide pathways were enriched, it is likely other targets may exist within these
critical pathways. One such nucleotide enzyme might be GMPS, which ranked the highest
in the IQR enzyme screen (Figure 3.2F) and was the fourth most significant when
examining high vs. low expression with all genes (Table 3.3). The association of increased
NT5E and survival has been seen before in other cancers (252, 253), but it is reported
here to have one of the largest impacts on survival of all enzymes in pancreatic cancer.
CD73 expression began accumulating in early stage PanINs and became
drastically elevated in tumors (Figures 3.1E-G), which suggests cancer evolution of
immune suppression begins at a very early stage. Such early stage PanINs may not have
the neoantigen profile necessary to drive a robust immune response; however, increased
CD73 could be generated as a byproduct of increased HIF-1α (50) or selected upon due
to the benefit extracellular adenosine on the tumor, such as increased proliferation and
survival (203, 254). Accordingly, previous studies have observed an association with
increased CD73 and stage in multiple cancers (252, 253), but shown here to be increased
through PanIN development and functionally increased through elevated adenosine in
KPC mice (Figures 3.1E-H).
One of the major mechanisms induced by CD73 is an alteration in the tumor
immune environment (64, 66). We report for the first time using multiple immunocompetent
models of the effect of targeting and altering CD73 expression in pancreatic cancer. We
repetitively saw drastically increased survival (Figures 3.3B, 3.3N, 3.6J, and 3.9A,D) and
decreased tumor burden (Figures 3.3C,D,F-H,L,M,O,P, 3.6F,I, 3.8B-D, and 3.9B,D) when
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knocking down CD73, knocking out CD73, or targeting CD73 in combination with
gemcitabine.
We show here the potential feed-forward mechanism of cancer-associated CD73
on GM-CSF induced MDSCs levels, which inversely correlate with T-cells (Figures 3.5).
Decreased levels of the MDSC growth cytokine, GM-CSF (245), was observed in CD73
knockdowns, which correlates with the reduced presence of MDSCs in the peripheral
blood and an increase of T-cells (Figure 3.5). MDSCs negatively regulate CD4 and CD8
T-cell effector function, and can even inhibit T-cell function in the peripheral blood within
two hours (246). To test if decreased CD73 tumors have decreased burden through a GMCSF–MDSC axis, we implanted a CD73 knockout and treated with GM-CSF or with GMCSF with MDSC depletion (Figure 3.8). GM-CSF supplementation inhibited the significant
difference in knockout tumor burden. However, depleting MDSCs in the presence of GMCSF supplementation restored the knockouts ability to improve tumor burden. These data
suggest that decreasing CD73 decreases GM-CSF, which acts in part through MDSCs
that correlate with CD4 and CD8 T-cell levels, which act to decrease tumor burden.
We further investigated the role of T-cells in the orthotopic models. We observed
in athymic nude mice that tumors were able to grow tumors instead of stagnate, the tumorfree phenotype was ablated, and there was a trend in decreased tumor burden, which was
seen to be not significant and significant in half of the knockdowns upon necropsy (Figures
3.6A-C). We also observed that mice previously implanted orthotopically with cancer
potentially had immunological memory (Figures 3.6E,F). Finally, the direct role of CD4+
cells were seen to significantly impact the ability of CD73 knockdown to improve tumor
burden. Surprisingly, CD8 depletion at day 120 had a marginal effect, suggesting a CD8independent mechanism; however, the remainder of the IgG2α/β cohort lived for more
than a year, which ultimately generated significance. These data suggest decreased CD73
promotes a beneficial CD4 subtype that acts largely independent of CD8α.
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Recent advances in immune check point inhibitors have shown tremendous clinical
advantages, while offering little-to-no benefit in the majority of PDAC where it lags behind
and is resistant such approaches due to its cold immune environment (255, 256).
Pancreatic cancer is highly immunosuppressive (257, 258) and can be described as an
immune quiescent tumor (225). Tumor mutational burden, mismatch repair deficiency, and
microsatellite instability are associated with immune response; unfortunately there are low
frequency of these events in PDAC (259-261). In addition, pancreatic cancer tends to have
elevated levels of PD-L1 and serves as an indicator of prognosis (261-267). However, no
clinical objective responses in pancreatic cancer with anti-PD-L1 has been observed
(227). We hypothesized that targeting PD-L1 in conjunction with CD73 and gemcitabine
could improve response to therapy. Gemcitabine is known to increase tumor antigenicity
(250, 251) and has been observed to have a beneficial immune response in pancreatic
cancer (268, 269). Targeting CD73 in vivo in combination with gemcitabine resulted in
decreased CD73 expression, decreased tumor burden, and enhanced survival compared
to each monotherapy alone (Figure 3.9). We also utilized KPC mice, which display a
similar immune microenvironment and drug immune response compared to humans (270).
This model of immune therapy showed an enhanced response to anti-CD73 antibody
therapy and a much greater combination therapy response compared to gemcitabine.
These data suggest a therapeutic avenue for targeting CD73 in the immunosuppressive
environment of pancreatic cancer (229).
These data open the doors to the therapeutic avenues when targeting CD73. Our
study has shown that CD73 expression is upregulated in human and mouse tumors and
that knocking down CD73 expression in tumors leads to reduced tumor burden and
prolonged survival. Unlike other studies, we observed a GM-CSF - MDSCs mechanism
that utilized CD4+ immune cells largely independent of CD8 T-cells. These data show a
great therapeutic response to targeting CD73 in the presence of the chemotherapy
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gemcitabine. We are excited about the possible approaches targeting CD73 could bring
to pancreatic cancer, including combination with other checkpoint inhibitors, such as PDL1, CTLA-4, and CD40, chemotherapies, and cancer vaccines. In addition, we believe this
warrants further investigation in other cancers.
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Figure 3.1: NT5E is overexpressed and impacts survival in pancreatic cancer. (A)
Pathway enrichment when utilizing enzymes contributing to a significant (p<0.05) overall
survival (OS) in The Cancer Genome Atlas (TCGA) when cohorts were derived by Z-score
or through the interquartile range (IQR). The order of the pathways were ranked for each
approach, added together to generate a combined score, and subsequently ranked. (B)
TCGA pancreatic cancer OS when comparing patients two standard deviations above
adjacent normal mRNA and those within two standard deviations. (C) IQR range OS
comparing TCGA patients with low (0%-25%), normal (25%-75%), and high (75-100%)
NT5E mRNA expression. (D) International Cancer Genome Consortium (ICGC) OS when
comparing patients with high and low IQR NT5E mRNA. (E) Representative
immunohistochemistry (IHC) of CD73 in control, low-grade and high-grade pancreatic
intraepithelial neoplasia, and tumor tissue used in (F) histological scoring of sections. Oneway ANOVA with Tukey’s multiple comparison test was performed for significance, with +
denoting a comparison to normal ductal slides. (G) Representative IHC images of Cre
(top) control and KPC (bottom) mice pancreases at 10, 15, and 25 weeks after birth, as
well as (H) the interstitial fluid levels of adenosine in these mice. One-way ANOVA with
Bonferroni’s multiple comparison test was performed for significance. The size of
measurement bar in the images denotes 250μM, with each small tick indicating 50μM.
The scale bar denotes 250 μm. Error bars depict the standard error of the mean. *P <
0.05, **P < 0.01, ***P < 0.001, +++P < 0.001.
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Figure 3.2: Pyrimidine and purine pathways are enriched in the survival-associated
enzyme cohorts. (A,B) Kyoto Encyclopedia of Genes and Genomes’ (KEGG) pyrimidine
and purine metabolism pathways were colored according to Mantel-Haenszel log-rank
survival p-value of genes when separating cohorts that are two standard deviations away
from normal adjacent tissue mRNA (Z-score). (C,D) KEGG’s pathways colored according
to Mantel-Haenszel log-rank survival p-value, however, patients were split into cohorts by
the interquartile range (IQR) of a given gene. Genes are colored based on the MantelHaenszel log-rank survival p-value < 0.05. Yellow indicates a weaker significant p-value,
orange indicates a moderately significant p-value, and red indicates the top spectrum of
the most significant p-value. Green indicates it was not seen as significant, whereas white
boxes indicate a non-human gene in the database. The color-coding scale for Z-score and
IQR charts are independent of each other. All enzymes within the analysis impact the color
scale regardless of their presence within a displayed pathway. (E) Z-score enzyme
survival p-values when ranked by high vs. normal mRNA expression and (F) IQR enzyme
survival p-values when ranking by all cohorts.
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Figure 3.3: Decreased CD73 improves survival and decreases tumor burdern. (A)
Nt5e mRNA measured by qPCR. (B) Overall survival of orthotopic implantation of 5x104
syngeneic control and knockdown (KD) 1245 cell lines into B6(Cg)-Tyrc-2J/J mice (C) and
tumor burden as measured by luciferase activity through Spectrum In Vivo Imaging
System. (D) Images used to quantify tumor burden with the same mice in each column,
but randomized within each square. (E) Immunoblot showing CD73 in 1245 through
western blotting. (F) Tumor burden measured by calipers of orthotopic implantation of
5x103 syngeneic 1245 cell lines into B6(Cg)-Tyrc-2J/J mice with necropsy pancreas and
tumor weight at (G) day 20 (H) and day 30 (I) with tumor observation at day 30, which
consisted of visual and palpitation of the removed pancreas. (J) Representative images
of the day 30 necropsy, except for KD2, which is representative of the tissues with a
tumor. (K) CD73 estimation in 1199 through western blotting. (L) Caliper measurement
of tumor burden of orthotopic implantation of 5x103 syngeneic 1199 cell lines into male
B6(Cg)-Tyrc-2J/J mice (M) with pancreas and tumor weight at necropsy (N) along with
overall survival to day 80, although the remainder of the mice lived for more than a year.
(O) Male (P) and female mice tumor volume measured through calipers at day 25. (Q)
Three representative tumors, except KD1, for which tumor was not observed when
sectioning. The size of measurement bar in the images denotes 250μM, with each small
tick indicating 50μM. Bar charts utilized a one-way ANOVA with Tukey’s multiple
comparison test, while longitudinal measurements utilized a two-way ANOVA with
Bonferroni’s multiple comparison test for significance. Percent of mice with tumors was
analyzed through Chi-square test. Error bars depict the standard error of the mean. *P <
0.05, ***P < 0.001.
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Figure 3.4: Long term survival and relapse observed in CD73 knockdowns. Mice
were orthotopically implanted with 5x103 luciferase positive KPC1245 Nt5e knockdowns
or control cells. Upon necropsy, control mice (n=10) had tumors while little-to-no tumor
was observed in KD1 (n = 10) and KD2 (n = 4). The remaining KD2 mice (n = 6) were
spared and monitored if they will develop a tumor. (A) Mice were injected with luciferin to
see if there was a tumor, as it appeared negative in the necropsy. The luminescence signal
observed was similar to the background (far right). (B) Mice were observed weekly and
found one mouse that developed a tumor. (C) Whole-body counts with the same area
were measured for each mouse. The red line indicates the mouse that developed a tumor,
while the blue lines are the other mice. The observation ended several weeks later;
however, one more mouse developed a tumor around day 200. After one year, mice were
examined again and found negative. (D) 478 days later, cage 1 was examined for
presence a luciferase signal after injecting luciferin.
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Figure 3.5: Nt5e expression regulates GM-CSF, peripheral T-cells, and peripheral
MDSCs. Flow cytometry gating scheme for (A) T-cells and (D) for monocytic and
granulocytic (M- and G-) MDSCs respectively. (B,C,E,F) Flow cytometry quantification of
the percentage of living cells within each gate. (G) Tumoral GM-CSF analyzed on a
multiplex cytokine assay. One-way ANOVA with a Dunnett’s multiple comparison test was
used for each figure. Error bars depict the standard error of the mean. *P < 0.05, **P <
0.01, ***P < 0.001.
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Figure 3.6: Immune depletion validation. Pilot experiments were carried out to verify
CD4 and CD8α depletion. (A) Layout of the injection schedule and experimental cohorts
excluding healthy age-matched mice as a control (normal). Peripheral blood was
collected through submandibular bleeding and gated for size, viability, and CD3+ before
gating for (B) CD8α+ (C) and CD4+. (D) Representative gating after gating for size and
viability. (E) Depletion strategy of mice implanted with 5x103 KPC1245 cells to examine
depletion in the setting with tumors and after a week’s break around the time of
necropsy. Submandibular peripheral blood was gated for size, viability, and CD3+ before
gating for (F) CD8α + (G) and CD4+. (H) Representative gating after gating for size,
viability, and CD3+ cells. Error bars depict the standard error of the mean.
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Figure 3.7: Nt5e knockdowns associate with an immune role. (A) Longitudinal caliper
measurements of orthotopic implantation with 5x103 1199 cell lines in the pancreas of
athymic nude mice. (B) Tumor volume, (C) tumor weight, (D) and representative tumor
images of the athymic nude mice euthanized 23 days after implantation. (E) Mice that
previously survived 1245 orthotopic implantation were categorized as tumor experienced
mice and were re-implanted with 1245 control or knockdown (KD) 2 cells subcutaneously
in addition to tumor naïve mice of the same sex. (F) Longitudinal caliper measurements
of re-challenged and naïve mice. Statistics was calculated by a one-way ANOVA of the
final 16th day. (G) Representative tumor images of re-challenged and naïve mice. (H)
Scheme of immune depletion regimen. (I) Caliper measurements with significance
calculated by using a generalized linear mixed model for longitudinal log-normal data
incorporating compound symmetry correlation among longitudinal data from the same
subjects. * and + denotes 1245 KD2 CD4-depletion comparison to KD2 IgG2α/β or KD2
CD8-depletion respectively. No differences between control cells were observed, but
differences between knockdown and control treated with IgG2α/β were seen to be
significant (p<0.001). (J) Overall survival and (K) and representative tumor images of CD4or CD8-depleted mice with an orthotopic implantation of 1245 control or KD2 mice. The
size of measurement bar in the images denotes 250μM, with each small tick indicating
50μM. Error bars depict the standard error of the mean. *P < 0.05, **P < 0.01, ***P <
0.001, +P < 0.05, ++P < 0.01.
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Figure 3.8: Tumor burden by CD73 knockouts are reversed by GM-CSF
supplementation and rescued with MDSC depletion. (A) Western blot of Cas9+ nontargeting single guide RNA (Sg NT) and CD73 knockout (CD73 KO). Pancreas weight
(top) and volume (bottom) of mice orthotopically implanted with 5x103 1245 CD73
knockout or control treated with (B) IgG2β, (C) GM-CSF, (D) and GM-CSF with anti-Gr-1
antibody to deplete MDSCs. Bar charts were compared with a student’s T-test for
significance. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 3.9: Gemcitabine and anti-CD73 combination therapy reduces tumor
burden and improves survival. Mice were orthotopically implanted with 5x104 congenic
1245 cells and treated with gemcitabine and/or anti-CD73 therapy, which were
measured for (A) overall survival, (B) tumor volume measured through calipers, (C) and
representative images of tumors near the median survival of each group. (D) Tumor
volumes measured by ultrasound. Significance of the growth measurements was
calculated using a generalized linear mixed model for longitudinal log-normal data
incorporating autoregressive correlation among longitudinal data from the same
subjects. (E) Images of tumors from KPC mice with gemcitabine and/or anti-CD73
therapy. *P < 0.05, **P < 0.01, ***P < 0.001.
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Table 3.1

Gene
UROD
NT5E
SGPL1
ST3GAL6
GALNT9
OXSM
STT3A
PRPS2
ALG10
PTGS2
NDUFA9
IMPAD1
POLR3G
CCBL2
HIBADH
DSE
UGDH
MTR
RIMKLB
POLA1
CHSY3
GMPS
ADH5
COQ5
RPN1
LDHA
GALNS
PRIM2
TPI1
PIK3C3

p-value High vs
Normal
3.62E-13
7.36E-11
8.73E-10
3.11E-09
2.40E-07
2.00E-06
2.91E-06
3.81E-06
5.08E-06
8.28E-06
1.36E-05
2.90E-05
2.93E-05
3.95E-05
3.98E-05
0.00012
0.00012
0.000129
0.000136
0.000147
0.000183
0.000188
0.000413
0.000433
0.000443
0.000499
0.000534
0.000654
0.000656
0.000689

p-value Low vs
Normal
0.0048
NA
0.966
0.392
0.0119
NA
NA
0.587
0.689
NA
0.656
0.813
0.598
0.889
NA
0.427
NA
0.49
0.1
1
0.395
0.3
0.0239
0.279
NA
NA
0.511
0.0432
NA
0.216

p-value High vs
Low
0.000183
NA
0.157
0.000108
0.000255
NA
NA
0.225
0.0801
NA
0.577
1
0.000138
0.017
NA
0.000989
NA
0.0168
0.00882
1
0.157
0.847
0.32
0.151
NA
NA
0.317
0.932
NA
0.0021

p-value
All
2.11E-15
7.36E-11
4.69E-09
1.35E-09
2.69E-07
2.00E-06
2.91E-06
1.78E-05
2.10E-05
8.28E-06
6.76E-05
0.000153
2.89E-05
0.000847
3.98E-05
0.00058
0.00012
0.000626
0.000444
0.000147
0.000555
0.000849
0.000328
0.00197
0.000443
0.000499
0.00189
0.00101
0.000656
0.00111
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Table 3.1: Enzyme survival p-values by generating mRNA Z-score cohorts.
Pancreatic patients from The Cancer Genome Atlas (TCGA) were split into cohorts
based on if the mRNA was lower, similar, or higher than normal mRNA based on if it was
more than two standard deviations below (low), above (high), or within (normal) two
standard deviations from the normal adjacent tissue mRNA expression. All cohorts were
analyzed pairwise or together (All). P-values represent the significance of a MantelHaenszel log-rank test. NA denotes that a value cannot be computed, such as in the
case where a cohort does not have any samples due to the mRNA not reaching two
standard deviations away from the expression in the normal tissue (n = 4). The top 30
genes ranked by “p-value High vs Normal” are shown above.
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Table 3.2
Gene
GMPS
NT5E
TYMS
PIP5K1B
PYGL
PAICS
DGKD
MTHFR
ATP6V0A1
EARS2
POLR3G
HSD17B1
ACSS1
CYP27A1
XDH
ST3GAL2
LDHA
PLA2G2A
PLCD4
WBSCR17
LIPT1
PI4K2B
SUCLG2
LPIN1
ENPP3
ADK
EXTL2
ATP6V1G2
CYP4A11
MINPP1

High vs Normal
7.22E-05
7.33E-04
1.02E-04
5.13E-01
2.49E-04
3.16E-03
9.70E-01
4.89E-01
4.45E-01
3.85E-03
2.18E-03
0.696
0.581
0.0815
0.000338
0.0383
0.0011
0.596
0.182
0.602
0.409
0.000908
0.0013
0.91
0.352
0.00116
0.358
0.966
0.122
0.0264

Low vs Normal
1.04E-01
4.25E-01
9.59E-01
4.23E-05
6.94E-01
6.64E-02
2.23E-04
4.44E-04
8.23E-04
3.95E-01
8.09E-01
0.000136
0.000279
0.00507
0.297
0.0486
0.666
0.00277
0.0125
0.000755
0.000488
0.0654
0.0419
0.0015
0.01
0.59
0.000781
0.00294
0.00102
0.00234

High vs Low
1.84E-05
5.82E-04
1.83E-03
1.21E-02
2.49E-03
5.50E-04
1.74E-02
2.08E-02
6.70E-03
1.26E-03
1.80E-03
0.0155
0.0258
0.00159
0.109
0.000508
0.0187
0.00846
0.00148
0.0265
0.0373
0.203
0.314
0.0201
0.0025
0.0302
0.063
0.0145
0.258
0.532

All
8.61E-07
1.41E-04
1.69E-04
1.91E-04
2.17E-04
2.45E-04
6.99E-04
9.97E-04
1.08E-03
1.12E-03
1.14E-03
0.00115
0.00121
0.00155
0.00158
0.00174
0.00196
0.00206
0.00219
0.00224
0.00225
0.00225
0.00236
0.00243
0.00245
0.00265
0.0029
0.00321
0.00331
0.00378
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Table 3.2: Enzyme survival p-values through generating mRNA interquartile range
cohorts. Pancreatic patients from The Cancer Genome Atlas (TCGA) were split into
cohorts based on if the mRNA was in the <25% (low), 25%-75% (normal), or >75%
(high) interquartile range. The data shown are the p-values for the significance of a
Mantel-Haenszel log-rank test. All cohorts were analyzed together in the all category.
The top 30 genes ranked by the “All” column are shown above.
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Table 3.3

Gene
IL17D
EPS8
ARID5A
GMPS
MAGOHB
C15orf23
MET
FKBP4
POT1
TMEM229A
DISP1
TRIM67
TPX2
SOBP
ITGA7
SLC46A2
PRDM6
CLEC3B
SLC25A44
GPR87
AQP7P3
FCN1
HOXB4
WHAMML2
ZNF18
BAI2
LOC283663
FIGNL2
EXOC4
C12orf32

p-value High vs
normal
0.0119
0.00204
0.0759
7.22E-05
0.00105
0.000347
3.73E-05
0.00704
3.51E-05
0.0393
0.507
0.177
0.00206
0.469
0.0774
0.0993
0.00702
0.102
0.704
0.000456
0.0721
0.467
0.0301
0.178
0.0755
0.147
0.184
0.0144
0.00378
0.103

p-value Low vs
normal
0.00311
0.144
0.000849
0.104
0.575
0.366
0.309
0.077
0.456
0.0143
6.41E-07
0.000208
0.268
9.31E-07
0.0033
0.00226
0.11
0.000269
9.42E-05
0.284
0.0183
0.000302
0.0302
0.000988
0.00418
0.00102
0.00916
0.0522
0.0233
0.0118

p-value High vs
Low
3.41E-07
8.05E-06
1.70E-05
1.84E-05
2.07E-05
2.21E-05
2.59E-05
2.78E-05
3.32E-05
3.35E-05
4.81E-05
5.15E-05
5.73E-05
8.31E-05
8.86E-05
9.42E-05
0.00011
0.00011
0.00012
0.000125
0.000125
0.000142
0.000143
0.000148
0.000155
0.000166
0.000179
0.00018
0.000181
0.000189

p-value
All
5.48E-06
6.14E-05
2.60E-05
8.61E-07
0.000118
3.29E-05
2.46E-06
0.000164
3.20E-06
0.000174
1.96E-07
1.24E-05
0.000124
9.88E-08
0.000133
7.63E-05
0.000768
1.85E-05
3.32E-05
3.97E-05
0.0011
7.80E-05
0.000824
0.000121
0.000239
0.00012
0.00119
0.000701
0.000137
0.00124
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Table 3.3: Survival p-values of all available genes through generating mRNA
interquartile range cohorts. Pancreatic patients from The Cancer Genome Atlas (TCGA)
were split into cohorts based on if the mRNA was in the <25% (low), 25%-75% (normal),
or >75% (high) interquartile range. P-values represent the significance of a MantelHaenszel log-rank test. NA denotes that a value cannot be computed, such as in the case
where a cohort does not have any samples due to the mRNA not reaching two standard
deviations away from the expression in the normal tissue (n = 4). The top 30 genes ranked
by “p-value High vs Low” are shown above.
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Chapter 4: Esophageal cancers show large metabolic and immune differences
across histological subtypes
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Introduction
Precision medicine holds strong potential for delivering more promising
therapeutics to the correct patients. For example, one subset of patients may respond
strongly to a given therapy, while another subset may show little-to-no improvement,
thereby increasing the risk of futilely decreasing quality of life for patients. Differences in
cancer etiology, environments, and evolutionary selection, such as pressures and
mitigations from founding mutations, may give rise to different subsets of cancer profiles,
which can have different vulnerabilities and inherent resistances.
Metabolism is a key reporter of cellular status. It is no surprise that founding
mutations of cancers alter metabolism. All functional genes either utilize a metabolic
reaction to exert their function, or their alteration impacts the cell in a manner that affects
proteins utilizing a metabolic reaction. It has been observed that expression of enzyme
mRNA can be utilized to estimate metabolic flux (271-273). This study hypothesizes that
metabolic alterations can reveal unique cancer subtypes that can give rise to precision
medicine based on differences in clinical attributes and their associated selection that
results from environmental factors and cancer etiology. Hence this study seeks to utilize
metabolic enzyme expression as a reporter to determine if differences can give rise to
distinctive subtypes that are uniquely targetable. The following 13 cancer cohorts were
screened through The Cancer Genome Atlas (TCGA): esophageal carcinoma, kidney
clear cell renal carcinoma, kidney renal papillary carcinoma, lung adenocarcinoma, lung
squamous

cell

carcinoma,

prostate

adenocarcinoma

acinar

type,

pancreatic

adenocarcinoma, colon adenocarcinoma, rectum adenocarcinoma, bladder urothelial
carcinoma, breast invasive carcinoma, stomach adenocarcinoma, and uterine corpus
endometrial carcinoma. Of these 13 cohorts, only esophageal cancer showed a drastic
change when patients were separated based on attribute of histological subtype.
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Worldwide, esophageal cancer is the eighth most common cancer, presenting
with the sixth-highest rate of cancer-associated deaths (274, 275). The five-year overall
survival rate in the United States is 19.9% (276), and the rate of incidence and
associated mortality has increased 15-20% in the last 30 years (277). Although
esophageal squamous cell carcinomas (ESCC) is more prevalent than esophageal
adenocarcinoma (EAC) worldwide (277, 278), the diagnosis rate of EAC has also
increased by over 600% in the last 30 years in the United States alone (278).
Differences in lifestyle and associated etiological factors may give rise to these different
subtypes of esophageal cancer (277), which could be targeted more precisely based on
the subtype.
Roughly half of the patients with esophageal cancer present with distant
metastases and are treated with chemotherapies despite heterogeneity-associated
resistance of ESCC and EAC to chemotherapy (279, 280). These observations have
prompted the field to examine potential immunological-based approaches for treatment
(279-281). Due to differences in metabolism between subtypes and the extent
metabolism can exert over the tumor microenvironment (56, 64, 192, 193, 195, 197-199,
202, 282, 283), this study determined it appropriate to examine subtypes based on the
extent of metabolic differences, clinical parameters, and the cytokine environment. This
study also examined their potential roles with immunity, checkpoint therapy, and
highlights that potential metabolic and immune differences can be exploited with
precision medicine when separating the two metabolic cohorts.
Methods
Data Retrieval
TCGA data were downloaded using the TCGA Data Matrix. TCGA mRNA and
clinical attributes were analyzed as performed previously (35). All RNA-Seq by
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expectation-maximization (RSEM) mRNA expression utilized was provided by the TCGA
as upper quartile normalized RSEM for the given cohort. A list of human metabolic
enzymes was downloaded from the Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway for hsa01100. Gene Ontology (GO) and KEGG pathways were from
the linked online sources that are supplied with Gene Set Enrichment Analysis (GSEA)
v2.2.3. For pathways to be considered metabolically associated, ≥90% of the genes
must be considered enzymes with a minimum of 10 enzymatic genes per pathway, as
defined from hsa01100.
Data and Statistical Analyses
ActiveState Perl5 version 5.24.1 (www.perl.org) was used as the top-level script
to gather and organize data, perform student t-tests, Benjamini–Hochberg corrections,
quartile quantifications, and to feed commands to GSEA through Java, to generate and
execute R scripts, and to record the output. Bar graphs were plotted and analyzed in
GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA). Machine learning was
conducted through the mixOmic’s shiny website, which also generated the subsequent
true positive and error rate plots and colored receiver operating characteristic (ROC)
curves. Partial least-squares discriminant analysis (PLS-DA) was generated through the
R package “mixOmics” (284-286). R versions 3.3.2 and 3.5.1 (www.www.r-project.org)
was responsible for the heatmaps not generated by the shiny website through the R
package “gplots.” For Figure 4.8, hierarchical cluster analysis was performed using
Ward’s minimum-variance method and applied to data with greater variability using the
“factoextra” package in R, while heatmaps were generated using Genesis 1.8.1 (Graz
University of Technology, Graz, Austria). Overall survival was plotted using the KaplanMeier method and compared between cluster groups using log-rank tests via SAS
version 9.4 (SAS Institute, Cary, NC). Survival analyses for the genes in the tables were
analyzed with the function “survdiff” from R package “survival” using the Mantel-
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Haenszel log-rank test. When Kaplan-Meier curves were presented, p-values were from
Graphpad Prism 5, using the Mantel-Cox log-rank test for significance. The Mann–
Whitney U test was conducted in R with function “wilcox.test” and Spearman’s
correlations were calculated utilizing R package “Hmisc.”
GraphPad Prism 5 was also utilized to calculate student’s t-test when two
categories existed and one-way ANOVA with Bonferroni’s multiple comparison test when
more than two categories existed. When bar charts are shown with continuous data,
error bars represent the standard error of the mean. Prism was also calculated Fisher’s
exact test when two categorical categories existed, and Chi-squared was used when
there were more than two categorical categories, except where mentioned.
The area under the curve was analyzed with SAS version 9.4 (SAS Institute),
utilizing procedures for logistic regression.

Immune Infiltration Prediction Algorithms
CIBERSORT(287) was analyzed through the project’s website
(https://cibersort.stanford.edu/) utilizing 1,000 permutations with quantile normalization
disabled, for the downloaded TCGA data already had upper quartile normalization. TIDE
(288) was run through the project’s main website (http://tide.dfci.harvard.edu/) utilizing
“Other” cancer without previous immunotherapy after supplying log2(RSEM+1) with
normalization to the average of the entire esophageal cohort. The xCell (289) data was
generated from the project’s website (https://xcell.ucsf.edu/). The docker provided by
tumor immunology miner (TIminer) (290) was downloaded from the project’s website
(https://icbi.i-med.ac.at/software/timiner/timiner.shtml), and the .gmx files for Angelova
(291) and Charoentong (292) were extracted to be run by GSEA utilizing pre-ranked files
generated by normalizing the RSEMs of each patient to the average of the normal
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adjacent tissue. Due to similar results for Th17 cells, the signature of Angelova was used
to represent TIminer due to the computation time.
Results
13 different cancer cohorts from the TCGA were downloaded to search for
metabolic distinctions between clinical attributes, including sex, stage, ethnicity, and
histological subtypes. Each of these covariates was controlled, and different
permutations were examined for potential differences, as visualized through PLS-DA.
However, only the attribute of histological subtype appeared interesting, as many
cancers appeared to have differences between adjacent normal and cancerous tissue
(Figure 4.1), which is in line with Warburg’s observation (191). However, the majority of
cancers examined appeared not to have any metabolic differences between histological
subtypes, although a slight difference may exist with breast and uterine cancer subtypes
(Figure 4.2). One exception is the astounding metabolic differences observed between
ESCC and EAC (Figure 4.3A). The univariate analysis revealed a global change in
enzyme mRNA expression (Figure 4.3B), confirming the observation of differential
metabolic regulation between ESCC and EAC histological subtypes.
A machine learning approach was used through mixOmics (284), utilizing only
expression of enzyme mRNA to discover the key metabolic differences between the
subtypes. Patients were separated by histological subtype and ranked alphanumerically,
sending the first half to the training cohort (Figure 4.3C) and the remaining to the testing
cohort (Figure 4.3D). The resulting training dataset gave a great performance score
(Figure 4.3E), with only one bad prediction (Figure 4.3F). Similarly, the testing cohort
had three EAC patients incorrectly predicted as ESCC patients. The error rate was 1%
from a leave-one-out resubstitution validation with a risk of overfitting of 2.22% for EAC
and 0% for ESCC. The responsible enzymes for the PLS-DA separation were further
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pursed. Combining up to six components was examined, but utilizing more than the first
principle component had a negligible performance impact (Figure 4.3G). Utilizing two
genes within the first component had the best error rate (Figure 4.3H), which were found
to be stable (Figure 4.3I).
The two best hit enzymes were further examined for their predictive capability.
GAL3ST1 had increased expression in EAC (Figure 4.4A), which contributed to a
remarkable ROC (Figure 4.4B). This study further examined if this gene expression
played a significant role in EAC or ESCC, as this expression appears low or even
negligible in ESCC. Interestingly, there appeared to be an aggressive phenotype only
shown in ESCC when increasing the expression of GAL3ST1 (Figures 4.4C,D). The
second gene, HGD, had greater expression and variation in EAC (Figure 4.4E), which
contributed to a decent separation as seen by the ROC (Figure 4.4F), but did not appear
to have an association with overall survival (Table 4.3).
Next, these data and methods were compared to normal tissue (Figure 4.5). The
variance with limited normal samples was high and thus normal tissues shared slight
similarities with both ESCC and EAC, although it mainly comprised of its own group
(Figure 4.5A). These data also found the genes HGD and GAL3ST1 to be the top
contributors for separation of cancerous tissue, but normal samples were best separated
with the addition of a second principal component, in which genes CKM, CKMT2, and
RRM2 were top contenders in separating normal from cancerous tissue (Figure 4.5B-I).
To further examine the malignant transformation into cancerous tissue in hopes of
discovering biomarkers, the study examined what genes were most diverged from
normal tissue in the transformation to malignant carcinogenesis. To examine their
potential use as future biomarkers, genes were included if they showed a 25-fold change
when comparing normal to EAC and ESCC, a Benjamini-Hochberg corrected student’s ttest of q < 0.001 between normal tissue and both EAC and ESCC subtypes, and a
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minimum area under the curve (AUC) of 0.95 compared to normal tissue for both
groups. Six genes appeared, which included two for matrix metallopeptidases (MMP11,
MMP12), homeobox genes (HOX8, HOX10, HOX11), CHRNA1, and IL8 (Figure 4.6,
Table 4.6).
Considering the profound metabolic differences observed (Figure 4.3),
esophageal cancer was further examined to identify if metabolic pathways differed
between the subtypes, as defined by a minimum of 10 enzymes, for which the pathway
must have at least 90% enzymes. All gene ontology (GO) subgroups, including cellular
component, biological process (BP), and molecular function were examined through
GSEA and revealed a separation of the histological subtypes (Figure 4.7A). Four
metabolic pathway subtypes were identified in EAC and two in ESCC, in which the
subtype of EAC impacted survival (Figure 4.8).
The approach was then refined to focus on metabolic pathways by using a
smaller database known as KEGG. Results again revealed a separation between EAC
and ESCC with enzyme pathways (Figure 4.7B). There appeared to be a correlation of
clinical features associated with histological subtypes in the heatmaps (Figures 4.7A,B).
These correlations were further examined in which histological subtypes had a
significant difference in clinical features (Figure 4.9). However, these clinical features
failed to show a relationship with enzyme expression with the exception of histological
subtype and patients with a history of Barrett’s goblet cell in EAC (Figure 4.10). A
relationship with clinical features and survival were also not observed (Figure 4.11).
Further validating differences between the subtypes in another dataset provided by the
Gene Expression Omnibus, when comparing only the enzymes as well as all the genes,
ESCC was found to be more dissimilar to esophageal, gastral, and gastroesophageal
adenocarcinomas (Figure 4.12).

132
This study sought to further examine differences in metabolic pathways shared
among KEGG and gene ontology GO BP that significantly impact survival. We observed
that the tricarboxylic acid (TCA) cycle pathway was shown to be significantly enriched in
adenocarcinomas (Figure 4.7C). The regulation of genes within the TCA pathway were
also found to be differentially regulated (Figure 4.7D). Kaplan-Meier survival curves
revealed the TCA cycle plays a significant role in patient survival for only ESCC
compared to EAC, suggesting the decreased pathway enrichment in ESCC promotes its
aggressiveness (Figures 4.7C,E). These data prompted further examination into TCAlinked energy metabolism. Interestingly, in EAC there is a very strong survival difference
associated with the gene expression of COQ3, which involves the electron transport
chain (ETC) electron carrier known as ubiquinone or coenzyme Q; but not in ESCC
(Figure 4.7F). Combining these subtypes together dampens the association, as it
reveals a weak significant difference. However, considering the significant survival
differences, this study next examined which metabolic enzyme had the most significant
survival alteration.
The protein-coding gene COQ3 appeared to be the most significant survival
altering enzyme for EAC, by a large magnitude, compared to the next largest alteration
(Table 4.1). On the other hand, ESCC had several enzymes that showed significant
correlations with survival, with the largest being QARS (Table 4.1, Figure 4.13). All
available genes listed in the TCGA and their impact on survival were further examined.
Surprisingly, COQ3 appeared to have the largest significant survival impact on EAC
when comparing all available genes, whereas QARS ranked number 10 in terms of the
p-value for EAC (Table 4.2, Figure 4.13). These data suggest ESCC is more aggressive
when TCA enrichment is decreased. In contrast, EAC appears to function in reverse,
being highly dependent on the ETC as seen with COQ3, which may allow for specific
targeting of subtypes to enhance patient response through survival.
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It was further observed that there was a difference in the enrichment and
expression of glycerolipid enzymes, as represented by the GO BP pathway glycerolipid
catabolic process and glycerolipid metabolism in KEGG (Figures 4.7G,H). Oddly, it
appears that increased enrichment of glycerolipid enzymes significantly enhances the
aggressiveness of ESCC but not EAC, which masked survival differences when
combining the cohorts (Figure 4.7I). This study hypothesizes that ESCC has limited
glycerolipid flux, and increasing the turnover rate could improve overall survival. To this
end, positive regulation of lipid transportation was found to be the second-highest
increased pathway in GO BP by EAC, showing a 98-fold change in enrichment
compared to ESCC, suggesting a potentially limited flux of lipids in ESCC (Table 4.3).
This study next aimed to identify which metabolic pathway is supplying the
carbon and energy for ESCC. It was observed here that the TCA cycle is enriched in
EAC and that increased EAC aggressiveness is associated with the ETC as seen
through COQ3. Furthermore, decreased enrichment in the TCA cycle increased ESCC
aggressiveness (Figures 4.7C, 4.7E, 4.7F), suggesting the ESCC energy flux lies
elsewhere. Anaerobic glycolysis is known to be upregulated in many cancer types (191).
In turn, this study next examined glucose uptake and metabolism. Differences were
observed between EAC and ESCC for SLC2A1 (the gene for GLUT1 for glucose entry),
HK2 (a limiting step in glycolysis), and LDHA (an important exit for glycolysis for NAD+
regeneration) (Figure 4.7J). This suggests ESCC receives its energy and carbon from
glycolysis, whereas EAC has upregulated oxidative metabolic pathways.
While positive regulation of lipid transportation was the second greatest pathway
increased in EAC for GO BP, the greatest enriched pathway in ESCC showed a 145-fold
change during the acute phase response pathway, which contains the genes involved in
an acute inflammatory response (Table 4.3). Significance was seen at both the individual
and group average level of enrichment (Figure 4.14A). Further examination of the top
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hits revealed regulation of acute inflammatory response as the third largest increase in
ESCC over EAC with a 36-fold change, which was significant for both the individual and
group level of enrichment (Figure 4.14B, Table 4.3). KEGG does not appear to have a
pathway dedicated solely to inflammation but contains a related cytokine-cytokine
receptor interaction pathway, which showed marginally significant enrichment (Figure
4.14C, Table 4.4). Therefore, a heatmap was constructed to examine the role of
inflammation and cytokines utilizing the genes contained in GO’s term “cytokine activity”
(Figure 4.14D). Two largely different environments were quickly seen, in which case, it
was observed that IL17-related cytokines clustered near each other and were highly
upregulated in EAC (Figure 4.14D). Significant upregulation of IL17A, IL17C, and IL17F
were confirmed (Figure 4.14E). Observing a cytokine-based signature of Th17 cells, we
further examined the signature for Th17 effector memory cells (293), in which markers
were found to be significantly upregulated, including IL26, CCR6, and CCL20 (Figure
4.14E). Consequently, the study next examined if the cytokine environment induced
Th17 cells.
IL-23 is known for further inducing Th17 response (293), but IL23A was
insignificantly upregulated (p = 0.06) (Figure 4.14E). IL-6, along with TGF-β, can induce
naïve CD4 T-cell maturation into Th17 (293). Although IL6 expression was unchanged,
TGFB1 expression increased in ESCC. It is possible that Th17 is promoted in the
presence of increased TGFB1 with non-diminished IL6 or that Th17 infiltrates to the
tumor, upon which the tumor microenvironment promotes memory differentiation. These
data ultimately show a difference in the inflammatory environment of EAC and ESCC, in
which the extent can be seen through cytokines, and further indicate a potential
difference in the immune environment.
To examine if the immune environment is altered between the subtypes EAC and
ESCC, this study aimed to bioinformatically validate the cytokine-based hypothesized
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alteration in Th17 presence and to explore additional alterations in the immune
environment. TIminer utilizes a marker enrichment-based procedure approach to predict
immune populations (290). The present study then examined Th17 through two
independent marker datasets by Angelova (291) and Charoentong (292). Both datasets
showed a significant increase in Th17 infiltration in EAC compared to ESCC (Figure
4.15), which agreed with the cytokine profile. This study, therefore, expanded to examine
Angelova’s full dataset in TIminer (Figure 4.16A). Differences were observed between
the EAC and ESCC, so the number of immune prediction algorithms and predictionbased logic was expanded to further validate and enhance coverage of immune
differences with xCell (289), a marker-based approach (Figure 4.16B), and CIBERSORT
(287), which utilizes partial deconvolution to predict the immune population (Figure
4.16C). An interesting enrichment was observed for dendritic cells (DCs) across all three
platforms, as activated DCs, classical DCs, and resting DCs were observed to increase
(Figures 4.17A-D). However, CIBERSORT did not show a significant change in
activation (Figure 4.17E). Furthermore, the status of CD8 T-cells was seen to be
significantly increased in ESCC compared to EAC, including signs of naïve and activated
CD8 T-cells (Figures 4.18A-B). However, differences in non-specific CD8 T-cell
signatures did not appear significant for xCell (p = 0.0543) and CIBERSORT (Figures
4.18C,D). This study further investigated possible markers revealing T-cell status
through lymphocyte markers. Markers associated with activation were shown to
significantly increase in ESCC, such as CD44 (294), CD109 (295), and CD70 (296, 297)
(Figures 4.18E-G). On the other hand, PF4 (Figure 4.18H), which is known to inhibit Tcell function (298), was the second largest significantly downregulated cytokine in ESCC
compared to EAC by a 54-fold change (Table 4.5). This study further examined helper Tcells and immunosuppressive immune cells, but did not observe a significant consistent
trend (Figures 4.19 and 4.20). Taken together, the strong possibility arises that ESCC
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represents a potential anti-tumorigenic immune environment through increased dendritic
cells and the presence of activated T-cells.
The effect of immune presence and response was examined for its potential
impact on patient survival. Examining CIBERSORT revealed the presence of CD8 Tcells (Figure 4.16E) and eosinophils had an impact on survival (Figure 4.21). When both
subgroups were combined, increased numbers of CD8 T-cells were found to enhance
survival, but ESCC was seen to have a more significant impact than EAC (Figure
4.16E). This study utilized the computational framework of Tumor Immune Dysfunction
and Exclusion (TIDE) (288) to examine the potential role of checkpoint inhibitors on
ESCC and EAC (288). TIDE predicted EAC will have an enriched benefit and response
to checkpoint inhibitor therapy compared to ESCC (Figures 4.16F,G). Interestingly, TIDE
suggests cytotoxic T lymphocytes are hindered by exclusion pressures in EAC and are
dysfunctional in ESCC (Figures 4.16H,I). Together, these data suggest ESCC has an
anti-tumor immune environment and can infiltrate better, in which infiltration is
associated with a significant survival benefit. Meanwhile, the anti-tumor immune
response in EAC is excluded, in which checkpoint inhibitors are predicted to be
significantly more effective in EAC than ESCC. Thus, if the exclusion pressures are
reduced, EAC is predicted to show an improved overall survival response.
As part of this study, literature was searched for genes associated with activation
and dysfunction in order to identify therapeutic opportunities. Clear differences were
found between EAC and ESCC (Figure 4.16D). These results include significant
differences in the costimulatory B7 molecules of CD274, CD86, and CD276 (Figures
4.22A-C), whose proteins bind PD-1, CLTA4/CD28, and unknown, respectively (299).
Furthermore, differences in CD40 were observed, but not in the mRNA encoding of the
ligand, CD40LG (Figures 4.22D,E). Interestingly, two of the adenosine receptors,
ADORA2A (Figure 4.22F) and ADORA2B (Figure 4.22G), were significantly increased in
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ESCC and EAC respectively. Both receptors have been shown to be stimulated by
adenosine and stimulate cAMP production, which plays an immune suppressive role
(69). The main sources of adenosine in cancer are typically CD39 and CD73, which are
encoded by ENTPD1 and NT5E respectively. A modest decline in ENTPD1 in ESCC
was observed, although EAC had similar levels to normal adjacent tissue (Figure 4.22H).
Despite the increased fold change in NT5E from normal, EAC was not statistically
different from ESCC (p = 0.502, student’s t-test) (Figure 4.22I). Together, these data
suggest there are further potential immune altering targets that are differentially
regulated between the histological subtypes, which could potentially be targeted to
restore the exclusion and dysfunction seen in EAC and ESCC respectively.
Tumor metabolism has been shown to play a significant role in immune
recruitment and function (56, 64, 192, 193, 195, 197-199, 202, 282, 283). To augment
the significance of this work, this study investigated if any enzymes are differentially
regulated between EAC and ESCC that potentially play a role in immune infiltration. To
this extent, 13 enzymes were found to be differentially expressed that correlated with the
immune prediction by more-advanced algorithms of CIBERSORT and TIDE (Figures
4.23A,B). The magnitude of the correlation of these genes with the immune environment
also appeared impacted by the histological subtype (Figures 4.24A, 4.24B). It is
reasonable to postulate that differences between subtypes exist and that a given
enzyme can influence the environment.
Of the 13 genes identified, the gene ALDH3B1 had the greatest association with
altered patient survival (Figure 4.23C) compared to the other genes CYP3A5, UGT1A7,
and PLA2G10 that were found to be significantly associated with survival (Figures
4.24C-E). The tumor immune dysfunction and exclusion score is postulated to be a
strong overall assessment of the immune environment. Therefore, this study examined
the 13 enzymes and the association with the scores reported by TIDE. Many of these
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differentially expressed genes were found to rank high in their correlation with immune
function. The enzyme correlation was then expanded to include all previously used
algorithms (Figure 4.25). Likewise, the expanded data supports a similar observation, in
which 7 out of the 13 genes identified, including CYP3A5, PLA2G10, UGT1A7, GCNT3,
SMPD3, DDC, and ST6GALNAC1 reappeared as top enzymes correlating with the
immune environment. These data indicate a casual role of differentially expressed
enzymes that correlate with the immune status and highlight the potential role of cancer
metabolism in the tumor microenvironment.
Discussion
Precision medicine holds the promise of correctly leveraging the cellular and
extracellular environment against cancer cells in order to benefit from unique
vulnerabilities. A shift in the metabolic profile of the cell reflects a change in the cellular
programming, which is altered through the cancerous transformation. Observing
metabolic differences is critical, as the change in the metabolic machinery reflects
altered consumption and production, which may further alter the cell and/or the
environment. These differences, ideally, can be targeted through precision medicine.
With the goal for discovering clinical differences that could be targeted to benefit
patients, as well as for the effort to discover metabolic differences, we examined multiple
cancers in the TCGA for clinical attributes including sex, cancer stages, ethnicity, and
histology. Interestingly, we did not find key differences in attributes among many cancer
cohorts, including histological differences (Figures 4.1 and 4.2). However, we discovered
an exception in the histological subtypes for esophageal cancer. These findings were
radically different (Figures 4.3A,B). The differences were so pronounced that some of
these enzymes could be used as biomarkers and have prognostic value, such as in the
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case of GAL3ST1 (Figure 4.4), although better non-enzymatic markers exist to
differentiate EAC and ESCC (Figure 4.6, Table 4.6).
Importantly, there appeared to be a difference in oxidative metabolism between
ESCC and EAC. Pathway differences were also found to be associated with survival
(Figure 4.7). EAC is associated with TCA cycle, glycerolipid metabolism, and is
extremely aggressive with increased electron transport chain gene, COQ3. In contrast,
ESCC appears to increase glycolysis for energy (Figure 4.7). These findings mirror a
recent study that found lung squamous cell carcinomas drastically increase GLUT1,
upregulate glycolysis, and are sensitive to glycolysis modulation compared to lung
adenocarcinomas (300). This difference in GLUT1 expression has also been observed
to be largely due to histology, as demonstrated in a meta-analysis between lung
squamous cell carcinomas and lung adenocarcinomas (301). Recently, it was observed
that YAP1 mediates an increase of GLUT1 in esophageal cancer to promote resistance
to therapy (302). This finding raises the question as to how these pathways and survival
differences can aid the possible therapeutic intervention to help the prognosis of the
patient. Recently, mubritinib cleared a Phase I clinical trial for Erb-B2 receptor tyrosine
kinase 2 (ERBB2+) solid tumors, which can also inhibit complex I (303). Although
ERBB2 is seen to significantly impact EAC and both subtypes when combined (Table
4.2), its potential effects could serve a further purpose in EAC by hampering the ETC.
However, the treatment of mubritinib for ERBB2 alone could prove advantageous for
EAC, as more genomic alterations are prevalent for ERBB2 in EAC (23% EAC vs. 3%
ESCC) (304). Similarly, another study found that 19% of EAC patients have
overexpression of ERBB2 (305). Although trastuzumab, the antibody against ERBB2, is
already approved for EAC, it is important to consider how far these findings extend to the
similarly related gastroesophageal adenocarcinomas (Figure 4.12), gastric
adenocarcinomas, and gastroesophageal junction adenocarcinomas, where ERRB2
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may be overexpressed as well (306). COQ3 is the most significant survival altering gene
in EAC, which could also be potentially be susceptible to the complex I inhibitor
metformin (307), for which it has already been shown to be beneficial in esophageal
cancer with combination therapy (308). Among this list, HDAC2 was strongly associated
with patient survival in EAC, which could also be potentially targeted with HDAC
inhibitors. Furthermore, ESCC could derive its energy from glycolysis, which might be
more sensitive to glycolysis inhibitors. These include inhibitors such as 2-deoxyglucose,
ionidamine, and silibinin (309), the latter of which was found to decrease SLC2A1, HK2,
and LDHA (236), which were observed in the present study to be increased in ESCC
(Figure 4.7J). Our research team previously observed an increased shift from glycolytic
to oxidative metabolism under acidic conditions (310). We also observed that acid reflux
is was found to be enriched in EAC (Figure 4.9A) and hence could drive the potential
shift away from glycolysis traditionally observed by the Warburg effect (191) and more
towards oxidative metabolism. If the proposed metabolic shift is true, then there is likely
to be an impact on response not only to therapies, but also to indicators, such as 2deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography
(311-316) and NMR (317, 318). Lastly, these results with the enzymatic differences
(Figure 4.4) and proposed biomarkers (Figure 4.6, Table 4.6) have the strong potential
to be utilized with a device similar to the cytosponge to reduce cost and discomfort
associated with traditional endoscopy (319-322).
Differences in glucose metabolism and hypoxic environments have been shown
to alter immunity (323-326). To this extent, two of the top three enriched pathways for
ESCC were observed to be associated with inflammation, and there was a drastic
change in the cytokine environment (Figure 4.14, Table 4.3). Many cytokines are
controlled under NF-κB, which is in part controlled by hypoxia and related stress (327332). These characteristics are in line with our overall view regarding metabolism and

141
potentially increased hypoxia in ESCC. The data presented here reinforces the
hypothesis that metabolic alterations can reveal unique subtypes and their associated
selection due to their environments and etiology. The present study further enhances
this finding with multiple algorithms to examine the immune status (Figure 4.16). CD8 Tcells and DCs were found to be altered between the subtypes (Figures 16, 4.17, and
4.18), suggesting adoptive DC therapy or T-cell therapy could have an advantageous
role in ESCC treatment. DCs have been associated with an advantage in ESCC
patients (333). A previous study examining advanced stage ESCC observed an immune
response with treated monocyte-derived DCs(334); however, DCs in ESCC may simply
be less suppressed than in EAC (335). On the other hand, esophageal cancer,
especially ESCC, demonstrated highly expressed (>50%) cancer/testis antigens,
including melanoma-associated antigen-A (MAGE-A), in which MAGE-A specific CD8 Tcells can be seen in peripheral blood of ESCC patients and respond to MAGE-A3-loaded
DCs to target MAGE-A3+ tumor cells (279). In the current study, we further observed
that CD8 T-cells play an important role in survival, similar to a previous observation
(336). Current results also show that EAC is much more likely to respond to checkpoint
therapy (Figures 4.16F-G). However, it is expected that ESCC will show some benefit to
checkpoint therapy, as it has been previously observed that programmed death ligand 1
(PD-L1) is increased in ESCC and that decreased tumor-infiltrating lymphocytes
decreases patient survival (337-339).
Recently the KEYNOTE-028 study utilizing the anti-programmed death-1 (PD-1)
antibody Pembrolizumab showed that 80% of EAC patients had decreasing tumor
volume from baseline compared to 46% in ESCC (340). Ultimately, KEYNOTE-181
study showed targeting PD-L1 was more efficacious than chemotherapy and shows the
promise of checkpoint therapy (341). KEYNOTE-180 also showed a great response in
ESCC (342), and ultimately, PD-L1 therapy was approved by the FDA to treat ESCC.
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Although these data highlight the observed correlation of CD8 infiltration and patient
survival in ESCC, we believe there could be even greater benefit in EAC and caution
future studies not to comingle histological subtype covariates. Furthermore, we believe
there could be further targetable genes and enzymes to help modulate the immune
environment (Figures 4.16; 4.23-4.25). Three of these genes belong to the B7 family of
ligands and two adenosine receptors, in addition to adenosine producing ENTPD1.
These findings indicate an improved response is possible for ESCC by utilizing
checkpoint inhibition and new combination targets in conjunction with anti-PD-1.
Ultimately, we observed a remarkable difference in esophageal metabolism,
clinical attributes, cytokines, potential response to therapy, and altered immune and
tumor environments between histological subtypes. Unique subtypes were further
observed within histological subtypes, which correlated with patient survival and require
further examination (Figure 4.8). As such, these data highlight the risks associated with
combining histological subtypes for studying esophageal cancer. By separating these
vastly different cancers, improved opportunities and options in precision medicine are
opened in order to tailor customized therapies suited for these drastic differences.
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Figure 4.1: Normal enzyme expression differs from cancerous tissue. A total of 13
cancers were screened to determine if clinical features can be used to separate enzyme
expression in TCGA cohorts. These five TCGA cancer cohorts contained only one
histological subtype in addition to normal tissue after filtering for a minimal sample size of
five. Enzyme mRNA PLS-DA and hierarchical clustering of primary tissue with normal
adjacent tissue for (A) kidney renal clear cell carcinoma (KIRC), (B) kidney renal papillary
cell carcinoma (KIRP), (C) lung adenocarcinoma (LAUD), (D) lung squamous cell
carcinoma (LUSC), (E) and prostate adenocarcinoma acinar type (PRAD).
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Figure 4.2: Cancers from the screen show that most histological subtypes cannot
be separated by enzyme expression. The 13 cancers were screened to determine if
clinical features can be used to separate enzyme expression. Shown here are the
remaining tissues in the screen, except for esophageal cancer (ESCA) and pancreatic
adenocarcinoma (PAAD), the latter was removed due to insufficient normal tissue (n =
4). PLS-DA and hierarchical clustering of enzyme mRNA expression for TCGA cohorts
(A) bladder urothelial carcinoma (BLCA), (B) breast invasive carcinoma (BRCA), (C)
colon adenocarcinoma (COAD), (D) rectum adenocarcinoma (READ), (E) stomach
adenocarcinoma (STAD), (F) and uterine corpus endometrial carcinoma (UCEC).
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Figure 4.3: Partial least squares discriminant analysis reveals histological
differences for metabolic enzymes. (A) PLS-DA and hierarchical clustering of enzyme
mRNA between EAC, ESCC, and normal tissue. (B) Heatmap Z-scores of log2 mRNA
expression. Patient identifiers were ranked A-Z for each histological subtype, and the
first half went to (C) the training dataset, while the remainder went to (D) the testing
dataset. (E) The receiver operating characteristic (ROC) curve of the training dataset
and (F) the confusion matrix with incorrect predicted classifications shown in red. (G)
The optimal number of principal components to utilize was examined by plotting the error
rate (black line) and the true positives (top lines). (H) The first principle component was
examined for the optimal number of genes (variables) to be included by plotting the error
rate and true positives. (I) The leading genes to be utilized were examined for stability.
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Figure 4.4: Key enzymatic markers between histological subtypes. (A) Detailed
here is GAL3ST1 expression in both ESCC and EAC and (B) the resulting receiver
operating characteristic (ROC) curve. The impact of GAL3ST1 on patient survival was
examined for (C) ESCC and (D) EAC by plotting the patients whose mRNA was in the
upper and lower quartiles of expression and tested for significance by Mantel-Cox logrank. (E) HGD expression in ESCC and EAC and (F) the resulting ROC curve.
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Figure 4.5: Machine learning separates esophageal cancers and adjacent normal
tissue by enzyme expression. Machine learning through principle component analysis
was carried out to test the ability of enzymes to separate normal adjacent tissue from
cancerous tissue. (A) Overall PLS-DA, (B) eigenvalues contributing to components 1 and
(C) 2. (D) Receiver operating characteristic curve utilizing the results of the machine
learning. (E) The error rate and true positives for each group were based on the number
of components utilized to discriminate between types. (F) The optimal number of enzymes
to distinguish groups in components 1 and (G) 2, along with the stability of these genes in
(H) components 1 and (I) 2.
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Figure 4.6: Biomarkers to differentiate cancerous tissue from normal adjacent
tissue. Use of a single enzyme resulted in a poor ability to differentiate normal tissue
from cancerous tissue in esophageal cancer. To better identify potential biomarkers to
differentiate normal tissue from cancerous tissue, all available genes were calculated for
their area under the curve. Best performing genes were characterized by a fold change
greater than 25 with a Benjamini-Hochberg’s corrected q < 0.001 after student’s t-test for
both subtypes compared to normal tissue. This revealed (A) MMP11, (B) MMP12, (C)
HOXC8, (D) HOXC10, (E) HOXC11, (F) IL8, (G) and CHRNA1.
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Figure 4.7: Metabolic pathways are altered between ESCC and EAC. Gene set
enrichment analysis (GSEA) compared each patient against the average of normal
tissues. Normalized enrichment scores (NES) were plotted and hierarchically clustered for
metabolic pathways, defined as ≥10 minimum enzymes with a minimum of 90% of
enzymes, for (A) all Gene Ontology (GO) classifications and (B) metabolic pathways within
the Kyoto Encyclopedia of Genes and Genomes (KEGG). (C) Z-score of each patient’s
NES (bar chart) and group average (GSEA plot) for the TCA cycle from GO biological
process (BP) (left) and KEGG (right) (D) along with the heatmaps of the comprising genes
within the pathway of GO (left) and KEGG (right). (E) Patient survival was plotted by
separating the upper and lower quartiles of TCA NES through KEGG’s pathway for ESCC
(left), EAC (middle), and both (right). (F) Patient survival was plotted by separating the
upper and lower quartiles of COQ3 expression in ESCC (left), EAC (middle), and both
(right). (G) Each patient’s NES (top) and group average (bottom) for glycerolipid
enrichment from GO BP (left) and KEGG (right) (H) with the heatmaps of the comprising
genes within the pathway of GO (top) and KEGG (bottom). Patient survival was plotted by
separating the upper and lower quartiles of glycerolipid NES through KEGG’s signature
for ESCC (left), EAC (middle), and both (right). (J) Gene expression within each subtype.
Pathway enrichment significance was calculated by a student’s t-test, Mantel-Cox log-rank
for survival, and gene expression was compared with a one-way ANOVA with a
Bonferroni’s multiple comparison test. **P < 0.01, ***P < 0.001.
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Figure 4.8: Metabolic-associated pathways show subtypes within histological
subtypes. Each patient had their gene enrichment score calculated by comparing their
expression to the average of normal adjacent tissue for all gene ontology terms. Pathways
were then filtered if they were deemed to be metabolically associated (n ≥ 10 enzymes
with ≥ 90% of genes being enzymes) for (A) EAC and (B) ESCC. (C) EAC with hierarchical
cluster analysis with Ward’s minimum-variance method was used to classify patients into
clusters, upon which the number of clusters was preceded by the index of within-cluster
sums of squares. (D) Kaplan-Meier curve for EAC clusters was followed by a log-rank test
for significance. (E) Cluster analysis was performed for ESCC and (F) the resulting
Kaplan-Meier curve of ESCC clusters.
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Figure 4.9: Clinical features associated with esophageal histological subtypes.
Clinical features were examined for their occurrence within both subtypes for (A) acid
reflux, (B) Barret’s esophagus, (C) primary location, (D) involved location, (E) mucosal
dysplasia, (F) columnar metaplasia, (G) columnar mucosa goblet cells, and (H) family
history. Statistics were calculated using Fisher’s exact test when only two categories
existed, and the Chi-squared method was used when there are more than two categories.
The asterisk (*) denotes when Proximal and Proximal|Mid was removed from the statistical
calculation as it had no patients in these categories for adenocarcinoma, which invalidates
the Chi-squared test.
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Figure 4.10: Clinical feature association with enzyme expression. Clinical features
were examined with PLS-DAs for their occurrence within both subtypes to determine if
these clinical features could influence enzyme mRNA expression in connection with (A)
acid reflux, (B) family history, (C) primary location, (D), degree of dysplasia, (E) Barrett’s
goblet cells, and (F) involved location.
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Figure 4.11: Clinical feature association with survival. Clinical features within
histological subtypes were examined based on their impact on survival. Kaplan-Meier
curves were plotted for (A) history of acid reflux, (B) history of Barrett’s esophagus, (C)
primary tumor location, (D) tumor involvement location, (E) columnar metaplasia, (F)
columnar mucosa goblet cells, and (G) family history. The Mantel-Cox log-rank test was
used to calculate significance.
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Figure 4.12: Independent study to confirm separation between subtypes. Gene
Expression Omnibus accession GSE27040 was examined to determine if separation
between subtypes was observable in an independent project. Shown here is the PLS-DA
of mRNA expression for (A) enzymes and (B) all available genes examined.
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Figure 4.13: QARS impact on survival in esophageal cohorts. Shown here are
Kaplan-Meier curves to examine the survival of patients, applying upper and lower
quartile ranges of QARS mRNA expression in (A) EAC, (B) ESCC, and (C) combined
subtypes. The Mantel-Cox log-rank test was used to calculate significance.

169
Figure 4.14

170
Figure 4.14: Inflammatory responses are largely different between histological
subtypes. Each patient’s normalized enrichment score (NES) was calculated in
comparison to normal as individuals (left) and as a group against the average of the
subtype (right) for gene ontology biological processes (GO BP). (A) The largest fold
change of ESCC compared to EA was discovered to be acute phase response, (B) while
the third was regulation of acute inflammatory response. (C) The same calculation was
made for the KEGG database to show the NES Z-score (left) and average group
enrichment (right). Heatmap mRNA Z-scores of differentially expressed genes (p < 0.05)
for GO term “cytokine activity” (GO: 0005125) with normal (grey), EAC (orange), and
ESCC (blue). (E) Further examination occurred for cytokines of interest relating to a
Th17 signature. Differences in enrichment scores were calculated by a student’s t-test
and corrected with a Benjamini-Hochberg correction when examining multiple pathways
in GO. Gene expression was compared with a one-way ANOVA with a Bonferroni’s
multiple comparison test. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4.15: Prediction of Th17 infiltration in histological subtypes. Validation of the
indication of Th17, as portrayed by cytokines, was examined through TIminer (290), with
the signature supplied by Angelova (291) and (B) Charoentong (292). Provided here are
Z-scores of each patient’s normalized enrichment score when compared to normal tissue
(left) and when compared to the average of adenocarcinoma group and to the average of
the squamous cell carcinoma group (right). Gene set enrichment analysis (GSEA) was
calculated by dividing the average group RSEM for EAC by ESCC. Statistics supplied by
GSEA utilized the q-value from Benjamini-Hochberg’s correction. Student’s t-test was
conducted for significance for bar charts. **P < 0.01, ***P < 0.001.
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Figure 4.16: Differences in the immune environment and response to immune
therapy between histological subtypes. Heatmap Z-scores, ranging from -2 (blue) to
2 (red), of differentially regulated (q < 0.05) immune infiltrates according to (A) TIminer
utilizing Angelova’s dataset, (B) xCell, (C) and CIBERSORT. (D) mRNA z-scores of
differentially expressed (> 1.5-fold, q < 0.05) genes of potential immune therapeutic
interest between EAC and ESCC. Coloring indicates esophageal tissue that are normal
(grey), adenocarcinomas (orange), and squamous cell carcinoma (blue). (E) Patient
survival was based on CIBERSORT’s immune prediction. (F) Shown here are therapy
benefit, (G) therapy response, (H), immune exclusion, (I) and immune dysfunction
prediction according to the computational method of Tumor Immune Dysfunction and
Exclusion (TIDE). Survival statistics utilized Mantel-Cox log-rank. Therapy prediction
utilized Fisher’s exact test and a student’s t-test for immune dysfunction, immune
exclusion, and heatmaps, with the latter corrected by Benjamini-Hochberg for q-values.
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Figure 4.17: Dendritic cell prediction in histological subtypes. Dendritic cell (DC)
immune status was predicted through several algorithms. This includes (A) classical DC
infiltration from xCell, (B) activated DCs from Angelova by TIminer (C) and the resulting
group enrichment plot, (D) resting DC infiltration, (E) and activated DC infiltration by
CIBERSORT. Gene set enrichment analysis (GSEA) was calculated by dividing the
average group RSEM for ESCC by EAC. Statistics supplied by GSEA with q-value
indicating Benjamini-Hochberg’s correction. Student’s t-test was conducted for
significance for bar charts. **P < 0.01, ***P < 0.001.
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Figure 4.18: CD8 T-cell prediction in histological subtypes. CD8 T-cell immune status
was predicted through several algorithms. This includes (A) naïve CD8 T-cell infiltration
by xCell, (B) Angelova’s signature for activated CD8 T-cell infiltration by TIminer, including
individually calculated Z-scores (left) and group comparison between subtypes (right), (C)
CD8 T-cell infiltration by xCell, (D) and CD8 T-cell infiltration by CIBERSORT. mRNA
expression was further examined for clues about CD8 T-cell status, including (E) CD44,
(F) CD109, (G) CD70, (H) and PF4. Gene set enrichment analysis (GSEA) was calculated
by dividing the group average RSEM for ESCC by EAC. Statistics supplied by GSEA with
q-value indicating Benjamini-Hochberg’s correction. A student’s t-test was conducted for
significance for immune infiltration and a one-way ANOVA with Bonferroni’s multiple
comparison test for mRNA expression. ***P < 0.001.
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Figure 4.19: Helper T-cell prediction in histological subtypes. CD4 helper T-cell
infiltration prediction from several algorithms. This includes (A) Th1 by xCell, (B)
Angelova’s signature for Th1 infiltration by TIminer, including individually calculated
normalized enrichment scores (left) and group comparison between subtypes (right), (C)
Th2 infiltration by xCell, (D) and Th2 infiltration by TIminer, including individually calculated
Z-scores (left) and group comparison between subtypes (right). Gene set enrichment
analysis (GSEA) was calculated by dividing the average group RSEM for ESCC by EAC’s
average. Statistics supplied by GSEA with q-value indicating Benjamini-Hochberg’s
correction. ***P < 0.001.
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Figure 4.20: Possible inhibitory infiltration prediction in histological subtypes.
Inhibitory anti-inflammatory immune infiltration was examined, but an obscure status was
seen through several algorithms. This includes (A) Treg infiltration by CIBERSORT, (B)
Angelova’s signature for Treg infiltration by TIminer, including the normalized enrichment
score of each patient compared to normal (left) and group comparison between
subtypes (right), (C) mRNA expression of TGFB1, (D) M2 infiltration predicted by xCell,
(E) M2 infiltration predicted by CIBERSORT, (F) MDSC infiltration predicted by TIDE (G)
and with Angelova’s signature through TIminer with individually calculated normalized
enrichment scores (left) and group comparison between subtypes (right). (H) Cancerassociated fibroblast (CAF) infiltration predicted by TIDE. Gene set enrichment analysis
(GSEA) was calculated by dividing the average group RSEM for EAC by ESCC.
Statistics supplied by GSEA with q-value indicating Benjamini-Hochberg’s correction. A
student’s t-test was conducted for significance for immune infiltration and a one-way
ANOVA with Bonferroni’s multiple comparison test for mRNA expression. *P < 0.05, ***P
< 0.001.
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Figure 4.21: Eosinophil infiltration impacts survival. Patient survival based on if
patients had more or less than the median CIBERSORT score for eosinophil infiltration.
Kaplan-Meier curves with Mantel-Cox log-rank test then examined (A) the entire
esophageal cohort, (B) only ESCC, (C) and only EAC.
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Figure 4.22: mRNA expression of potentially targetable immune altering genes.
Potentially targetable prevalent genes associated with immune function and infiltration
were examined for their mRNA expression. This includes (A) CD274, (B) CD86, (C)
CD276, (D) CD40, (E) CD40LG, (F) ADORA2A, (G) ADORA2B, (H) ENTPD1, (I) and
NT5E. Statistics were calculated with a one-way ANOVA with Bonferroni’s multiple
comparison test, except for NT5E, which utilized a student’s t-test, to highlight the lack of
significance despite the fold change. *P < 0.05, P < 0.01, ***P < 0.001.
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Figure 4.23: Enzyme expression correlates with immune function prediction. (A)
Legend for (B) Z-score of differentially expressed enzymes between subtypes (C) and
Spearman’s rho for correlation between expression and immune function prediction from
CIBERSORT and Tumor Immune Dysfunction and Exclusion (TIDE) utilizing both
subtypes. (D) Kaplan-Meier survival curves for ALDH3B1. (E) Ranked Spearman’s rho
correlation between enzyme mRNA and TIDE score for tumor immune dysfunction and
exclusion utilizing both subtypes. Survival statistics utilized Mantel-Cox log-rank. *P <
0.05, **P < 0.01.
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Figure 4.24: Enzymes associated with immune alteration and their impact on
survival. The correlation of significantly altered enzyme expression was further
examined between cohorts, along with the resulting impact on survival, to examine the
impact of differences in histological subtypes. Heatmaps showing Spearman’s rho were
constructed to examine the 13 significant genes within (A) ESCC and (B) EAC utilizing
CIBERSORT and TIDE. The 13 genes were examined for their impact on survival, but
significance was only seen with (C) CYP3A5, (D) UGT1A7, (E) and PLA2G10 for EAC
(left), ESCC (middle), or both subtypes (right).
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Figure 4.25: Differentially expressed enzyme correlation with all algorithms for
immune function. Immune correlation with enzymes was examined with CIBERSORT,
xCell, TIminer with Angelova, and TIDE. Enzymes were correlated with immune
predictions and then plotted as heatmaps with Spearman’s rho if the genes were
contained within the top or bottom 100 Spearman rhos among enzymes, which were then
filtered if they had a minimum of 5-fold change with p < 0.05 (student’s t-test) and impacted
at least one category when comparing both subtypes. The resulting heatmaps were then
plotted for (A) both subtypes, (B) adenocarcinomas, and (C) squamous cell carcinomas.
To refine results to identify enzymes of the greatest significance, enzymes were plotted
when they were found to play a significant role in at least 5 categories in both subtypes
for (D) all esophageal patients, (E) adenocarcinomas, and (F) squamous cell carcinomas.
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Table 4.1

Gene
COQ3
HAAO
PTGES3
PGK1
MGAT4A
CHKB
ANPEP
RRM2
ALDH3B1
ALDH1A2
NADSYN1
INPP5A
FOLH1
KLF15
NME3
GCLM
PDHA1
AHCY
ALG6
PLA2G16
ALAD
MGAT4C
RRM1
POLA1
HYAL1
POLR3F
ATP6V0D2
GFPT1
AMD1
XYLB

Adenocarcinoma
p-value
0.000006
0.003
0.003
0.004
0.005
0.005
0.006
0.006
0.006
0.007
0.009
0.009
0.009
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.02
0.02
0.02

Squamous
p-value
0.5
0.6
0.4
0.6
0.2
0.8
0.5
0.4
0.9
0.3
0.05
0.9
0.4
0.5
0.3
0.9
0.8
0.8
0.4
0.4
0.6
0.6
0.03
0.3
0.2
0.005
0.01
0.5
0.4
0.3

Combined p-value
0.02
0.2
0.002
0.003
0.5
0.01
0.1
0.06
0.03
0.05
NA
0.2
0.005
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.1
0.07
0.06
0.03
0.002
0.002
0.0005
0.8
0.7
0.7
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Table 4.1: Survival impact of enzymes between histological subtypes. A MantelHaenszel log-rank test was conducted for all enzymes between patients containing the
top or bottom 25% mRNA expression within each histological subtype or when combined
for the entire esophageal cohort. The top 30 genes ranked by adenocarcinoma p-value
are shown above.
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Table 4.2

Gene
COQ3
POTEG
GXYLT1
TMED2
UNC93B1
BMP8B
HDAC2
C15orf60
KIAA1539
KIF4A
KPNB1
TRIM34
KIAA1919
FSD1
KCP
ANKRD32
CRHR2
CDK5R2
CCT6A
EHBP1L1
ESM1
ZSCAN4
ESF1
SFRS7
PLEKHM1P
CHST6
ZBTB33
ABLIM2
SLC19A3
C20orf3

Adenocarcinoma pvalue
0.000006
0.00005
0.00009
0.0001
0.0001
0.0002
0.0002
0.0003
0.0003
0.0003
0.0003
0.0004
0.0004
0.0005
0.0005
0.0005
0.0007
0.0008
0.0009
0.0009
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.002

Squamous pvalue
0.5
0.6
0.9
0.9
0.8
0.8
0.4
0.2
0.8
0.3
0.3
0.5
0.9
0.1
0.7
0.09
0.2
0.6
0.9
0.2
0.06
0.5
0.6
0.7
0.7
0.5
0.7
0.3
0.4
0.03

Combined p-value
0.02
0.02
0.08
0.02
0.1
0.01
0.02
0.00005
0.007
0.01
0.02
0.01
0.04
0.0008
0.002
0.03
0.1
0.003
0.01
0.3
0.0009
0.004
0.004
0.007
0.06
0.09
0.1
0.4
0.4
0.0001
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Table 4.2: Survival impact of all genes between histological subtypes. A MantelHaenszel log-rank test was conducted for all genes between patients containing the top
or bottom 25% mRNA expression within each histological subtype or when combined as
the whole esophageal cohort. The top 30 genes ranked by adenocarcinoma p-value are
shown above. The top 30 genes ranked by adenocarcinoma p-value are shown above.
The top 30 genes ranked by adenocarcinoma p-value are shown above.
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Table 4.3

Category
GO_ACUTE_P
HASE_RESPO
NSE
GO_STRIATE
D_MUSCLE_
ADAPTATION
GO_REGULA
TION_OF_AC
UTE_INFLAM
MATORY_RE
SPONSE
GO_SULFATI
ON
GO_SULFUR_
COMPOUND
_TRANSPORT
GO_ANION_
TRANSPORT
GO_EPIDERM
IS_MORPHO
GENESIS
GO_SYNCYTI
UM_FORMA
TION
GO_PRIMITIV
E_STREAK_F
ORMATION
GO_POSITIVE
_REGULATIO
N_OF_PEPTI
DE_SECRETIO
N

t-test BH
q-value

MannWhitney
q-value

Squamous
average

Adenocarcin
oma average

Adenocarcin
oma by
Squamous FC

1.20E-11

5.40E-13

-1.305

-0.009

145.209

1.05E-09

4.07E-08

-0.754

-0.018

41.312

9.10E-10

1.59E-06

-1.114

-0.031

36.055

1.20E-11

3.10E-15

-1.181

-0.042

28.019

4.82E-07

0.000470567

-0.720

-0.031

22.921

1.20E-11

3.10E-15

-1.698

-0.077

22.068

0

3.10E-15

1.340

0.066

20.305

1.20E-11

3.10E-15

1.187

0.063

18.852

6.18E-08

5.91E-11

-0.711

-0.038

18.706

1.35E-11

6.62E-15

-0.838

-0.053

15.936
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Table 4.3: Gene ontology biological process enrichment scores for esophageal
patients. A summary is provided for the gene set enrichment analysis conducted for all
esophageal patients, which was completed by comparing each patient individually to the
average of the adjacent normal tissue. Data were then examined for significance with
alpha of 0.05 utilizing a student’s t-test and a Mann-Whitney U test, with q-values being
derived from the Benjamini-Hochberg (BH) correction. Fold change is defined as a ratio,
or the negative inverse when the ratio was less than one. The last column indicates the
absolute value of the fold change of the squamous histology divided by the
adenocarcinoma histology.
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Table 4.4
EAC/ESCC

ESCC/EAC

EAC avg

ESCC avg

MannWhitney
q-value

student's
T-test qvalue

Category
KEGG_O_GLYCAN_BIOSYNTHESIS
KEGG_RIBOFLAVIN_METABOLISM
KEGG_SPHINGOLIPID_METABOLISM
KEGG_ARGININE_AND_PROLINE_
METABOLISM
KEGG_VALINE_LEUCINE_AND_
ISOLEUCINE_DEGRADATION
KEGG_N_GLYCAN_BIOSYNTHESIS
KEGG_TIGHT_JUNCTION
KEGG_VIBRIO_CHOLERAE_INFECTION
KEGG_RENAL_CELL_CARCINOMA
KEGG_GLYCEROLIPID_METABOLISM

0 3.41E-15 0.58 1.45 0.40 2.49
0 3.41E-15 1.02 1.30 0.79 1.27
0 3.41E-15 1.77 2.26 0.79 1.27
0 3.41E-15 2.05 2.52 0.81 1.23
0
0
0
0
0
1.88E-15

8.69E-15
4.79E-13
3.41E-15
3.41E-15
3.41E-15
4.75E-14

2.87
3.05
3.29
3.29
4.64
1.35

3.20
3.33
3.74
3.70
4.18
1.67

0.90
0.92
0.88
0.89
1.11
0.81

1.12
1.09
1.14
1.12
0.90
1.24
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Table 4.4: KEGG enrichment scores for all esophageal patients. A sample of 10
pathways is provided for the KEGG gene set enrichment analysis conducted for all
esophageal patients, which was completed by comparing each patient individually to the
average of the adjacent normal tissue. Data were then examined for significance with an
alpha of 0.05 utilizing a student’s t-test and a Mann-Whitney U test, with q-values being
derived from the Benjamini-Hochberg (BH) correction. Average RSEM expression for the
cohorts are given, along with the expression ratio of EAC by ESCC.
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Table 4.5
Gene
Fold change p-value
q-value
ESCC
EA
Normal
CCL25
819.32 1.51E-02 3.63E-02
0.883
723.504
0.198
PF4
54.19 4.02E-05 1.59E-04
0.539
29.209
1.415
SCG2
11.78 9.75E-02 1.72E-01
31.831
375.041 221.283
CER1
10.46 8.04E-02 1.44E-01
0.159
1.667
0.116
FAM3D
9.76 1.55E-08 1.40E-07 152.171 1484.607 879.476
TNFRSF11B
8.26 4.05E-05 1.59E-04
54.712
451.929
27.137
IL17C
7.58 1.66E-03 5.12E-03
4.432
33.616
0.917
IL17A
7.05 8.47E-05 3.07E-04
1.588
11.200
0.049
CXCL3
6.90 6.29E-11 1.01E-09
98.841
682.085
47.542
CCL28
6.72 5.07E-08 3.87E-07
67.976
457.028 130.261
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Table 4.5: mRNA expression of genes with gene ontology term cytokine activity.
Average cytokine mRNA expression from TCGA was collected into histological subtypes
or adjacent normal tissue for genes contained within gene ontology term “cytokine
activity” (GO: 0005125). Fold change is defined as a ratio, or the negative inverse when
the ratio was less than one. Student’s t-test calculated the p-value with alpha equal to
0.05 and Benjamini-Hochberg corrected for the q-value. ESCC, EAC, and Normal
indicates the average RSEM for the cohort.
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Table 4.6

Gene
ESCC / EA
ESCC vs. EA aFC
EPS8L3
1.78E-03
MUC13
2.34E-03
HNF4A
3.52E-03
TM4SF5
9.52E-04
SEMA4G
4.72E-02

ESCC vs EA
p-value
561.32
426.54
283.69
1050.38
21.17

0
0
0
2.93E-06
0

ESCC vs EA AUC
0.9992
0.9992
0.9987
0.9983
0.9983

ESCC vs Normal ESCC vs Normal
p-value
AUC
0.023
0.956
0.093
0.878
0.015
0.820
0.014
0.926
0.064
0.866

Gene
EPS8L3
MUC13
HNF4A
TM4SF5
SEMA4G

ESCC /Normal ESCC vs Normal aFC
0.009
115.72
0.051
19.52
0.018
55.34
0.005
215.29
0.129
7.76

Gene
EPS8L3
MUC13
HNF4A
TM4SF5
SEMA4G

EA vs Normal
EA vs Normal
EA / Normal
EA vs Normal aFC
p-value
AUC
4.851
4.851
6.32E-09
0.9122
21.852
21.852
1.62E-12
0.9775
5.126
5.126
1.55E-10
0.9213
4.879
4.879
4.38E-04
0.7835
2.727
2.727
1.18E-02
0.8468

Gene
EPS8L3
MUC13
HNF4A
TM4SF5
SEMA4G

ESCC

EA
4.0
37.8
10.4
0.4
89.7

Normal
2220.7
16106.2
2956.4
438.8
1898.3

457.8
737.1
576.7
89.9
696.1
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Table 4.6: Biomarker differences between subtypes and normal tissue. Each
available gene in the TCGA was examined for potential differences between each
subtype and normal tissue. Table shows the ratio, absolute fold change (aFC), student’s
t-test p-value with alpha of 0.05, and area under the curve (AUC). The bottom rows
columns ESCC, EAC, and Normal indicates the average RSEM for the cohort. The ratio
is calculated by taking the average expression of each cohort and performing the
division shown in the column header. aFC is calculated as the ratio in the column to the
left, or the absolute value of the negative inverse when the ratio was less than one.
Student’s t-test calculated the p-value with alpha equal to 0.05 and Benjamini-Hochberg
corrected for the q-value. Table was truncated to show the top 5 genes when ordering by
ESCC vs. EAC AUC. Due to the large size, run-on columns were separated into its own
stack proceeded by the gene name.
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Chapter 5: Discussion and future directions
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This thesis focused on the relationship between metabolism and the tumor
immune environment, as well as potentially critical metabolic enzymes. Immune evasion
is critical for the aggressive growth of cancer, and without immune evasion, cancer
recedes and becomes undetectable (Figures 3.3 and 3.4). The last decade has clinically
shown the promise of immunotherapy, whereby overcoming immune evasion allows
durable progression-free survival in cancers that otherwise show a delayed death with
frontline chemotherapy (343-347). However, this is not the case for PDAC, which
recently saw PD-1 and CTLA-4 therapies unable to achieve a meaningful response
(228). The ideal cancer treatment specifically targets cancer cells without harming the
healthy cells, and the activation of the immune system is the ideal treatment, for it has
had hundreds of millions of years of evolution to perform this task (348). An altered
metabolism is also critical for tumor aggressiveness and provides a vulnerability to
cancer, as altered metabolism is ubiquitous and greatly altered compared to healthy
cells (1, 17-21). In many cases, cancer can become dependent on the metabolic
reprogramming and disruption can lead to cancer cell death (349). Many
chemotherapies, including antimetabolites such as gemcitabine and fluorouracil, utilize
this faucet to target cancers (350). This thesis shows that metabolism and immunity can
go hand-in-hand, were cancer cell metabolism can regulate the immune system to
prevent its destruction, whereby blocking the metabolic alteration greatly hindered
cancer growth and potentially promoted immune clearance (Chapter 3).
This thesis sheds light on the metabolic immune regulation. It began by
acknowledging that the foundational mutations are typically seen to promote an altered
metabolism, and that immune evasion is needed to bypass cancer surveillance. In
pancreatic cancer, KRAS mutations are frequent (351). Mutated KRAS associates with
elevated CD73 and GM-CSF (26, 64). Similarly, Chapter 3 reports a CD73 and GM-CSF
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correlation, and suggests that immune evasion and metabolic changes can occur very
early on in cancer.
The thesis then explored mucin alterations, which can occur later on in cancer
development, as some of the mucin family members can strongly promote or inhibit
cancer through many various mechanisms, including an altered metabolism and immune
evasion, such as those induced by MUC1 (41, 150, 151). MUC1 was observed to be
frequently altered in cancers, in which it tends to be hypomethylated (Figure 2.10), copy
number amplified in several tissues (Figure 2.9), and highly expressed (Figure 2.6).
However, it appears infrequently mutated, except for three tissues, by the time it reaches
stage II (Figure 2.1). One of the three tissues is pancreatic cancer, where there is an
interesting occurrence of a unique T112P mutation (Figures 2.2, 2.4). MUC1 mRNA is
also significantly upregulated (Figure 2.5), which suggests MUC1 might be playing an
interesting role in pancreatic cancer. MUC1 is known to stabilize the hypoxia-inducible
factor 1α transcription factor to the hypoxia-responsive elements (HRE) (42). Many
glycolytic genes contain HRE and are enhanced in hypoxia, as is CD73 (42, 50, 78).
Here, the expression of CD73 was seen to alter the peripheral immune system (Figure
3.5), and the clearance depends in part on CD4 and possibly CD8 T cells (Figure 3.6).
Mucin expression also showed a few other interesting findings, such as the expression
in colon and rectal cancers to be quite similar (Figure 2.5). In contrast, esophageal
adenocarcinomas and esophageal squamous cell carcinomas disagreed in the direction
of expression for all mucins, except MUC16, when examining cohorts with expression
significantly different from normal tissue. These cancers, in addition to prostate cancer,
were then examined for metabolic differences, in which a partial least-squares
discriminant analysis and hierarchical clustering showed enormous differences, which
were then examined in detail (Chapter 4). These metabolic differences also correlated
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with predicted immune infiltration differences, which suggest that the differences could
result in significantly different responses to immune checkpoint therapy (Chapter 4).
Limitations of this thesis exist but can serve as future directions. In short, much of
the data relies on correlations, especially bioinformatic correlations; however, wet lab
validation in Chapter 3 revealed the strength of these predictions. While Chapter 2
examined potential differences among mucin family members, it cannot examine protein
turnover, nuclear localization, or altered glycosylation. Furthermore, statistics for
mutations would have been a significant improvement but was limited due to controlled
access, as either the entire the full genome would be needed for calculating the
background mutation rate or an extremely high amount of patients would be needed
similar to a genome-wide association screen. It would be a great future direction to next
take a look at the founding mutations and the impact on metabolism and the immune
system.
While Chapter 3 pursued survival alterations predicted bioinformatically with
CD73, much more work is needed to fully understand the mechanistic basis. While the
study postulates GM-CSF, MDSCs, and CD4+ cells are the main drivers behind the
mechanism, which CD4+ cell(s) are suppressing tumor growth and how remains to be
determined (Figures 3.5, 3.6, and 3.8). CD73 is theoretically promoting MDSCs, possibly
by elevated GM-CSF (Figure 3.5E-H); however, it remains to be explored how this is
occurring. While pancreatic cancer is known to produce GM-CSF after the founding Kras
mutation, how Kras and CD73 regulate this needs to be explored (26). It has been
observed that TP53 and KRAS mutations can promote CD73, which, combined with the
data presented here, suggests a link to how early cancerous lesions may avoid immune
destruction (64). Interestingly, MDSCs are stimulated by adenosine binding to its
receptor, much like Tregs (100, 352). Theoretically, adenosine alone could produce this
effect independently of GM-CSF. However, the addition of GM-CSF promoted tumor
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volumes that were not significantly different from the non-targeting knockout control
(Figure 3.8). This appeared to depend on MDSCs in a manner that impacted CD73
knockout and not the non-targeting control (Figure 3.8). It would be interesting to see the
effects of knocking out Csf2, the gene for GM-CSF, and test if knocking out Nt5e, the
gene for CD73, inhibited growth and infiltration differences. Although the addition of
adenosine would be a great way to test the primary driving mechanism at play, it has a
very short half-life in the plasma (241). It is tempting to perform co-cultures with GM-CSF
neutralizing antibodies to study this in vitro with Nt5e knockouts. However, MDSCs
require GM-CSF-supplemented media, thus preventing GM-CSF neutralizing antibodies,
and masking the effects of Csf2 knockouts in vitro (353, 354). However, the effect of
Csf2 knockouts with or without Nt5e knockouts in vivo would be quite informative.
Given that CD73 had such a profound impact on tumor growth, the question
arises if there are any other metabolomic checkpoint inhibitors or stimulators that can be
targeted. Chapter 4 discovered two grossly different enzyme profiles and sought to find
what differences there might be, in which an immune-associated pathway ranked as the
largest difference and subsequently showed large cytokine and predicted immune cell
differences (Chapter 4). Large immune-associated differences were also observed to
exist in these different environments (Chapter 4). However, it remains to be tested if the
altered enzymes produce a different metabolic environment. Currently, it is purely
correlational. The altered cytokine profile could promote the different immune signature,
which could potentially alter the enzyme expression. The goal of the study was to
postulate targets to potentially test and validate through wet lab. However, this study
does undoubtedly show that the environments are extremely different, which gives rise
to different vulnerabilities, as pointed out in the chapter’s discussion. It even potentially
alters the response to checkpoint therapy (Figure 4.16), of which, is not being fully
explored in clinical trials (340, 355, 356). This includes Keynote-028, which specifically
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states: “Because the anti–PD-1 antibody pembrolizumab targets immune cells and not
tumor cells […] we expected antitumor activity in esophageal cancer regardless of
histologic subtype” and proceeded to show a greater benefit in adenocarcinoma patients
(340). However, due to the low sample size of the adenocarcinoma patients, clinical
trials proceeded to test the effects in esophageal squamous cell carcinoma in keynote180 and -181, which ultimately gained FDA approval for esophageal squamous cell
carcinoma (355, 356).
Despite the limitations of the studies performed in this limited time, significant,
novel, and potentially beneficial contribution has been made to the field of cancer
research. By further examining mucins, a novel mutation was discovered in MUC1 for
pancreatic cancer (Figures 2.2 and 2.4). These mutations seem very specific for T112P
in pancreatic cancer; however the effects cannot be readily elucidated due to limited
follow-up data (Figures 2.2 and 2.4). Furthermore, MUC2 appears highly mutated in a
select region, and these mutations mainly occur in kidney renal papillary cell carcinoma
(Figure 2.1 and Table 2.2). The examination also revealed new biomarker candidates
(Figures 2.7 and 2.8) and an interesting potential for MUCL1 involvement with
tumorigenesis (Figures 2.5 and 2.8).
Examining CD73 shows for the first time, the immunogenetic potential it has as a
checkpoint inhibitor in pancreatic cancer. It also highlights the significance of nucleotide
metabolism on survival. Furthermore, it suggests CD73 acts through a GM-CSF –
MDSC axis, which is novel. By modeling CD73 inhibition with a common frontline
chemotherapy reagent through ultrasound in a spontaneous model, the thesis was able
to show combination therapy might bring clinical benefit.
Lastly, by examining esophageal cancer, differences in the metabolic and
immune environment were revealed, along with potential treatments to target the
discovered vulnerabilities (Chapter 4). Interestingly, COQ3, a critical gene involved in
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oxidative phosphorylation, was discovered to impact the survival of esophageal
adenocarcinoma more than any gene, which could be targeted by metformin or
mubritinib (Figure 4.7F, Table 4.2) (303, 307). Furthermore, esophageal
adenocarcinoma may respond more to checkpoint therapy, given the difference in the
metabolic and immune landscape (Chapter 4).
Although a fraction of the highlights has been succinctly described here, it is the
hope that the novel work performed for this thesis will translate into clinical benefit.

212
References
1.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.
2011;144(5):646-74.
2.
Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-46.
3.
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and
immunoediting. Immunity. 2004;21(2):137-48.
4.
Ochsenbein AF. Principles of tumor immunosurveillance and implications for
immunotherapy. Cancer Gene Ther. 2002;9(12):1043-55.
5.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from
immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991-8.
6.
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and
lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature.
2001;410(6832):1107-11.
7.
Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation.
2005;80(2 Suppl):S254-64.
8.
Penn I. Tumors of the immunocompromised patient. Annu Rev Med. 1988;39:63-73.
9.
Engel AM, Svane IM, Rygaard J, Werdelin O. MCA sarcomas induced in scid mice are
more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J
Immunol. 1997;45(5):463-70.
10.
Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, Werdelin O. Chemically
induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic
normal mice. Eur J Immunol. 1996;26(8):1844-50.
11.
Faget DV, Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of SASP
in cancer. Nat Rev Cancer. 2019;19(8):439-53.
12.
Ghosh K, Capell BC. The Senescence-Associated Secretory Phenotype: Critical Effector in
Skin Cancer and Aging. J Invest Dermatol. 2016;136(11):2133-9.
13.
Kilbey A, Terry A, Cameron ER, Neil JC. Oncogene-induced senescence: an essential role
for Runx. Cell Cycle. 2008;7(15):2333-40.
14.
Lopes-Paciencia S, Saint-Germain E, Rowell MC, Ruiz AF, Kalegari P, Ferbeyre G. The
senescence-associated secretory phenotype and its regulation. Cytokine. 2019;117:15-22.
15.
Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al.
Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell.
2008;133(6):1019-31.
16.
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence
and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature.
2007;445(7128):656-60.
17.
Min HY, Lee HY. Oncogene-Driven Metabolic Alterations in Cancer. Biomol Ther (Seoul).
2018;26(1):45-56.
18.
Nagarajan A, Malvi P, Wajapeyee N. Oncogene-directed alterations in cancer cell
metabolism. Trends Cancer. 2016;2(7):365-77.
19.
Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26(9):877-90.
20.
Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer.
2011;11(2):85-95.
21.
Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14.
22.
Pupo E, Avanzato D, Middonti E, Bussolino F, Lanzetti L. KRAS-Driven Metabolic Rewiring
Reveals Novel Actionable Targets in Cancer. Front Oncol. 2019;9:848.

213
23.
Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, et al. Oncogenic
KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun.
2018;9(1):4945.
24.
Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, et al.
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Cell. 2012;149(3):656-70.
25.
Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, et al. Oncogenic
KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. Cell. 2016;165(4):910-20.
26.
Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GMCSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21(6):83647.
27.
Lacroix M, Riscal R, Arena G, Linares LK, Le Cam L. Metabolic functions of the tumor
suppressor p53: Implications in normal physiology, metabolic disorders, and cancer. Mol Metab.
2020;33:2-22.
28.
Labuschagne CF, Zani F, Vousden KH. Control of metabolism by p53 - Cancer and
beyond. Biochim Biophys Acta Rev Cancer. 2018;1870(1):32-42.
29.
Stine ZE, Walton ZE, Altman BJ, Hsieh AL, Dang CV. MYC, Metabolism, and Cancer.
Cancer Discov. 2015;5(10):1024-39.
30.
Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism.
Clin Cancer Res. 2012;18(20):5546-53.
31.
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent
glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab.
2012;15(1):110-21.
32.
Makinoshima H, Takita M, Matsumoto S, Yagishita A, Owada S, Esumi H, et al. Epidermal
growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated
lung adenocarcinoma. J Biol Chem. 2014;289(30):20813-23.
33.
Takebayashi S, Tanaka H, Hino S, Nakatsu Y, Igata T, Sakamoto A, et al. Retinoblastoma
protein promotes oxidative phosphorylation through upregulation of glycolytic genes in
oncogene-induced senescent cells. Aging Cell. 2015;14(4):689-97.
34.
Clem BF, Chesney J. Molecular pathways: regulation of metabolism by RB. Clin Cancer
Res. 2012;18(22):6096-100.
35.
King RJ, Yu F, Singh PK. Genomic alterations in mucins across cancers. Oncotarget.
2017;8(40):67152-68.
36.
Suh H, Pillai K, Morris DL. Mucins in pancreatic cancer: biological role, implications in
carcinogenesis and applications in diagnosis and therapy. Am J Cancer Res. 2017;7(6):1372-83.
37.
Xu F, Liu F, Zhao H, An G, Feng G. Prognostic Significance of Mucin Antigen MUC1 in
Various Human Epithelial Cancers: A Meta-Analysis. Medicine (Baltimore). 2015;94(50):e2286.
38.
Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer
progression. Trends Mol Med. 2014;20(6):332-42.
39.
Gautam SK, Kumar S, Cannon A, Hall B, Bhatia R, Nasser MW, et al. MUC4 mucin- a
therapeutic target for pancreatic ductal adenocarcinoma. Expert Opin Ther Targets.
2017;21(7):657-69.
40.
Shukla SK, Gunda V, Abrego J, Haridas D, Mishra A, Souchek J, et al. MUC16-mediated
activation of mTOR and c-Myc reprograms pancreatic cancer metabolism. Oncotarget.
2015;6(22):19118-31.
41.
Mehla K, Singh PK. MUC1: a novel metabolic master regulator. Biochim Biophys Acta.
2014;1845(2):126-35.

214
42.
Chaika NV, Gebregiworgis T, Lewallen ME, Purohit V, Radhakrishnan P, Liu X, et al.
MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in
pancreatic cancer. Proc Natl Acad Sci U S A. 2012;109(34):13787-92.
43.
Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, et al.
Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer
cells. Br J Cancer. 2007;97(3):345-57.
44.
Olou AA, King RJ, Yu F, Singh PK. MUC1 oncoprotein mitigates ER stress via CDAmediated reprogramming of pyrimidine metabolism. Oncogene. 2020;39(16):3381-95.
45.
Goode G, Gunda V, Chaika NV, Purohit V, Yu F, Singh PK. MUC1 facilitates metabolomic
reprogramming in triple-negative breast cancer. PLoS One. 2017;12(5):e0176820.
46.
Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of
hypoxia-inducible factor-1alpha in cancer. Cancer Sci. 2019;110(5):1510-7.
47.
Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-Modified Cancer Cell
Metabolism. Front Cell Dev Biol. 2019;7:4.
48.
Semenza GL. HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet
Dev. 2010;20(1):51-6.
49.
Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez
R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of
specific glycolytic isoforms. Mini Rev Med Chem. 2009;9(9):1084-101.
50.
Synnestvedt K, Furuta GT, Comerford KM, Louis N, Karhausen J, Eltzschig HK, et al. Ecto5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes
in intestinal epithelia. J Clin Invest. 2002;110(7):993-1002.
51.
Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed).
2012;4:734-45.
52.
Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO.
Oncogene. 2008;27(28):3889-900.
53.
Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in
inflammation, and immune activation. Front Biosci (Landmark Ed). 2015;20:1116-43.
54.
Yu J, Du W, Yan F, Wang Y, Li H, Cao S, et al. Myeloid-derived suppressor cells suppress
antitumor immune responses through IDO expression and correlate with lymph node metastasis
in patients with breast cancer. J Immunol. 2013;190(7):3783-97.
55.
Song H, Park H, Kim YS, Kim KD, Lee HK, Cho DH, et al. L-kynurenine-induced apoptosis
in human NK cells is mediated by reactive oxygen species. Int Immunopharmacol.
2011;11(8):932-8.
56.
Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, et al. Reversal of
indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine
depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36(8):758-64.
57.
Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression
mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer.
2019;120(1):16-25.
58.
Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells
by tumours. Nat Rev Immunol. 2012;12(4):253-68.
59.
Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloidderived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res.
2010;70(1):68-77.
60.
Won WJ, Deshane JS, Leavenworth JW, Oliva CR, Griguer CE. Metabolic and functional
reprogramming of myeloid-derived suppressor cells and their therapeutic control in
glioblastoma. Cell Stress. 2019;3(2):47-65.

215
61.
Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30(1-2):42-59.
62.
Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and
tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180-91.
63.
Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I
production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor
expression and antigen-specific T-cell responses. Cancer Res. 2004;64(16):5839-49.
64.
Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel
checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121-44.
65.
Alam MS, Kurtz CC, Rowlett RM, Reuter BK, Wiznerowicz E, Das S, et al. CD73 is
expressed by human regulatory T helper cells and suppresses proinflammatory cytokine
production and Helicobacter felis-induced gastritis in mice. J Infect Dis. 2009;199(4):494-504.
66.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation
catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J
Exp Med. 2007;204(6):1257-65.
67.
Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, et al. A
CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic
loop in human T lymphocytes. Oncoimmunology. 2013;2(9):e26246.
68.
Vuerich M, Robson SC, Longhi MS. Ectonucleotidases in Intestinal and Hepatic
Inflammation. Front Immunol. 2019;10:507.
69.
Sek K, Molck C, Stewart GD, Kats L, Darcy PK, Beavis PA. Targeting Adenosine Receptor
Signaling in Cancer Immunotherapy. Int J Mol Sci. 2018;19(12).
70.
Peng ZW, Rothweiler S, Wei G, Ikenaga N, Liu SB, Sverdlov DY, et al. The
ectonucleotidase ENTPD1/CD39 limits biliary injury and fibrosis in mouse models of sclerosing
cholangitis. Hepatol Commun. 2017;1(9):957-72.
71.
Tsukamoto H, Chernogorova P, Ayata K, Gerlach UV, Rughani A, Ritchey JW, et al.
Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease.
Blood. 2012;119(19):4554-64.
72.
Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, et al. CD73-deficient
mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer
Res. 2011;71(8):2892-900.
73.
Ohtsuka T, Changelian PS, Bouis D, Noon K, Harada H, Lama VN, et al. Ecto-5'nucleotidase (CD73) attenuates allograft airway rejection through adenosine 2A receptor
stimulation. J Immunol. 2010;185(2):1321-9.
74.
Friedman DJ, Kunzli BM, YI AR, Sevigny J, Berberat PO, Enjyoji K, et al. From the Cover:
CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase
susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A. 2009;106(39):16788-93.
75.
Feliu C, Peyret H, Poitevin G, Cazaubon Y, Oszust F, Nguyen P, et al. Complementary Role
of P2 and Adenosine Receptors in ATP Induced-Anti-Apoptotic Effects Against Hypoxic Injury of
HUVECs. Int J Mol Sci. 2019;20(6).
76.
Lim To WK, Kumar P, Marshall JM. Hypoxia is an effective stimulus for vesicular release
of ATP from human umbilical vein endothelial cells. Placenta. 2015;36(7):759-66.
77.
Gourine AV, Llaudet E, Dale N, Spyer KM. Release of ATP in the ventral medulla during
hypoxia in rats: role in hypoxic ventilatory response. J Neurosci. 2005;25(5):1211-8.
78.
Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its
potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med.
2007;80(2):51-60.

216
79.
Eckle T, Kewley EM, Brodsky KS, Tak E, Bonney S, Gobel M, et al. Identification of
hypoxia-inducible factor HIF-1A as transcriptional regulator of the A2B adenosine receptor
during acute lung injury. J Immunol. 2014;192(3):1249-56.
80.
Sandilos JK, Bayliss DA. Physiological mechanisms for the modulation of pannexin 1
channel activity. J Physiol. 2012;590(24):6257-66.
81.
Sridharan M, Adderley SP, Bowles EA, Egan TM, Stephenson AH, Ellsworth ML, et al.
Pannexin 1 is the conduit for low oxygen tension-induced ATP release from human erythrocytes.
Am J Physiol Heart Circ Physiol. 2010;299(4):H1146-52.
82.
Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, et al. Adenosine A2A
receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl
Acad Sci U S A. 2009;106(26):10684-9.
83.
Silva-Vilches C, Ring S, Mahnke K. ATP and Its Metabolite Adenosine as Regulators of
Dendritic Cell Activity. Front Immunol. 2018;9:2581.
84.
Wang J, Kubes P. A Reservoir of Mature Cavity Macrophages that Can Rapidly Invade
Visceral Organs to Affect Tissue Repair. Cell. 2016;165(3):668-78.
85.
Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, et al. ATP-dependent
recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after
anticancer chemotherapy. Oncoimmunology. 2013;2(6):e24568.
86.
Yoshida O, Kimura S, Jackson EK, Robson SC, Geller DA, Murase N, et al. CD39 expression
by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemiareperfusion injury in mice. Hepatology. 2013;58(6):2163-75.
87.
Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation.
Trends Mol Med. 2013;19(6):355-67.
88.
Oishi S, Sasano T, Tateishi Y, Tamura N, Isobe M, Furukawa T. Stretch of atrial myocytes
stimulates recruitment of macrophages via ATP released through gap-junction channels. J
Pharmacol Sci. 2012;120(4):296-304.
89.
Kawamura H, Kawamura T, Kanda Y, Kobayashi T, Abo T. Extracellular ATP-stimulated
macrophages produce macrophage inflammatory protein-2 which is important for neutrophil
migration. Immunology. 2012;136(4):448-58.
90.
Hasko G, Pacher P. Regulation of macrophage function by adenosine. Arterioscler
Thromb Vasc Biol. 2012;32(4):865-9.
91.
Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, et al. Ecto-nucleoside
triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by
hydrolyzing released ATP to adenosine. J Biol Chem. 2008;283(42):28480-6.
92.
Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, et al. ATP release guides
neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314(5806):1792-5.
93.
Mehla K, Singh PK. Metabolic Regulation of Macrophage Polarization in Cancer. Trends
Cancer. 2019;5(12):822-34.
94.
Saez PJ, Vargas P, Shoji KF, Harcha PA, Lennon-Dumenil AM, Saez JC. ATP promotes the
fast migration of dendritic cells through the activity of pannexin 1 channels and P2X7 receptors.
Sci Signal. 2017;10(506).
95.
Montalban Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, Wockel A, et al.
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into
adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73dependent mechanism for tumor immune escape. J Immunother Cancer. 2016;4:49.
96.
Barletta KE, Ley K, Mehrad B. Regulation of neutrophil function by adenosine.
Arterioscler Thromb Vasc Biol. 2012;32(4):856-64.

217
97.
Chen Y, Shukla A, Namiki S, Insel PA, Junger WG. A putative osmoreceptor system that
controls neutrophil function through the release of ATP, its conversion to adenosine, and
activation of A2 adenosine and P2 receptors. J Leukoc Biol. 2004;76(1):245-53.
98.
Neuberger A, Ring S, Silva-Vilches C, Schrader J, Enk A, Mahnke K. Expression of CD73
slows down migration of skin dendritic cells, affecting the sensitization phase of contact
hypersensitivity reactions in mice. J Dermatol Sci. 2017;87(3):292-9.
99.
Schenk U, Frascoli M, Proietti M, Geffers R, Traggiai E, Buer J, et al. ATP inhibits the
generation and function of regulatory T cells through the activation of purinergic P2X receptors.
Sci Signal. 2011;4(162):ra12.
100. Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells.
Front Immunol. 2014;5:304.
101. Ring S, Enk AH, Mahnke K. ATP activates regulatory T Cells in vivo during contact
hypersensitivity reactions. J Immunol. 2010;184(7):3408-16.
102. Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S, et al. Oxidative stress controls
regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat
Immunol. 2017;18(12):1332-41.
103. Linden J, Cekic C. Regulation of lymphocyte function by adenosine. Arterioscler Thromb
Vasc Biol. 2012;32(9):2097-103.
104. Uotila P. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular
immunity in cancer. Cancer Immunol Immunother. 1996;43(1):1-9.
105. Rodriguez G, Ross JA, Nagy ZS, Kirken RA. Forskolin-inducible cAMP pathway negatively
regulates T-cell proliferation by uncoupling the interleukin-2 receptor complex. J Biol Chem.
2013;288(10):7137-46.
106. Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A, et al. TCR- and CD28mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J
Immunol. 2004;173(8):4847-58.
107. Wehbi VL, Tasken K. Molecular Mechanisms for cAMP-Mediated Immunoregulation in T
cells - Role of Anchored Protein Kinase A Signaling Units. Front Immunol. 2016;7:222.
108. Huse M. The T-cell-receptor signaling network. J Cell Sci. 2009;122(Pt 9):1269-73.
109. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell
development and activation. Oncogene. 2004;23(48):7990-8000.
110. Rossy J, Williamson DJ, Benzing C, Gaus K. The integration of signaling and the spatial
organization of the T cell synapse. Front Immunol. 2012;3:352.
111. Min L, Joseph RE, Fulton DB, Andreotti AH. Itk tyrosine kinase substrate docking is
mediated by a nonclassical SH2 domain surface of PLCgamma1. Proc Natl Acad Sci U S A.
2009;106(50):21143-8.
112. Wange RL. LAT, the linker for activation of T cells: a bridge between T cell-specific and
general signaling pathways. Sci STKE. 2000;2000(63):re1.
113. Finco TS, Kadlecek T, Zhang W, Samelson LE, Weiss A. LAT is required for TCR-mediated
activation of PLCgamma1 and the Ras pathway. Immunity. 1998;9(5):617-26.
114. Serrano CJ, Graham L, DeBell K, Rawat R, Veri MC, Bonvini E, et al. A new tyrosine
phosphorylation site in PLC gamma 1: the role of tyrosine 775 in immune receptor signaling. J
Immunol. 2005;174(10):6233-7.
115. Lee JU, Kim LK, Choi JM. Revisiting the Concept of Targeting NFAT to Control T Cell
Immunity and Autoimmune Diseases. Front Immunol. 2018;9:2747.
116. Vaeth M, Feske S. NFAT control of immune function: New Frontiers for an Abiding
Trooper. F1000Res. 2018;7:260.

218
117. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev
Immunol. 2005;5(6):472-84.
118. Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell.
2002;109 Suppl:S67-79.
119. Chow CW, Davis RJ. Integration of calcium and cyclic AMP signaling pathways by 14-3-3.
Mol Cell Biol. 2000;20(2):702-12.
120. Brezar V, Tu WJ, Seddiki N. PKC-Theta in Regulatory and Effector T-cell Functions. Front
Immunol. 2015;6:530.
121. Isakov N, Altman A. PKC-theta-mediated signal delivery from the TCR/CD28 surface
receptors. Front Immunol. 2012;3:273.
122. Sheridan CM, Heist EK, Beals CR, Crabtree GR, Gardner P. Protein kinase A negatively
modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by
glycogen synthase kinase-3. J Biol Chem. 2002;277(50):48664-76.
123. Siegmund K, Thuille N, Posch N, Fresser F, Leitges M, Baier G. Novel mutant mouse line
emphasizes the importance of protein kinase C theta for CD4(+) T lymphocyte activation. Cell
Commun Signal. 2019;17(1):56.
124. Gruber T, Pfeifhofer-Obermair C, Baier G. PKCtheta is necessary for efficient activation
of NFkappaB, NFAT, and AP-1 during positive selection of thymocytes. Immunol Lett.
2010;132(1-2):6-11.
125. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol.
2002;20:761-94.
126. Saibil SD, Jones RG, Deenick EK, Liadis N, Elford AR, Vainberg MG, et al. CD4+ and CD8+ T
cell survival is regulated differentially by protein kinase Ctheta, c-Rel, and protein kinase B. J
Immunol. 2007;178(5):2932-9.
127. Manicassamy S, Sadim M, Ye RD, Sun Z. Differential roles of PKC-theta in the regulation
of intracellular calcium concentration in primary T cells. J Mol Biol. 2006;355(3):347-59.
128. Liu Y, Witte S, Liu YC, Doyle M, Elly C, Altman A. Regulation of protein kinase Ctheta
function during T cell activation by Lck-mediated tyrosine phosphorylation. J Biol Chem.
2000;275(5):3603-9.
129. Werlen G, Jacinto E, Xia Y, Karin M. Calcineurin preferentially synergizes with PKC-theta
to activate JNK and IL-2 promoter in T lymphocytes. EMBO J. 1998;17(11):3101-11.
130. Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and
function. Annu Rev Immunol. 1997;15:707-47.
131. Dutta D, Barr VA, Akpan I, Mittelstadt PR, Singha LI, Samelson LE, et al. Recruitment of
calcineurin to the TCR positively regulates T cell activation. Nat Immunol. 2017;18(2):196-204.
132. Joseph N, Reicher B, Barda-Saad M. The calcium feedback loop and T cell activation:
how cytoskeleton networks control intracellular calcium flux. Biochim Biophys Acta.
2014;1838(2):557-68.
133. Cope AP. Studies of T-cell activation in chronic inflammation. Arthritis Res. 2002;4 Suppl
3:S197-211.
134. Hayden-Martinez K, Kane LP, Hedrick SM. Effects of a constitutively active form of
calcineurin on T cell activation and thymic selection. J Immunol. 2000;165(7):3713-21.
135. Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, et al. Purinergic
control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal.
2008;1(39):ra6.
136. Yip L, Woehrle T, Corriden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of Tcell activation by ATP release and P2X7 receptors. FASEB J. 2009;23(6):1685-93.

219
137. Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S. The P2X7 Receptor in Infection
and Inflammation. Immunity. 2017;47(1):15-31.
138. Kalekar LA, Mueller DL. Relationship between CD4 Regulatory T Cells and Anergy In Vivo.
J Immunol. 2017;198(7):2527-33.
139. Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F. The P2X7 receptor is a key
modulator of aerobic glycolysis. Cell Death Dis. 2012;3:e370.
140. Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N, et al. A2A adenosine
receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich
microenvironments. J Immunol. 2009;183(9):5487-93.
141. Zarek PE, Huang CT, Lutz ER, Kowalski J, Horton MR, Linden J, et al. A2A receptor
signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of
adaptive regulatory T cells. Blood. 2008;111(1):251-9.
142. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine
receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A. 2006;103(35):131327.
143. Koshiba M, Kojima H, Huang S, Apasov S, Sitkovsky MV. Memory of extracellular
adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem.
1997;272(41):25881-9.
144. Bottoni P, Scatena R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical
Aspects. Advances in experimental medicine and biology. 2015;867:229-44.
145. Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, et al. Tn and sialyl-Tn antigens,
aberrant O-glycomics as human disease markers. Proteomics Clinical applications. 2013;7(910):618-31.
146. Andrianifahanana M, Moniaux N, Batra SK. Regulation of mucin expression: mechanistic
aspects and implications for cancer and inflammatory diseases. Biochimica et biophysica acta.
2006;1765(2):189-222.
147. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for
alterations in the growth and survival of cancer cells. Oncogene. 2010;29(20):2893-904.
148. Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, et al. Glycan motif profiling
reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
Mol Cell Proteomics. 2015;14(5):1323-33.
149. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell
surface. Nat Rev Cancer. 2004;4(1):45-60.
150. Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction.
Trends Cell Biol. 2006;16(9):467-76.
151. Maeda T, Hiraki M, Jin C, Rajabi H, Tagde A, Alam M, et al. MUC1-C Induces PD-L1 and
Immune Evasion in Triple-Negative Breast Cancer. Cancer Res. 2018;78(1):205-15.
152. Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins.
Annu Rev Physiol. 2008;70:431-57.
153. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nature reviews Cancer.
2009;9(12):874-85.
154. Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol
Ther. 2009;8(13):1197-203.
155. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, et al. Plateletderived growth factor receptor beta-mediated phosphorylation of MUC1 enhances invasiveness
in pancreatic adenocarcinoma cells. Cancer Res. 2007;67(11):5201-10.
156. Ho JJ, Chung YS, Yuan M, Henslee JG, Kim YS. Differences in expression of SPan-1 and
CA15-3 antigens in blood and tissues. Int J Cancer. 1992;52(5):693-700.

220
157. Moasser MM. The oncogene HER2: its signaling and transforming functions and its role
in human cancer pathogenesis. Oncogene. 2007;26(45):6469-87.
158. McCarter C, Kletter D, Tang H, Partyka K, Ma Y, Singh S, et al. Prediction of glycan motifs
using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured
pancreatic cancer cells. Proteomics Clinical applications. 2013;7(9-10):632-41.
159. Jiang K, Tan E, Sayegh Z, Centeno B, Malafa M, Coppola D. Cancer Antigen 125 (CA125,
MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal
Adenocarcinoma. Applied immunohistochemistry & molecular morphology : AIMM / official
publication of the Society for Applied Immunohistochemistry. 2016.
160. Itoh Y, Kamata-Sakurai M, Denda-Nagai K, Nagai S, Tsuiji M, Ishii-Schrade K, et al.
Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin.
Glycobiology. 2008;18(1):74-83.
161. Mukhopadhyay P, Chakraborty S, Ponnusamy MP, Lakshmanan I, Jain M, Batra SK.
Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.
Biochimica et biophysica acta. 2011;1815(2):224-40.
162. Duncan TJ, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. The role of MUC1 and
MUC3 in the biology and prognosis of colorectal cancer. World journal of surgical oncology.
2007;5:31.
163. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from
high-throughput sequencing data. Nucleic acids research. 2010;38(16):e164.
164. Liu X, Jian X, Boerwinkle E. dbNSFP: a lightweight database of human nonsynonymous
SNPs and their functional predictions. Human mutation. 2011;32(8):894-9.
165. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis
of complex cancer genomics and clinical profiles using the cBioPortal. Science signaling.
2013;6(269):pl1.
166. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer
genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer
discovery. 2012;2(5):401-4.
167. Cox DR. Regression Models and Life-Tables. Royal Statistical Society, Series B
(Methodology). 1972;34(2):187-220.
168. Benjamini Y H, Y. Controlling the false discovery rate: a practical and powerful approach
to multiple testing. Royal Statistical Society, Series B (Methodology). 1995;57(1):289-300.
169. Lek M, Karczewski K, Minikel E, Samocha K, Banks E, Fennell T, et al. Analysis of proteincoding genetic variation in 60,706 humans. bioRxiv. 2016.
170. Rachagani S, Torres MP, Moniaux N, Batra SK. Current status of mucins in the diagnosis
and therapy of cancer. BioFactors. 2009;35(6):509-27.
171. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, et al. Colorectal cancer in mice
genetically deficient in the mucin Muc2. Science. 2002;295(5560):1726-9.
172. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, et al.
Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. The
Journal of biological chemistry. 1990;265(25):15286-93.
173. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in
carcinomas of various sites: an immunohistochemical study. American journal of clinical
pathology. 2004;122(1):61-9.
174. Vincent A, Ducourouble MP, Van Seuningen I. Epigenetic regulation of the human mucin
gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone
modifications mediated by DNA methyltransferases and histone deacetylases. FASEB journal :

221
official publication of the Federation of American Societies for Experimental Biology.
2008;22(8):3035-45.
175. Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 activates
HER2 signalling and enhances the motility of human ovarian cancer cells. British journal of
cancer. 2008;99(3):520-6.
176. Bafna S, Kaur S, Momi N, Batra SK. Pancreatic cancer cells resistance to gemcitabine: the
role of MUC4 mucin. British journal of cancer. 2009;101(7):1155-61.
177. Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for
diagnosis and therapy. Cancer research. 2007;67(2):433-6.
178. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, et al. MUC4
expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung cancer.
2007;55(2):195-203.
179. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease:
understanding resistance to HER2-targeted therapy in human breast cancer. Nature clinical
practice Oncology. 2006;3(5):269-80.
180. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression
suppresses pancreatic tumor cell growth and metastasis. Cancer research. 2004;64(2):622-30.
181. Swartz MJ, Batra SK, Varshney GC, Hollingsworth MA, Yeo CJ, Cameron JL, et al. MUC4
expression increases progressively in pancreatic intraepithelial neoplasia. American journal of
clinical pathology. 2002;117(5):791-6.
182. Giuntoli RL, 2nd, Rodriguez GC, Whitaker RS, Dodge R, Voynow JA. Mucin gene
expression in ovarian cancers. Cancer research. 1998;58(23):5546-50.
183. Bavarva JH, Tae H, McIver L, Garner HR. Nicotine and oxidative stress induced exomic
variations are concordant and overrepresented in cancer-associated genes. Oncotarget.
2014;5(13):4788-98.
184. Sharma P, Dudus L, Nielsen PA, Clausen H, Yankaskas JR, Hollingsworth MA, et al.
MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands
in human bronchial airways. American journal of respiratory cell and molecular biology.
1998;19(1):30-7.
185. Bhavanandan VP. Cancer-associated mucins and mucin-type glycoproteins.
Glycobiology. 1991;1(5):493-503.
186. Kobata A. Altered glycosylation of surface glycoproteins in tumor cells and its clinical
application. Pigment cell research / sponsored by the European Society for Pigment Cell
Research and the International Pigment Cell Society. 1989;2(4):304-8.
187. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185
countries. CA Cancer J Clin. 2018;68(6):394-424.
188. Rawla P, Sunkara T, Gaduputi V. Epidemiology of Pancreatic Cancer: Global Trends,
Etiology and Risk Factors. World J Oncol. 2019;10(1):10-27.
189. Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in
the EU by 2017. Acta Oncol. 2016;55(9-10):1158-60.
190. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting
cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas
cancers in the United States. Cancer Res. 2014;74(11):2913-21.
191. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the
metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-33.

222
192. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic
Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell.
2015;162(6):1229-41.
193. Sugiura A, Rathmell JC. Metabolic Barriers to T Cell Function in Tumors. J Immunol.
2018;200(2):400-7.
194. Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic
Fitness for Optimal Cancer Immunotherapy. Clin Cancer Res. 2018;24(11):2473-81.
195. Ngwa VM, Edwards DN, Philip M, Chen J. Microenvironmental Metabolism Regulates
Antitumor Immunity. Cancer Res. 2019;79(16):4003-8.
196. Mehla K, Singh PK. Metabolic Regulation of Macrophage Polarization in Cancer. Trends
in Cancer.
197. Gupta S, Roy A, Dwarakanath BS. Metabolic Cooperation and Competition in the Tumor
Microenvironment: Implications for Therapy. Front Oncol. 2017;7:68.
198. Najjar YG, Menk AV, Sander C, Rao U, Karunamurthy A, Bhatia R, et al. Tumor cell
oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight.
2019;4(5).
199. Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, et al. CD73: an emerging
checkpoint for cancer immunotherapy. Immunotherapy. 2019;11(11):983-97.
200. Timosenko E, Hadjinicolaou AV, Cerundolo V. Modulation of cancer-specific immune
responses by amino acid degrading enzymes. Immunotherapy. 2017;9(1):83-97.
201. Munder M. Arginase: an emerging key player in the mammalian immune system. Br J
Pharmacol. 2009;158(3):638-51.
202. Vigano S, Alatzoglou D, Irving M, Menetrier-Caux C, Caux C, Romero P, et al. Targeting
Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Front Immunol. 2019;10:925.
203. Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in
cancer. Nat Rev Cancer. 2017;17(12):709-24.
204. Dosch M, Gerber J, Jebbawi F, Beldi G. Mechanisms of ATP Release by Inflammatory
Cells. Int J Mol Sci. 2018;19(4).
205. Manica A, Da Silva AM, Cardoso AM, Moreno M, Leal DB, Dutra Da Silva A, et al. High
levels of extracellular ATP lead to chronic inflammatory response in melanoma patients. J Cell
Biochem. 2018;119(5):3980-8.
206. Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature.
2014;509(7500):310-7.
207. Chow MT, Moller A, Smyth MJ. Inflammation and immune surveillance in cancer. Semin
Cancer Biol. 2012;22(1):23-32.
208. Stachon P, Geis S, Peikert A, Heidenreich A, Michel NA, Unal F, et al. Extracellular ATP
Induces Vascular Inflammation and Atherosclerosis via Purinergic Receptor Y2 in Mice.
Arterioscler Thromb Vasc Biol. 2016;36(8):1577-86.
209. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol.
2011;11(3):201-12.
210. Zhao H, Liao X, Kang Y. Tregs: Where We Are and What Comes Next? Front Immunol.
2017;8:1578.
211. Sitkovsky M, Lukashev D, Deaglio S, Dwyer K, Robson SC, Ohta A. Adenosine A2A
receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol.
2008;153 Suppl 1:S457-64.
212. Linnemann C, Schildberg FA, Schurich A, Diehl L, Hegenbarth SI, Endl E, et al. Adenosine
regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling.
Immunology. 2009;128(1 Suppl):e728-37.

223
213. Mastelic-Gavillet B, Navarro Rodrigo B, Decombaz L, Wang H, Ercolano G, Ahmed R, et
al. Adenosine mediates functional and metabolic suppression of peripheral and tumorinfiltrating CD8(+) T cells. J Immunother Cancer. 2019;7(1):257.
214. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma
production in murine CD4+ T cells. J Immunol. 2005;174(2):1073-80.
215. Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, et al. Activation of Th1
and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven
expansion in vivo. Blood. 2005;105(12):4707-14.
216. Cekic C, Sag D, Day YJ, Linden J. Extracellular adenosine regulates naive T cell
development and peripheral maintenance. J Exp Med. 2013;210(12):2693-706.
217. Csoka B, Himer L, Selmeczy Z, Vizi ES, Pacher P, Ledent C, et al. Adenosine A2A receptor
activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J.
2008;22(10):3491-9.
218. Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, et al. Autocrine
adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol.
2012;23(9):1528-37.
219. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis
and function in regulatory T cell biology. J Immunol. 2010;185(4):1993-8.
220. Ring S, Pushkarevskaya A, Schild H, Probst HC, Jendrossek V, Wirsdorfer F, et al.
Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac-Rap1
pathway. J Immunol. 2015;194(8):3735-44.
221. Novitskiy SV, Ryzhov S, Zaynagetdinov R, Goldstein AE, Huang Y, Tikhomirov OY, et al.
Adenosine receptors in regulation of dendritic cell differentiation and function. Blood.
2008;112(5):1822-31.
222. Ben Addi A, Lefort A, Hua X, Libert F, Communi D, Ledent C, et al. Modulation of murine
dendritic cell function by adenine nucleotides and adenosine: involvement of the A(2B)
receptor. Eur J Immunol. 2008;38(6):1610-20.
223. Desrosiers MD, Cembrola KM, Fakir MJ, Stephens LA, Jama FM, Shameli A, et al.
Adenosine deamination sustains dendritic cell activation in inflammation. J Immunol.
2007;179(3):1884-92.
224. Hasko G, Cronstein B. Regulation of inflammation by adenosine. Front Immunol.
2013;4:85.
225. Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic
cancer. Cancer Lett. 2016;381(1):244-51.
226. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin
Cancer Res. 2019;38(1):255.
227. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity
of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65.
228. O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, et al. Durvalumab With or
Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A
Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019.
229. Daniel SK, Sullivan KM, Labadie KP, Pillarisetty VG. Hypoxia as a barrier to
immunotherapy in pancreatic adenocarcinoma. Clin Transl Med. 2019;8(1):10.
230. Szomolay B, Eubank TD, Roberts RD, Marsh CB, Friedman A. Modeling the inhibition of
breast cancer growth by GM-CSF. J Theor Biol. 2012;303:141-51.
231. Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, et al. Myeloid
suppressor cell depletion augments antitumor activity in lung cancer. PLoS One.
2012;7(7):e40677.

224
232. Mauti LA, Le Bitoux MA, Baumer K, Stehle JC, Golshayan D, Provero P, et al. Myeloidderived suppressor cells are implicated in regulating permissiveness for tumor metastasis during
mouse gestation. J Clin Invest. 2011;121(7):2794-807.
233. Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses
identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47-52.
234. Kanehisa M, Sato Y, Furumichi M, Morishima K, Tanabe M. New approach for
understanding genome variations in KEGG. Nucleic Acids Res. 2019;47(D1):D590-D5.
235. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids
Res. 2000;28(1):27-30.
236. Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J, et al. Silibininmediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor
growth. Oncotarget. 2015;6(38):41146-61.
237. Gunda V, Souchek J, Abrego J, Shukla SK, Goode GD, Vernucci E, et al. MUC1-Mediated
Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer. Clin Cancer Res.
2017;23(19):5881-91.
238. Golde WT, Gollobin P, Rodriguez LL. A rapid, simple, and humane method for
submandibular bleeding of mice using a lancet. Lab Anim (NY). 2005;34(9):39-43.
239. Sullivan MR, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, et al. Quantification of
microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient
availability. Elife. 2019;8.
240. Haslene-Hox H, Oveland E, Berg KC, Kolmannskog O, Woie K, Salvesen HB, et al. A new
method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis
of ovarian carcinoma tissue. PLoS One. 2011;6(4):e19217.
241. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog
blood. Am J Physiol. 1989;256(4 Pt 1):C799-806.
242. Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell
differentiation. Nat Immunol. 2014;15(12):1104-15.
243. Tanel A, Fonseca SG, Yassine-Diab B, Bordi R, Zeidan J, Shi Y, et al. Cellular and molecular
mechanisms of memory T-cell survival. Expert Rev Vaccines. 2009;8(3):299-312.
244. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16:201-23.
245. Ma N, Liu Q, Hou L, Wang Y, Liu Z. MDSCs are involved in the protumorigenic potentials
of GM-CSF in colitis-associated cancer. Int J Immunopathol Pharmacol. 2017;30(2):152-62.
246. Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, et al. Tumor-induced MDSC
act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife.
2016;5.
247. O’Sullivan T, Saddawi-Konefka R, Gross E, Tran M, Mayfield Stephen P, Ikeda H, et al.
Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells. Cell
Reports. 2014;7(4):989-98.
248. Masuda K, Ripley B, Nyati KK, Dubey PK, Zaman MM, Hanieh H, et al. Arid5a regulates
naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. J Exp Med.
2016;213(4):605-19.
249. Shukla SK, Purohit V, Mehla K, Gunda V, Chaika NV, Vernucci E, et al. MUC1 and HIF1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine
Resistance to Pancreatic Cancer. Cancer Cell. 2017;32(1):71-87 e7.
250. Gravett AM, Trautwein N, Stevanovic S, Dalgleish AG, Copier J. Gemcitabine alters the
proteasome composition and immunopeptidome of tumour cells. Oncoimmunology.
2018;7(6):e1438107.

225
251. Jackaman C, Majewski D, Fox SA, Nowak AK, Nelson DJ. Chemotherapy broadens the
range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother.
2012;61(12):2343-56.
252. Wang R, Zhang Y, Lin X, Gao Y, Zhu Y. Prognositic value of CD73-adenosinergic pathway
in solid tumor: A meta-analysis and systematic review. Oncotarget. 2017;8(34):57327-36.
253. Jiang T, Xu X, Qiao M, Li X, Zhao C, Zhou F, et al. Comprehensive evaluation of
NT5E/CD73 expression and its prognostic significance in distinct types of cancers. BMC Cancer.
2018;18(1):267.
254. Zhou L, Jia S, Chen Y, Wang W, Wu Z, Yu W, et al. The distinct role of CD73 in the
progression of pancreatic cancer. J Mol Med (Berl). 2019;97(6):803-15.
255. Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD1 Inhibition. N Engl J Med. 2017;377(25):2500-1.
256. Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S,
Amigorena S, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol.
2019;10:168.
257. Thind K, Padrnos LJ, Ramanathan RK, Borad MJ. Immunotherapy in pancreatic cancer
treatment: a new frontier. Therap Adv Gastroenterol. 2017;10(1):168-94.
258. Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and
current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor
microenvironment. J Exp Clin Cancer Res. 2019;38(1):162.
259. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor
Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse
Cancers. Mol Cancer Ther. 2017;16(11):2598-608.
260. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al.
Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21.
261. Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging Role of
Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci. 2018;19(11).
262. Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Clinical significance of B7-H1 and B7-1
expressions in pancreatic carcinoma. World J Surg. 2010;34(5):1059-65.
263. Chen Y, Sun J, Zhao H, Zhu D, Zhi Q, Song S, et al. The coexpression and clinical
significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer.
Onco Targets Ther. 2014;7:1465-72.
264. Geng L, Huang D, Liu J, Qian Y, Deng J, Li D, et al. B7-H1 up-regulated expression in
human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol.
2008;134(9):1021-7.
265. Loos M, Giese NA, Kleeff J, Giese T, Gaida MM, Bergmann F, et al. Clinical significance
and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Lett.
2008;268(1):98-109.
266. Birnbaum DJ, Finetti P, Lopresti A, Gilabert M, Poizat F, Turrini O, et al. Prognostic value
of PDL1 expression in pancreatic cancer. Oncotarget. 2016;7(44):71198-210.
267. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and
therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in
human pancreatic cancer. Clin Cancer Res. 2007;13(7):2151-7.
268. Johnson BA, 3rd, Yarchoan M, Lee V, Laheru DA, Jaffee EM. Strategies for Increasing
Pancreatic Tumor Immunogenicity. Clin Cancer Res. 2017;23(7):1656-69.
269. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in
subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 2005;54(9):91525.

226
270. Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Genetically Engineered Mouse
Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Curr Protoc
Pharmacol. 2016;73:14 39 1-14 39 20.
271. Xiao Z, Dai Z, Locasale JW. Metabolic landscape of the tumor microenvironment at
single cell resolution. Nat Commun. 2019;10(1):3763.
272. Mehrmohamadi M, Liu X, Shestov AA, Locasale JW. Characterization of the usage of the
serine metabolic network in human cancer. Cell Rep. 2014;9(4):1507-19.
273. Lee D, Smallbone K, Dunn WB, Murabito E, Winder CL, Kell DB, et al. Improving
metabolic flux predictions using absolute gene expression data. BMC Syst Biol. 2012;6:73.
274. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide
burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-917.
275. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25
cancers in 1990. Int J Cancer. 1999;83(1):18-29.
276. Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A,
Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016
Bethesda, MD: National Cancer Institute; [
277. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-52.
278. Spechler SJ, Berta M, Patterson CO. Risk Stratification for Esophageal Adenocarcinoma
Screening and Surveillance. Gastroenterol Hepatol (N Y). 2006;2(11):798-9.
279. Huang TX, Fu L. The immune landscape of esophageal cancer. Cancer Commun (Lond).
2019;39(1):79.
280. Zhao Q, Yu J, Meng X. A good start of immunotherapy in esophageal cancer. Cancer
Med. 2019;8(10):4519-26.
281. Kelly RJ. The emerging role of immunotherapy for esophageal cancer. Curr Opin
Gastroenterol. 2019.
282. Thapa B, Lee K. Metabolic influence on macrophage polarization and pathogenesis. BMB
Rep. 2019;52(6):360-72.
283. Rivadeneira DB, Delgoffe GM. Antitumor T-cell Reconditioning: Improving Metabolic
Fitness for Optimal Cancer Immunotherapy. Clinical Cancer Research. 2018;24(11):2473-81.
284. Rohart F, Gautier B, Singh A, Le Cao KA. mixOmics: An R package for 'omics feature
selection and multiple data integration. PLoS Comput Biol. 2017;13(11):e1005752.
285. Gonzalez I, Cao KA, Davis MJ, Dejean S. Visualising associations between paired 'omics'
data sets. BioData Min. 2012;5(1):19.
286. Le Cao KA, Gonzalez I, Dejean S. integrOmics: an R package to unravel relationships
between two omics datasets. Bioinformatics. 2009;25(21):2855-6.
287. Abbas AR, Wolslegel K, Seshasayee D, Modrusan Z, Clark HF. Deconvolution of blood
microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS
One. 2009;4(7):e6098.
288. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and
exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550-8.
289. Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity
landscape. Genome Biol. 2017;18(1):220.
290. Tappeiner E, Finotello F, Charoentong P, Mayer C, Rieder D, Trajanoski Z. TIminer: NGS
data mining pipeline for cancer immunology and immunotherapy. Bioinformatics.
2017;33(19):3140-1.
291. Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, et al.
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals

227
distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol.
2015;16:64.
292. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pancancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and
Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18(1):248-62.
293. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol.
2009;27:485-517.
294. Schumann J, Stanko K, Schliesser U, Appelt C, Sawitzki B. Differences in CD44 Surface
Expression Levels and Function Discriminates IL-17 and IFN-gamma Producing Helper T Cells.
PLoS One. 2015;10(7):e0132479.
295. Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK, et al. Cellular
expression of a GPI-linked T cell activation protein. Cell Immunol. 1994;156(2):357-70.
296. Brugnoni D, Airo P, Marino R, Notarangelo LD, van Lier RA, Cattaneo R. CD70 expression
on T-cell subpopulations: study of normal individuals and patients with chronic immune
activation. Immunol Lett. 1997;55(2):99-104.
297. Tesselaar K, Xiao Y, Arens R, van Schijndel GM, Schuurhuis DH, Mebius RE, et al.
Expression of the murine CD27 ligand CD70 in vitro and in vivo. J Immunol. 2003;170(1):33-40.
298. Fleischer J, Grage-Griebenow E, Kasper B, Heine H, Ernst M, Brandt E, et al. Platelet
factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol.
2002;169(2):770-7.
299. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy.
Blood. 2013;121(5):734-44.
300. Goodwin J, Neugent ML, Lee SY, Choe JH, Choi H, Jenkins DMR, et al. The distinct
metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to
glycolytic inhibition. Nat Commun. 2017;8:15503.
301. Tan Z, Yang C, Zhang X, Zheng P, Shen W. Expression of glucose transporter 1 and
prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients. Oncotarget.
2017;8(37):60954-61.
302. Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, et al. YAP1-Mediated CDK6 Activation Confers
Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6
Inhibitors in Esophageal Cancer. Clin Cancer Res. 2019;25(7):2264-77.
303. Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, et al. Mubritinib
Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS
Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019;36(1):84-99 e8.
304. Wang K, Johnson A, Ali SM, Klempner SJ, Bekaii-Saab T, Vacirca JL, et al. Comprehensive
Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal
Adenocarcinomas Reveals Similarities and Differences. Oncologist. 2015;20(10):1132-9.
305. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, et al. Exome and wholegenome sequencing of esophageal adenocarcinoma identifies recurrent driver events and
mutational complexity. Nat Genet. 2013;45(5):478-86.
306. Battaglin F, Naseem M, Puccini A, Lenz HJ. Molecular biomarkers in gastro-esophageal
cancer: recent developments, current trends and future directions. Cancer Cell Int. 2018;18:99.
307. Cameron AR, Logie L, Patel K, Erhardt S, Bacon S, Middleton P, et al. Metformin
selectively targets redox control of complex I energy transduction. Redox Biol. 2018;14:187-97.
308. Qie S, Yoshida A, Parnham S, Oleinik N, Beeson GC, Beeson CC, et al. Targeting
glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal
squamous cell carcinoma. Nat Commun. 2019;10(1):1296.

228
309. Sborov DW, Haverkos BM, Harris PJ. Investigational cancer drugs targeting cell
metabolism in clinical development. Expert Opin Investig Drugs. 2015;24(1):79-94.
310. Abrego J, Gunda V, Vernucci E, Shukla SK, King RJ, Dasgupta A, et al. GOT1-mediated
anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells.
Cancer Lett. 2017;400:37-46.
311. Kim N, Cho H, Yun M, Park KR, Lee CG. Prognostic values of mid-radiotherapy (18)F-FDG
PET/CT in patients with esophageal cancer. Radiat Oncol. 2019;14(1):27.
312. Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, et al. Clinical
staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J
Thorac Oncol. 2014;9(8):1202-6.
313. Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, et al. Lack of fludeoxyglucose
F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival
after subsequent surgery in multimodality treatment for patients with locally advanced
esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2008;136(1):205-12, 12 e1-3.
314. Jadvar H, Henderson RW, Conti PS. 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission
tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol.
2006;8(3):193-200.
315. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of
tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and
response to treatment. J Clin Oncol. 2004;22(5):900-8.
316. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of
the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor
volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Radiother Oncol. 2008;89(3):278-86.
317. Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z, et al. Esophageal cancer
metabolite biomarkers detected by LC-MS and NMR methods. PLoS One. 2012;7(1):e30181.
318. Zhang X, Xu L, Shen J, Cao B, Cheng T, Zhao T, et al. Metabolic signatures of esophageal
cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Biochim Biophys Acta. 2013;1832(8):1207-16.
319. Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, et al.
Safety and Acceptability of Esophageal Cytosponge Cell Collection Device in a Pooled Analysis of
Data From Individual Patients. Clin Gastroenterol Hepatol. 2019;17(4):647-56 e1.
320. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, et al.
Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.
Sci Transl Med. 2018;10(424).
321. Ross-Innes CS, Debiram-Beecham I, O'Donovan M, Walker E, Varghese S, Lao-Sirieix P, et
al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil
factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS
Med. 2015;12(1):e1001780.
322. Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, et al. Cost Effectiveness
of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a
Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017;15(9):1397-404 e7.
323. Krzywinska E, Stockmann C. Hypoxia, Metabolism and Immune Cell Function.
Biomedicines. 2018;6(2).
324. Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated
immune escape in cancer. Cancer Res. 2014;74(24):7185-90.

229
325. Li Y, Patel SP, Roszik J, Qin Y. Hypoxia-Driven Immunosuppressive Metabolites in the
Tumor Microenvironment: New Approaches for Combinational Immunotherapy. Front Immunol.
2018;9:1591.
326. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, et al. Hypoxia: a key player in
antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. Am J
Physiol Cell Physiol. 2015;309(9):C569-79.
327. Patel H, Zaghloul N, Lin K, Liu SF, Miller EJ, Ahmed M. Hypoxia-induced activation of
specific members of the NF-kB family and its relevance to pulmonary vascular remodeling. Int J
Biochem Cell Biol. 2017;92:141-7.
328. D'Ignazio L, Rocha S. Hypoxia Induced NF-kappaB. Cells. 2016;5(1).
329. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B, Scholz CC, Byrne A, et al. An intact
canonical NF-kappaB pathway is required for inflammatory gene expression in response to
hypoxia. J Immunol. 2011;186(2):1091-6.
330. Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, Rocha S. Mechanism of hypoxiainduced NF-kappaB. Mol Cell Biol. 2010;30(20):4901-21.
331. Oliver KM, Garvey JF, Ng CT, Veale DJ, Fearon U, Cummins EP, et al. Hypoxia activates
NF-kappaB-dependent gene expression through the canonical signaling pathway. Antioxid Redox
Signal. 2009;11(9):2057-64.
332. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor kappa B
through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res.
1994;54(6):1425-30.
333. Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell
infiltration in esophageal squamous cell carcinoma. Oncol Rep. 1998;5(5):1185-9.
334. Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, et al. Immune responses in
patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int J
Oncol. 2015;46(4):1699-709.
335. Liu Q, Hao C, Su P, Shi J. Down-regulation of HLA class I antigen-processing machinery
components in esophageal squamous cell carcinomas: association with disease progression.
Scand J Gastroenterol. 2009;44(8):960-9.
336. Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated
CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61(10):3932-6.
337. Yagi T, Baba Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, et al. PD-L1 Expression,
Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected
Esophageal Cancer. Ann Surg. 2019;269(3):471-8.
338. Chen MF, Chen PT, Chen WC, Lu MS, Lin PY, Lee KD. The role of PD-L1 in the radiation
response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell
immunosuppression. Oncotarget. 2016;7(7):7913-24.
339. Cho Y, Miyamoto M, Kato K, Fukunaga A, Shichinohe T, Kawarada Y, et al. CD4+ and
CD8+ T cells cooperate to improve prognosis of patients with esophageal squamous cell
carcinoma. Cancer Res. 2003;63(7):1555-9.
340. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, et al. Safety and Antitumor
Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced
Esophageal Carcinoma. J Clin Oncol. 2018;36(1):61-7.
341. Shah MA, Adenis A, Enzinger PC, Kojima T, Muro K, Bennouna J, et al. Pembrolizumab
versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3
KEYNOTE-181 study. Journal of Clinical Oncology. 2019;37(15_suppl):4010-.
342. Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al.
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced,

230
Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2
KEYNOTE-180 Study. JAMA Oncol. 2019;5(4):546-50.
343. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in
cancer: meta-analysis. BMJ. 2018;362:k3529.
344. Hao C, Tian J, Liu H, Li F, Niu H, Zhu B. Efficacy and safety of anti-PD-1 and anti-PD-1
combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and
meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325.
345. Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, et al. Anti-Programmed Cell Death (PD)-1
Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol.
2016;9(1):32-40.
346. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al.
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma
receiving nivolumab. J Clin Oncol. 2014;32(10):1020-30.
347. Couzin-Frankel J. Cancer Immunotherapy. Science. 2013;342(6165):1432-3.
348. Mikhail FA GJ, Grey K, Narbonne GM, Patricia VR. The Rise of Animals: Evolution and
Diversification of the Kingdom Animalia. Baltimore, Maryland: The Johns Hopkins University
Press; 2007.
349. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends
Biochem Sci. 2010;35(8):427-33.
350. Kaye SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br J
Cancer. 1998;78 Suppl 3:1-7.
351. Waters AM, Der CJ. KRAS: The Critical Driver and Therapeutic Target for Pancreatic
Cancer. Cold Spring Harb Perspect Med. 2018;8(9).
352. Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived
suppressor cells. J Leukoc Biol. 2015;98(6):913-22.
353. Park MY, Lim BG, Kim SY, Sohn HJ, Kim S, Kim TG. GM-CSF Promotes the Expansion and
Differentiation of Cord Blood Myeloid-Derived Suppressor Cells, Which Attenuate Xenogeneic
Graft-vs.-Host Disease. Front Immunol. 2019;10:183.
354. Dufait I, Schwarze JK, Liechtenstein T, Leonard W, Jiang H, Escors D, et al. Ex vivo
generation of myeloid-derived suppressor cells that model the tumor immunosuppressive
environment in colorectal cancer. Oncotarget. 2015;6(14):12369-82.
355. Kojima T, Muro K, Francois E, Hsu C-H, Moriwaki T, Kim S-B, et al. Pembrolizumab versus
chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181
study. Journal of Clinical Oncology. 2019;37(4_suppl):2-.
356. Manish S, Jaafar B, Lin S, Peter E, Qiao L, Ildiko C, et al. P-279: Pembrolizumab for
patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the
esophagus: phase 2 KEYNOTE-180 study. Ann Oncol. 2016;27(Suppl 2):ii81-ii.

